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 Pancreatic ductal adenocarcinoma (PDAC) is a lethal disease that remains 
incurable for a majority of patients. Constitutive activation of the KRAS protein, and 
subsequent hyperactivation of its effector pathways, is the key genetic event responsible 
for nearly all PDAC cases. In an effort to overcome the toxicity and limited efficacy of 
conventional chemotherapies, we set out to comprehensively describe the signaling 
intricacies that drive tumor growth and metastasis. This work is divided into two major 
parts: (1) how PDAC cells respond to ablation of mutant KRAS, with an emphasis on 
measuring the activity of kinase signaling networks and (2) the identification of an ERK 
inhibitor as an unexpected, but highly synergistic, addition to a pan-RAF inhibitor to 
suppress PDAC proliferation and induce apoptosis.  
 Oncogenic KRAS drives proliferation through a diverse, but incompletely 
delineated, network of signaling proteins. KRAS modulates intracellular processes by 
direct and indirect regulation of both protein activity and protein abundance. Using a 
chemical proteomics strategy, we established a comprehensive profile of kinase signaling 
(the kinome) in PDAC and compared this profile in KRAS-suppressed cells. We found 
that > 12% of kinases detected were significantly altered in our panel of six PDAC cell 
lines, and that many of these kinases are critical for PDAC growth in the presence, or 
iv 
absence, of mutant KRAS. These findings led us to the conclusion that system-wide 
delineation of the KRAS-regulated kinome can help identify therapeutic targets in PDAC. 
 Mutant KRAS signaling is dependent on the RAF-MEK-ERK kinase cascade, 
which consequently serves as an attractive therapeutic target. Prior attempts to use 
BRAF-selective inhibitors induced rebound activation of ERK via stabilization of other 
RAF isoforms, which led us to trial a pan-RAF inhibitor as the basis of targeted therapy 
combinations. Chemical and genetic screening against a diverse set of proteins led us to 
identify ERK as the most promising clinical target in combination with pan-RAF inhibition. 
Concurrent inhibition of RAF and ERK at low doses caused apoptosis in the majority of 
PDAC cells, despite each inhibitor only exhibiting cytostatic effects alone. Subsequent 
comprehensive profiling of this combination showed that inhibition of RAF and ERK was 
insensitive to feedback reactivation and induced a system-wide collapse of pro-survival 
processes. These findings led to our conclusion that low-dose vertical inhibition of the 
RAF-MEK-ERK pathway is a viable therapeutic strategy for the treatment of KRAS-
mutant PDAC.   
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CHAPTER 1 - INTRODUCTION 
1.1.  IMPORTANCE AND PATHOGENESIS OF PANCREATIC CANCER 
 Cell proliferation, or expansion of a population of cells, is regulated by an array of 
intrinsic and extrinsic signals that determine the timing and the frequency of cell division. 
In normal somatic cell physiology, the balance of pro- and antiproliferative signals 
facilitate normal tissue development and cell homeostasis. Cancer develops from cells 
that gain persistent growth signaling and lose anti-proliferative protective mechanisms. 
Advances in genetic, molecular, and bioinformatics techniques since the turn of the 
century have enabled researchers to pinpoint the driving factors in many cancer types, 
including pancreatic cancer, though targeted exploitation of these drivers remains under 
investigation. 
1.1.1. PANCREATIC ADENOCARCINOMA 
 Pancreatic adenocarcinoma (PDAC) diagnoses are estimated to surpass 60,000 
new cases in the United States in 2021, continuing a steady upward trend in pancreas 
cancer incidence (1). PDAC is more common in men (31,950 vs. 26,480 estimated cases) 
and  accounts for ~90% of all neoplasms of the pancreas (2). Less common types of 
tumors originating in the pancreas include acinar cell carcinoma, pancreatoblastoma, 
solid-pseudopapillary tumors, and a diversity of functioning and non-functioning 
endocrine tumors (3). Risk factors for developing PDAC include tobacco use, age (> 50 
years), chronic pancreatitis, obesity and diabetes mellitus (4). 
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1.1.2. CLINICAL FEATURES OF PDAC 
 The clinical presentation of PDAC is often delayed due to the late onset of 
noticeable symptoms, which typically include jaundice, midepigastric pain and weight loss 
(5). Less frequently, a diagnosis of pancreatic cancer may be heralded by recent onset 
of type II diabetes mellitus (6). Diagnostic workup for patients with this constellation of 
symptoms includes transabdominal ultrasound or abdominal computed tomography (CT) 
scan to confirm the presence of a pancreas mass and to assess the surgical resectability 
of the mass (7,8). Given the insidious course of the disease, however, most patients 
present with invasive disease that precludes definitive surgical management. PDAC can 
invade or encase local structures (such as the superior mesenteric artery or the celiac 
artery) or metastasize distantly to the liver, peritoneum, or extra-abdominal location, any 
of which would make resection contraindicated (9). Overall 5-year survival for patients 
diagnosed with any stage of pancreas cancer is 10%, though it decreases dramatically if 
surgery is not an option (1).   
1.1.3. GENOMIC FEATURES OF PDAC AND PATHOPHYSIOLOGY  
  Pancreatic ductal adenocarcinoma most frequently arises from a precursor lesion, 
pancreatic intraepithelial neoplasia (PanIN, Fig. 1.1) (10). PanINs first develop through 
acinar-to-ductal metaplasia concurrent with an activating point mutation in the KRAS 
oncogene (10). Recent single cell sequencing analysis of these precursor lesions 
revealed that PanIN lesions can contain different subtypes of metaplastic cells with  
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Figure 1.1. Step-wise development of pancreatic adenocarcinoma (PDAC). Green 
gene identifiers denote activating mutations and red gene identifiers denote inactivating 
mutations or deletions. 
 
differing carcinogenic potential (11). Investigation of PanIN lesions has yielded insight 
into the stepwise accumulation of genomic alterations seen in PDAC. Genomic 
characterization of PDAC is typified by activating mutations in KRAS (93%) and 
inactivating mutations or deletions of TP53 (70.5%), CDKN2A (p16, 17.4%), and SMAD4 
(24.2%) (12-14). Subsequent analyses revealed similar findings alongside a host of less 
frequent mutations, including the identification of germline mutations in BRCA2 and ATM 
that predispose patients to developing PDAC. While most PDAC cases are similar in their 
dependence on activated KRAS, there is a wide range of co-occurring mutations that 
contribute to clinical heterogeneity among patients with PDAC. This heterogeneity in 
genetic drivers among PDAC is likely to blame, in part, for the varied responses to current 
treatment modalities (9). 
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1.1.4. RESEARCH MODELS FOR PDAC  
 Preclinical models of pancreatic cancer are essential for the understanding and 
development of novel therapeutics. Traditional cell line models of human PDAC (e.g., MIA 
PaCa-2, PANC-1), maintained in culture for decades, remain the most widely used cell 
models to dissect the molecular features that drive PDAC behavior (proliferation, 
avoidance of apoptosis, genomic instability) as well as relationships among signaling 
pathways in human PDAC (15,16). Recently, low passage cell lines established from 
patient-derived tumor xenografts (PDX) provide cell models that better represent the 
heterogeneity of patient tumors.  
The recent development of organoid models of PDAC offer much of the same utility 
that researchers have with adherent cultures while adding an element of three-
dimensional growth similar to human tumors (17). Not only can researchers evaluate the 
proliferative impact of an investigational inhibitor or genetic perturbation, organoids offer 
the ability to evaluate cell-cell and cell-stroma interactions following treatment (18). What 
remains lacking in both adherent cultures as well as organoid models of PDAC is 
capturing the immunosurveillance by the host of the tumor. For this reason, preclinical 
syngeneic orthotopic mouse models remain a critical tool needed to study the 
pathophysiology of PDAC and the response to investigational treatments (19). Orthotopic 
models also model the highly desmoplastic nature of PDAC, where cancer cells comprise 
only 10-15% of the tumor mass. 
 Animal models of PDAC can be generally divided into two distinct categories: 
transplanted tumor animal models and spontaneous tumor animal models (19). 
Xenotransplantation tumor models often involve subcutaneous injection of tumor cells 
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into an immunocompromised mouse host. This offers researchers the ability to easily 
monitor tumor progression of a human cell line-driven tumor. The primary drawback of 
this model, however, is the lack of a competent immune system in the mouse, which fails 
to recapitulate the physiological context of most patient’s disease  (20). Patient derived 
tumor xenografts (PDX) are created by injection of dissociated patient-derived tumor cells 
or implantation of a bulk human tumor section into an immunocompromised mouse host 
(21,22). The PDX tumors that develop often retain the histological characteristics of the 
original tumor as well as retention of tumor supporting cell types such as cancer-
associated fibroblasts.  
Spontaneous tumor models were developed to better capture the tissue-specific 
tumorigenesis process in an immunocompetent animal host. Earlier models involved 
chemical induction of pancreas tumors, though the tumors that formed often varied widely 
in their histologic subtype and did not mimic the primary PDAC subtype seen in human 
patients (23,24).  Subsequent work permitted the development of genetically-engineered 
mouse models (GEMMs) that supported pancreas-specific tumor formation and more 
closely matched the genetic features of PDAC seen in humans (25-29). In particular, the 
KPC (KrasG12D/+/Tp53R172H/R172H) GEMM developed by Tuveson and colleagues is 
considered the gold standard for the field. This model recapitulates key characteristics of 
the human disease, including highly desmoplastic, poorly vaculularized tumors. The 
metastatic spread as well as poor response to gemcitabine also mirror the patient cancer.  
1.1.5. CURRENT TREATMENT STRATEGIES FOR PDAC 
 Upon diagnosis of PDAC, only 15 to 20 percent of patients are candidates for 
surgical resection, which currently offers the only chance of a cure (30). Outside of a 
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clinical trial, there are relatively few options for medical management of a patient with 
locally advanced or metastatic PDAC. For the majority of patients with unresectable 
disease, first line systemic therapy depends on a patient’s comorbidities and expected 
performance status (Fig. 1.2). Guidelines for assessment of comorbidities include 
evaluation of a patient’s hemoglobin, platelet count, and bilirubin levels. If the patient is 
capable of tolerating an intensive approach and has favorable blood counts, the 
recommended treatment is the combination chemotherapy regimen known as 
FOLFIRINOX (folinic acid, fluorouracil, irinotecan, and oxaliplatin) (31). In patients that 
have less favorable, but still adequate, comorbidities, single-agent gemcitabine or 
gemcitabine plus nab-paclitaxel is often recommended. Some institutions also favor 
gemcitabine plus nab-paclitaxel versus FOLFIRINOX in any patient with adequate 
comorbidities. In patients that do not have favorable blood counts, chemotherapy should 
only be offered on a case-by-case basis with an emphasis on supportive care. 
Fluorouracil-based combination regimens, such as FOLFIRINOX and FOLFOX (folinic 
acid, fluorouracil, oxaliplatin) have been shown to improve all metrics of patient survival 
in comparison to gemcitabine alone (progression-free survival, objective response rate, 
overall survival) (32,33). 
 Given the known systemic toxicity of the majority of chemotherapeutic regimens 
available for PDAC, there has been a recent emphasis on the identification of cancer-
driver targeted therapies (34). The goal for a successful targeted therapy is the 
preferential disruption of cancer cell proliferation without limiting non-cancerous, somatic 
cell survival. The EGFR-targeted small molecule inhibitor erlotinib achieved statistical 
success but clinically insignificant improvement in overall survival (median increase of 
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0.33 months) when combined with gemcitabine (35). Despite FDA approval for PDAC, 
erlotinib remains a second-line agent for advanced PDAC due to its limited benefit 
 
Figure 1.2. First-line medical management options for metastatic PDAC. Flowchart 
developed from recent ASCO guidelines (31). Favorable and relatively favorable 
comorbidity definitions are available in the online publication. ǂ Only offered in a setting 
where proactive dosing and schedule adjustments can be made to minimize toxicity. 
 
and added toxicity profile (36).  
While heritable pancreatic cancer is rare, some patients that harbor germline 
mutations in BRCA1, BRCA2, or PALB2 genes will present with PDAC. Germline or 
somatic mutations in any of these genes disrupt DNA-damage repair mechanisms in the 
PDAC cell. Patients with these tumors will uniquely benefit from platinum-based 
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chemotherapy, which directly disrupt normal DNA structure through the formation of DNA 
adducts and interstrand crosslinks. Additionally, patients may be amenable to 
maintenance therapy with a PARP inhibitor such as olaparib which also disrupts DNA-
damage repair and has a favorable tolerability profile (37).  
 
1.2.  THE KRAS PROTEIN 
 The KRAS oncogene belongs to the RAS gene family. The identification of HRAS, 
NRAS, and KRAS in human cancer cells established RAS-family genes as the first 
oncogenes discovered (38,39). There are three RAS-gene family members (HRAS, 
NRAS, KRAS) which encode four RAS-family proteins (HRAS, NRAS, KRAS4A, 
KRAS4B). KRAS has two splice variants which vary in expression in a tissue-dependent 
manner; KRAS4B is the most abundant splice variant in PDAC and other cancer types, 
accounting for the focus on KRAS4B rather than KRAS4A in the vast majority of studies 
(40). Since their discovery, decades of research has cemented their place among key 
cancer-promoting proteins in their capacity to initiate and maintain tumor growth in a 
range of tissue types (41). 
 RAS-family mutations are found in a multitude of human cancer types (Fig. 1.3).  
PDAC is unique among cancer types in its singular dependence on an activating RAS 
mutation for tumorigenesis; the next most frequently RAS-mutant cancer types are 
colorectal (52% RAS mutations) and lung adenocarcinoma (32% RAS mutations) (42). 
Among RAS family members, KRAS is the most frequently mutated (83% of all RAS 
mutations in cancer overall), however the distribution of mutant RAS isozymes differs 
among various cancer types. KRAS is the most frequently mutated in pancreatic and lung 
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adenocarcinoma, as well as colorectal cancer. Melanoma and acute myelogenous 
leukemia are dominated by activating NRAS mutations, while bladder and head and neck 
squamous cell carcinoma are most frequently HRAS mutant (42). Why a specific RAS 
isoform is seen preferentially in different cancer types remains an unresolved issue in the 
field. 
 
Figure 1.3. Prevalence of RAS mutations in human cancers.  
 
KRAS, as well as other RAS family members, is a GTPase that functions as a 
molecular switch (43). KRAS cycles between GTP-bound and GDP-bound states which 
is facilitated by guanine nucleotide exchange factors (GEFs) and GTPase-activating 
proteins (GAPs, Fig. 1.4) (44). GEFs interact with KRAS-GDP and promote the exchange 
of GTP for GDP, functionally activating KRAS. KRAS-GTP is uniquely able to bind and 
activate effector proteins. GAPs, on the other hand, interact with KRAS-GTP to cause the 
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hydrolysis of GTP to GDP, inactivating KRAS. This activation-inactivation cycling of KRAS 
is tightly controlled in normal cells, and helps integrate external growth-promoting stimuli 
with downstream signaling pathways. 
 Mutational activation of KRAS is the initiating genetic even in PDAC and is found 
in 95% of cases (14). Missense alterations at Gly-12, Gly-13, and Glu-61 are the most  
 
Figure 1.4. KRAS activation-inactivation cycle in normal and tumor cells. 
 
common hotspots locations for mutations in RAS genes, and induce the constitutive 
activation of KRAS seen in cancer (Fig. 1.4) (42). Mutant KRAS is traditionally considered 
to be GAP-insensitive, leading to its accumulation in the GTP-bound, or active, state. 
Tumorigenesis via constitutive KRAS signaling can also be achieved through loss of 
GAPs (NF1), upstream activating mutations in the EGF receptor tyrosine kinase, or 
mutational activation of downstream effectors (e.g., BRAF). 
 Upon GTP binding and activation, KRAS is capable of stimulating several known 
signaling pathways through effector binding (41). The best characterized, and most 
essential in PDAC, are the RAF serine/threonine kinases (ARAF, BRAF, RAF1/CRAF) 
(45). RAF is the first tier of a three-tier protein kinase cascade (RAF-MEK-ERK) that 
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comprise one of three major mitogen-activated protein kinase (MAPK) cascades. KRAS-
GTP binds to RAF through its RAS-binding domain (RBD), promoting normally cytosolic 
RAF translation to the plasma membrane, where other protein kinases phosphorylate and 
activate the kinase activity of RAF. Activated RAF can phosphorylate and activate the 
highly related MEK1 and MEK2 dual specificity kinases, which in turn phosphorylate and 
activate the ERK1 and ERK serine/threonine kinases (herein referred to as ERK). 
Whereas RAF and MEK exhibit highly restricted substrates, activated ERK has hundreds 
of substrates, though the critical effectors that facilitate PDAC growth have only been 
partially described (46). The ERK MAPK cascade is a major focus of my research studies. 
The second best characterized KRAS effector pathway involves the class I 
phosphoinositide 3-kinases (PI3K). KRAS-GTP binds and activates PI3K, which 
promotes the formation of phosphatidylinositol (3,4,5)-triphosphate; this signaling 
molecule leads to the activation of the AKT and mTOR protein kinases (47). 
Other key KRAS effectors in PDAC include GEFs for other RAS superfamily 
GTPases. As with other RAS effectors, these GEFs contain either RBD or RAS 
association (RA) domains that bind preferentially to GTP-bound RAS. RAS binds TIAM1, 
leading to activation of the RAC1 RHO family GTPase. RAS binding to a family of 
RALGEFs (RALGDS, RGL1, RGL2 and RGL3) leads to activation of the related RALA 
and RALB RAS family small GTPase (48,49). Like RAS, these GTPases are activated by 
their respective GEF proteins to form their active GTP-bond states. Altogether, KRAS-
GTP can interact with these as well as other RBD/RA domain containing proteins to 
regulate a diversity of cytoplasmic signaling networks that in turn regulate a myriad of 
cellular functions. There is also considerable crosstalk between the individual effector 
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networks to facilitate processes such as cell survival, metabolic activity, cell migration, 
and proliferation (45). 
KRAS is critical to both PDAC tumorigenesis as well as tumor maintenance. 
Doxycycline-inducible mouse models of PDAC clearly demonstrated that expression of 
KRASG12D was sufficient to induce PDAC formation (50). Additionally, removal of 
doxycycline  and loss of KRASG12D expression caused a regression of the PDAC tumor. 
Oncogenic KRAS mediates these effects by binding and activating a complex effector 
network. Many of these indirect and direct effectors are kinases, which both transmit 
intracellular signaling and are tractable drug targets (51). The KRAS-regulated kinase 
effector network in PDAC is directly or indirectly responsible for processes which include 
cell cycle progression, DNA-damage repair, nucleotide processing, RNA processing  and 
protein translation (51-53). A comprehensive characterization of this effector kinase 
network is lacking in PDAC and is a focus of this dissertation. 
  
1.3.  MAPK SIGNALING 
 Mitogen-activated protein kinase (MAPK) cascades are critical for transducing 
extracellular signals to cellular responses. Three families of MAPKs have been well 
described: classical MAPK (RAF-MEK-ERK), c-Jun N-terminal kinase and stress-
activated protein kinase (JNK/SAPK) and the p38 kinase cascade (54). All three cascades 
can play a role in proliferation, differentiation and development. JNK/SAPK is notable for 
its role in inflammation and the stress response as well as activation of the transcription 
factor c-Jun. p38 plays a role in interferon signaling and NF-κB signaling. The best 
characterized MAPK is the ERK pathway, or RAF-MEK-ERK. In the absence of mutant 
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KRAS, the ERK MAPK cascade is generally activated by upstream growth factor binding 
to receptor tyrosine kinases (e.g., EGF binding EGFR). The ERK MAPK cascade, 
particularly in the presence of an activating KRAS mutation, is one primary focus of this 
dissertation work. 
The ERK kinases (MAPK1 and MAPK3; encoding ERK2 and ERK1, respectively) 
serve as the third tier in the RAF-MEK-ERK MAPK protein kinase cascade. ERK 
activation has been shown to play a key role in regulating cell cycle division, proliferation, 
and survival of PDAC cells (Fig. 1.5) (55). Given the importance of ERK signaling in 
cancer, there are substantial ongoing efforts both to understand the breadth and 
significance of ERK activity as well as to develop ERK-selective small molecule inhibitors 
(56).  
1.3.1. ERK-REGULATED PHOSPHORYLATION 
ERK1/2 are serine/threonine (S/T) protein kinases with a diverse array of 
substrates. ERK substrates generally contain either a D-domain and/or a DEF motif, both 
of which promote ERK binding and phosphorylation (57,58). While some proteins are 
near-universally identifiable as an ERK substrate (e.g., RSK), a recent meta-analyses of 
ERK-substrate literature revealed an expansive list of >2500 direct and indirect ERK 
phosphosites (46). Multiple research groups have attempted to dissect and characterize 
the ERK phosphoproteome in various cancer types and cell lines, including colon, cervical 
and melanoma (59-64). These efforts generally have poor cross-validity, however, in part 
due to their varied choice of model cell lines (HEK293, NIH3T3), non-human cell lines (rat 
IEC-6), and cancer cells with heterogeneous oncogene drivers. Notably, many of the 
studies that laid the foundation for defining ERK substrates used extracellular growth 
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factor (EGF) stimulation to induce signaling through the EGF receptor (EGFR) and the 
downstream ERK MAPK pathway (59,65-70). Not only is this treatment non-specific for 
activating ERK signaling, it also does not accurately recapitulate KRAS-mutant signaling 
in pancreatic cancer. The dissimilarity in ERK substrate lists between these studies 
demonstrates the need for additional robust research with an exclusive focus on 
identifying ERK-interacting partners and key substrates in pancreatic cancer. 
 ERK has a diverse and incompletely defined array of substrates, some of which 
are also protein kinases. Known kinase families that are activated by ERK signaling 
include p90 ribosomal S6 kinases (RSK1-4), MAPK-interacting kinases (MNK2), and 
mitogen- and stress-activated kinases (MSK1/2) (71). The RSKs play a role in nuclear 
signaling, cell cycle progression, proliferation, protein synthesis and cell survival. MSK 
may also play a role in the chromatin landscape in addition to directly activating multiple 
transcription factors. Notably, activated MSKs can stabilize and activate the transcription 
factor CREB; phosphorylated CREB helps activate the transcriptional activity of c-Fos, 
JunB, and Egr1 (72). MNK family kinases control protein synthesis through regulation of 
ribosomal initiating factors eIF4E and eIF4G; MNK may also have RNA-binding protein 
targets (73,74). Dissection of the ERK-regulated kinase landscape, or kinome, is another 
important aspect of the research in this dissertation. 
1.3.2. ERK-REGULATED TRANSCRIPTIONAL ACTIVITY 
 Once ERK is activated via phosphorylation by MEK1/2, ERK can translocate to the 
nucleus (75). Many of the known and putative ERK targets are transcription factors, such 
as MYC, JUN, FOS, FOSL1, and ELK1. Each of these transcription factors regulates a 
diverse array of transcriptional programs, expanding the list of indirect ERK-regulated 
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genes. MYC, JUN, and FOS have all been identified as oncogenes that can also facilitate 
cancer growth and maintenance (76-78). Recent work from our lab has also 
demonstrated that loss of ERK signaling by small molecule inhibition has both an 
immediate and delayed impact on the transcriptional profile of PDAC cells (79,80). Sears 
and coauthors demonstrated that MYC is regulated directly by ERK phosphorylation at 
Ser-62, and that MYC stabilization is essential for PDAC maintenance (81-83). Therefore, 
ERK activation serves to both directly and indirectly activate pro-growth and pro-survival 
transcriptional programs through key transcription factors. 
1.3.3. ERK IS THE KEY KRAS EFFECTOR 
 Given that 95% of PDAC is driven by a constitutively-activating KRAS mutation, 
evaluation of driver mutations in KRAS-WT PDAC cases may provide insight into the 
conserved mechanisms of PDAC tumorigenesis. Activating mutations in BRAF have been 
shown to both drive PDAC and to be mutually exclusive with KRAS mutations, suggesting 
that constitutive activation of downstream MAPK nodes can phenocopy mutant KRAS 
(84). It is also worth noting that the widely studied BxPC-3 pancreatic cancer cell line, 
which are frequently used as a KRAS WT counterpart to KRAS-mutant PDAC cell lines 
to define KRAS-driven activities, harbors an atypical activating BRAF mutation (85). 
Taken together, these results suggest that nearly all cases of human PDAC, whether they 
are KRAS-mutant or KRAS-WT, are driven by hyperactivation of MAPK signaling through 
RAF-MEK-ERK. 
 An additional line of evidence in favor of ERK as the key KRAS effector in PDAC 
is derived from mouse models of PDAC tumorigenesis. The BRAFV600E activated mutant 
is sufficient to induce PanIN formation in the pancreas of a mouse (86). When TP53 is 
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also lost, BRAF-mutant PanINs progress to adenocarcinoma of the pancreas. These 
results recapitulate found between the KC (KrasLSL G12D/+; Pdx-1-Cre) and KPC (KrasLSL 
G12D/+;Trp53R172H/+;Pdx-1-Cre) mouse models of PDAC, respectively (87). Thus, activation 
of the ERK MAPK cascade alone is sufficient to phenocopy KRAS and drive development 
of fully invasive and metastatic PDAC. 
1.3.4. ERK ACTIVITY IN CANCER DEVELOPMENT AND PROGRESSION 
 KRAS activation through hotspot point mutation is the foundational event in PDAC 
tumorigenesis, and the ERK MAPK pathway is the primary signaling output for mutant 
KRAS (86). Despite the demonstrable importance of ERK MAPK in PDAC and other 
cancer types, activating mutations in EGFR, KRAS, and downstream effectors, such as 
BRAF, are mutually exclusive of one another (84). Additionally, co-mutations in EGFR 
and KRAS are shown to cause senescence and apoptosis, likely due to hyperactivation 
of ERK signaling (88,89). A similar detrimental effect has been observed with BRAF and 
KRAS activating mutations (90). These findings are indicative of the inhibitory impact of  
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Figure 1.5. RAF-MEK-ERK signaling and feedback loops. Activation of RAF-MEK-
ERK signaling also induces upregulation (transcriptional and post-translational) of 
feedback inhibitors of MAPK signaling, which in turns promotes a complex signaling 
environment mediated through ERK. 
 
ERK hyperactivation on cell growth and proliferation, possibly due to increased cellular 
stress responses. 
 RAF-MEK-ERK signaling is often portrayed as a linear pathway with singular 
inputs and outputs. Despite this simplified depiction, the ERK MAPK cascade is subject 
to feedback inhibition at multiple nodes (91). Multiple families of proteins, particularly 
dephosphorylases such as DUSPs, are directly regulated by ERK signaling and remove 
activating phosphate groups from multiple MAPK nodes. Along with other research 
groups, this thesis research showed that inhibition of ERK alone causes rebound increase 
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in pathway activation. This occurred alongside loss of DUSP4 and other negative 
regulators of the MAPK cascade. Recently, the development of a covalent KRASG12C 
inhibitor has shown substantial promise in clinical trials. Despite this success, KRASG12C 
inhibitors may be similarly limited by rebound activation of ERK and other downstream 
effectors. Our lab and other groups have shown ERK reactivation within 24 to 72 hours 
of G12Ci treatment in KRASG12C driven lung, colon, and pancreatic cancer cell lines. ERK 
MAPK reactivation in the presence of a direct inhibitor suggests that signaling through 
this pathway may not be as linear as the field once thought. Additionally, pursuing 
combination targeted therapies may offer the best solution to counter reactivation of key 
pathways in the presence of a single drug. 
1.3.5. RESISTANCE TO TARGETED THERAPY 
PDAC treatment for select patients has evolved from gemcitabine to poly-
chemotherapy regimens with moderate improvement in patient survival (31). Despite 
these advances in chemotherapy for PDAC patients, the prognosis of a patient with 
unresectable disease remains poor and generates a demand for effective, biologically-
driven treatment strategies (34,92). Given the demonstrable dependence of PDAC on 
ERK MAPK signaling, there is excitement about the development of selective MAPK node 
inhibitors, such as EGFR inhibitors (cetuximab, erlotinib), RAF inhibitors (vemurafenib, 
dabrafenib, sorafenib, LY3009120), MEK inhibitors (trametinib, binimetinib) and ERK 
inhibitors (SCH772984, LY3214996, ulixertinib, Fig. 1.6) (93). Initially, MEK1/2 selective 
inhibition with trametinib was first approved for the treatment of melanoma (94). BRAF-
mutant selective inhibitors, such as vemurafenib targeting BRAFV600E, were subsequently 
shown to be effective in a subset of BRAF-mutant melanoma cancers and was also 
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approved (95). ERK inhibitors continue to be studied and developed; ERK may serve as 
a superior therapeutic target due to its position as the terminal node in the canonical 
MAPK pathway and possesses a broad range of targets (55). Both the discovery and 
rapid development of MEK and BRAF inhibitors generated broad interest in MAPK 
targeted therapies, and were shown to be effective alone or in combination in melanoma, 
lung cancer and colon cancer (96-99). 
Despite the approval of select MAPK inhibitors in other cancer types, the 
excitement for MAPK selective inhibitors in KRAS-driven PDAC was tempered by their 
relative lack of efficacy over standard-of-care chemotherapy (100-105). The only cell-
surface receptor target upstream of the MAPK pathway is EGFR, however treatment of 
PDAC tumors with cetuximab, a monoclonal anti-EGFR antibody, yielded no significant 
improvement in patient outcomes (106). KRAS-directed therapies offer promise, but are 
currently limited to KRASG12C mutant PDAC tumors which constitute only ~2% of all PDAC 
cases (107). Importantly, direct, small molecule inhibition of KRAS may be subject to 
similar feedback reactivation as RAF and MEK inhibitors, as previously mentioned. 
Downstream of KRAS, multiple kinases in the MAPK pathway offer promising targets for 
small molecule inhibition in PDAC. The MEK inhibitors trametinib and selumetinib were 
trialed as monotherapy but did not produce a significant shift in clinical outcomes for 
advanced PDAC patients (103,108). Treatment with a MEK inhibitor is also complicated 
by a range of normal tissue dose-limiting toxicities, such as rash, fatigue, diarrhea, 
peripheral edema, and more rarely, cardiac dysfunction (93). Preclinical identification of 
dose-limiting toxicities seen in human clinical trials may not have been possible in murine 
models due to differences in the pharmacokinetics and pharmacodynamics of MEK  
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Figure 1.6. Summary of recent RAF-MEK-ERK targeted therapies. aApproved for the 
treatment of BRAF-mutant melanoma. bApproved for the treatment of pediatric patients 
with NF1 mutant plexiform neurofibromas. cApproved multi-kinase angiogenesis inhibitor. 
dApproved for compassionate use 
 
inhibitors between species (109,110). Small molecule inhibitors of ERK remain under 
evaluation in clinical trials (e.g., ulixertinib; Fig. 1.6), though rarely in single agent 
treatment arms; currently there is no FDA approved ERK-selective inhibitor available. 
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1.4.  THE PATH FORWARD IN PDAC THERAPY 
Perhaps unsurprisingly, single-agent inhibition of various kinases in the MAPK 
pathway did not yield a meaningful impact on clinical outcomes in PDAC. Additionally, 
any single-agent targeted therapy is unlikely to significantly prolong survival in the 
majority of PDAC cases; overcoming this obstacle with combination targeted therapies is 
a central focus of this dissertation (111). While some cancer types seem to have a 
singular dependence on signaling through one driver mutation (e.g. Philadelphia 
chromosome rearrangement in CML), Ozkan-Dagliyan and colleagues identified a 
therapeutic strategy to counter a mechanism whereby KRAS-driven tumors can survive 
single-agent inhibition (80). While inhibition of RAF with a pan-RAF inhibitor is sufficient 
to suppress growth, vertical inhibition of both RAF and ERK synergized to induce 
apoptosis in a majority of cancer cell lines tested. Vertical inhibition of the MAPK pathway 
also suppressed growth of organoid cultures as well as xenograft mouse models of 
PDAC. Bryant and colleagues sought to better understand the metabolic mechanisms 
that PDAC relies on for survival (79). In contrast to published literature, suppression of 
KRAS signaling through the ERK MAPK pathway increased the cell’s dependency on 
autophagy for survival. When ERK inhibition was combined with hydroxychloroquine, an 
inhibitor of autophagy, synergistic induction of apoptosis in PDAC cells was observed. 
They extended these analyses both to organoid and mouse models, which showed a 
promising reduction in tumor growth. Concurrently, Kinsey and colleagues treated a 
patient with PDAC, who had previously failed all conventional chemotherapies, and 
achieved a partial response when treated with trametinib plus hydroxychloroquine (112). 
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This preclinical work has served as the foundation from which multiple clinical trials have 
been launched (NCT04386057, NCT01634893).  
 Immunotherapy has emerged at the forefront of the next generation of treatment 
strategies for a multitude of tumor types (113). Therapeutic antibodies that can block 
CTLA-4 or PD-1 on lymphocytes or PD-L1 expressed on some tumor cells are capable 
of preventing tumors from suppressing the immune response mounted against them 
(114). In the presence of one of these antibodies, candidate tumors will be targeted and 
destroyed by the host immune system. These antibody-based therapies have shown 
efficacy in RAS-driven tumors, such as lung cancer and melanoma (115,116). When 
tested in patients with PDAC, however, less than five percent of patients showed any 
clinical benefit from the therapy (117). To better understand the current inefficacy of 
immunotherapy in PDAC, one group found that the tumor-specific T cell population in 
PDAC is relatively low (118). A low abundance of T-cells, or a lack of responsiveness 
among existing T-cells, could render immuno-checkpoint blockade unable to produce any 
benefit. Additionally, PDAC tumors harbor far more stroma than other cancer types that 
have responded to immunotherapy (119,120). It is possible that the dense stroma of 
PDAC may prevent access of tumor-specific T-cells to target and destroy cancer cells. 
Improving access or reactivity of T-cells in PDAC patients will be a necessary step before 
achieving success with antibody-based immune checkpoint blockade. 
In summary, PDAC remains one of the most difficult types of cancer to treat, with 
limited effective therapies that are currently available. Work from our lab and many others 
over the last three decades has substantially advanced the field’s understanding of the 
genetic and signaling mechanisms that drive PDAC tumorigenesis and tumor 
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maintenance. To date, the majority of developing therapeutic strategies have failed to 
meaningfully impact outcomes in patients this deadly disease. This dissertation will shed 
light on previously undescribed signaling dependencies in KRAS-driven PDAC that may 
lead to the development of novel combination strategies. Additionally, this work will outline 
a vertical combination inhibition strategy that has direct implications for clinical trials. It is 
my hope that this body of work will aid our understanding of the fundamental signaling 





CHAPTER 2 – DEFINING THE KRAS-REGULATED KINOME IN KRAS-MUTANT 
PANCREATIC CANCER 
2.1.  INTRODUCTION  
Pancreatic ductal adenocarcinoma (PDAC) is among the deadliest cancers, with a 
5-year survival rate of 10% (1). Despite significant advances in our understanding of the 
genetic and molecular drivers of PDAC (121), effective targeted therapies are still lacking. 
Current standards-of-care are comprised of conventional cytotoxic drugs (122). 
Mutational activation of the KRAS oncogene is the initiating genetic event and is 
found in 95% of PDAC (107). There is now substantial experimental evidence that KRAS 
is essential for the maintenance of PDAC growth, and consequently, the National Cancer 
Institute has identified the development of anti-KRAS therapeutic strategies as one of four 
major initiatives for the field (123). Recent early-stage clinical findings with direct inhibitors 
of one KRAS mutant, G12C, support the potential clinical impact of an effective KRAS 
inhibitor (124,125). However, while KRASG12C mutations are common in lung 
adenocarcinoma, they comprise only 2% of KRAS mutations in PDAC (45,107). 
Therefore, indirect strategies to block aberrant KRAS signaling remain arguably the best 
approach for the majority of KRAS-mutant PDAC (126). 
One key approach is to inhibit downstream effector signaling. Of the multitude of 
KRAS effectors, at least four are validated drivers of KRAS-dependent PDAC growth (45). 
The best characterized and potentially most crucial is the RAF-MEK-ERK mitogen-
activated protein kinase (MAPK) cascade. That activated Braf can phenocopy mutant 
Kras and, together with Tp53 mutations, drive full development of metastatic PDAC in 
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mouse models supports the key role of the MAPK cascade in driving Kras-dependent 
PDAC growth (86). While the substrates of RAF and MEK kinases are highly restricted, 
ERK1/2 serine/threonine kinase activation can cause direct or indirect phosphorylation of 
a diverse spectrum of more than one thousand proteins (46). Since ERK substrates 
include other protein kinases (e.g., RSK1-4, MNK2 and MSK1/2), ERK activation can 
regulate a highly diverse phosphoproteome (71). However, the specific components are 
context-dependent, and the ERK-regulated phosphoproteome downstream of KRAS in 
PDAC is not well delineated.  
The second best characterized KRAS effector are phosphoinositide 3-kinases 
(PI3K) (47). KRAS activation of PI3K promotes formation of phosphatidylinositol (3,4,5)-
triphosphate, leading to activation of the AKT and mTOR serine/threonine kinases. 
Activation of PI3K-AKT-mTOR signaling has also been observed as a compensatory 
response to ERK inhibition, driving resistance to ERK MAPK inhibitors (82,127). Thus, 
concurrent PI3K inhibition synergistically enhances the anti-tumor activity of ERK MAPK 
inhibitors (86). Other key KRAS effectors include the RAL and RAC small GTPases, that 
activate TBK1 and PAK serine/threonine kinases (45). With their high tractability as 
therapeutic targets, these and other protein kinase components of KRAS effector 
signaling have been pursued as indirect approaches to KRAS inhibition (128). We 
propose that still other kinases may also be of interest as targets in KRAS-mutant PDAC. 
Additionally, a limitation of essentially all targeted anti-cancer therapies is the onset 
of treatment-induced acquired resistance (129,130). In response to pharmacologic 
inhibition of a key cancer driver, cancer cells can induce a complex array of responses 
that functionally compensate for target inhibition. One major mechanism of resistance is 
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loss of the negative feedback signaling that tempers the strength of growth regulatory 
signaling networks (131).  For example, although aberrant ERK activation can drive 
cancer growth, excessive ERK activity is deleterious, causing growth cessation through 
induction of senescence or apoptosis (88,89,132). Therefore, a multitude of ERK-
dependent negative feedback loops exist to dampen ERK activity (133). Thus, upon 
pharmacological inhibition of ERK, loss of ERK-dependent negative feedback leads to 
ERK reactivation to overcome inhibitor action. Similar responses are also seen upon 
inhibition of the PI3K-AKT-mTOR pathway (134).  
An important strategy to improve the long-term efficacy of targeted therapies is the 
elucidation of treatment-induced resistance mechanisms, which can then be used to 
identify drug combinations capable of blocking or even reversing the onset of resistance. 
Unbiased system-wide screening methods applied for this purpose include powerful 
genetic approaches such as CRISPR- or RNAi-mediated loss-of-function or cDNA 
overexpression/activation gain-of-function screens (135). For example, a CRISPR-Cas9 
screen demonstrated that ERK reactivation is a primary mechanism limiting the efficacy 
of KRASG12C inhibitors (136). These findings have guided initiation of ongoing clinical trials 
to evaluate KRASG12C inhibitors in combination with inhibitors that act either upstream 
(e.g., on EGFR) or downstream (e.g., on MEK) of KRAS (clinicaltrials.gov). Similarly, 
Wood et al. applied an activated signaling expression library to identify both known and 
novel mechanisms that drive resistance to ERK MAPK inhibitors (137). In a 
complementary approach, our chemical library screen demonstrated that concurrent 
inhibition of other ERK MAPK components, to block compensatory ERK reactivation, 
synergistically enhanced the efficacy of RAF inhibitors in KRAS-mutant PDAC (80). 
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In light of the key role of kinome reprogramming in driving resistance, it is crucial 
to be able to detect changes in kinase activity and/or expression in response to 
pharmacologic inhibition of an oncogenic signaling driver. Chemical proteomics is a 
particularly powerful experimental technique that enables kinome-wide profiling of these 
changes. One version of this type of assay, MIB/MS, incorporates multiplexed inhibitor 
beads (MIBs), coupled to mass spectrometry (MS) (138). MIBs, comprised of broad-
spectrum kinase inhibitors covalently coupled to Sepharose beads, can be used to 
monitor protein kinase expression and/or activation, where MIB-associated kinases are 
identified by MS. In our initial application of MIB/MS, we identified activation of multiple 
receptor tyrosine kinases (RTKs) in response to MEK inhibitor (MEKi) treatment that may 
drive MEKi resistance in KRAS-mutant breast cancer (139). Accordingly, concurrent 
inhibition of RTKs and MEK more effectively impaired transformed and tumor growth in 
vitro and in vivo than MEKi alone. We have also applied MIB/MS to identify novel inhibitors 
of chemotherapy-resistant PDAC (140), to pinpoint tumor cell-type specific responses to 
the clinical kinase inhibitor dasatinib in diffuse large B cell lymphoma (141), and to identify 
EGFR/HER2 activation of the MEK5-ERK5 MAPK cascade as compensatory response 
to ERK1/2 inhibition, which drives resistance to ERK inhibitor treatment by stabilizing the 
MYC oncoprotein (81). 
In the present study, we hypothesized that a system-wide delineation of KRAS-
regulated kinases can identify therapeutic targets that may not have been considered 
based on our current knowledge of KRAS effector signaling networks. We speculated that 
KRAS may require additional kinases beyond the classical RAF-MEK-ERK and PI3K-
AKT-mTOR effector pathways to promote its transforming functions, and that these would 
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be downregulated upon KRAS depletion. In contrast, we anticipated that yet other kinases 
would be upregulated as compensatory responses to this depletion. Thus, identification 
of both upregulated as well as downregulated kinases may establish novel targets for 
anti-KRAS therapies. We therefore applied the kinome-wide MIB/MS assay to elucidate 
an unbiased profile of the KRAS-dependent kinome in PDAC. Our strategy further 
elucidates the complex spectrum of protein kinases functionally linked to aberrant KRAS 
activation and identifies unanticipated signaling vulnerabilities and potential therapeutic 
approaches for PDAC. 
 
2.2.  RESULTS  
2.2.1  KRAS SUPPRESSION ALTERS THE ACTIVITY OF DIVERSE KINASES IN 
PDAC 
Although oncogenic KRAS effector signaling activates the ERK MAPK cascade 
and other protein kinases, we speculated that the full spectrum of KRAS-regulated protein 
kinases remained to be elucidated. To gain a full understanding of the KRAS-dependent 
kinome in KRAS-mutant PDAC, we suppressed KRAS expression in a panel of six KRAS-
mutant PDAC cell lines using validated short interfering RNA (siRNA) (Fig. A1 A) (82). 
After 72 hours, a time point at which compensatory changes in the kinome have been 
initiated in response to loss of KRAS (80), cell lysates were processed for MIB/MS label-
free proteomics to monitor kinome-wide changes in activity and/or expression (Fig. A1 B). 
Our approach detected a total of 227 kinases of sufficient abundance for quantification in 
one or more PDAC cell lines (Fig. A1 C). As expected, given the genetic heterogeneity of 
PDAC tumors, there was significant heterogeneity in the kinase profile of each cell line 
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(Fig. A1 C). Interestingly, the quantified kinases were upregulated and downregulated to 
the same degree (63 and 62 kinases, respectively; Fig. A1 D). Across all six lines, we 
identified 15 kinases that were significantly upregulated and 13 that were downregulated 
in common (Fig. 2.1 A and Fig. A1 E).  
To determine if the deregulated kinases represented specific subgroups, we 
applied the UniProt kinase classification annotation that is based in part on catalytic 
domain sequence identity and in part on biological function (Fig. A1 F). Notably, although 
the downregulated kinases did not share much sequence identity (7/13 or 53.8% were 
"Other" kinases versus 32/227 or 14.1% of all detected kinases) (Fig. A1, F and G), nearly 
all have established roles in regulating cell cycle transitions, particularly through mitosis 
(e.g., Aurora kinase A (AURKA), CHK1 (CHEK1), WEE1) (table A1). 
In contrast, the upregulated kinases were enriched in tyrosine kinases (TK) and 
tyrosine-like kinases (TKL) (7/15; 46.7%), which comprised 23.3% (53/227) of all detected 
kinases (Fig. A1, F and H). Strikingly, a driver role in cancer has been attributed to all 15 
upregulated kinases (e.g., ERK1 (MAPK3) (table A2), SRC and JAK), supporting the 
strong likelihood that upregulated kinases serve compensatory growth-promoting roles 
that attenuate the deleterious consequences of KRAS deficiency. Supporting this 
possibility, we showed recently that ERK inhibitor treatment of PDAC cell lines caused 
upregulation of SRC activity and that concurrent SRC inhibition further enhanced ERK 
inhibitor-mediated growth suppression (81). 
To complement these kinome analyses, we used reverse phase protein array 
(RPPA) pathway activation mapping (142) to evaluate the signaling consequences of 72 
hours of siRNA-mediated KRAS suppression (Fig. A1 I). The RPPA panel included 149 
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phospho-specific and total antibodies to monitor the activation state or expression, 
respectively, of signaling proteins involved in regulation of cell proliferation, survival, 
motility, etc. (table A3). As expected, phosphorylated and total ERK proteins were 
increased, consistent with loss of ERK-dependent negative feedback signaling (Fig. A1 
J). Nevertheless, phosphorylation of key ERK substrates important for driving ERK-
dependent growth (RSK, ELK1 and MYC) remained strongly suppressed (Fig. A1 J). 
Thus, similar to our previous observations with pharmacologic inhibition of ERK (82,127), 
the level of ERK phosphorylation did not reliably reflect the level of ERK signaling. 
Among the decreases in expression and/or activation of multiple proteins involved 
in cell cycle regulation were a dramatic reduction in the mitotic marker, phosphorylated 
histone H3 at Ser10, as well as loss of the proliferation markers Ki67 and phosphorylation 
of RB at Ser780 (Fig. A1 I). RPPA analyses also revealed alterations in expression (e.g., 
BIM) or phosphorylation (e.g., FADD Ser194) of proteins associated with apoptosis, a well-
described consequence of loss of mutant KRAS function (143). Finally, reductions were 
also detected in phosphorylated S6 ribosomal protein, involved in regulation of protein 
translation (Fig. A1, I and J). Thus, KRAS loss is associated with the activation and 
inactivation of diverse growth regulatory signaling pathways.  
 We next wanted to determine the contribution of the ERK MAPK effector pathway 
to the regulation of the KRAS-dependent kinome. We treated the same panel of six PDAC 
cell lines for 24 hours with the ERK1/2-selective inhibitor SCH772984 (ERKi) (144), then 
performed MIB/MS analyses. Quantification of kinases revealed that, of 264 kinases 
detected, 26 were significantly altered in expression and/or activity across all six cell lines 
(Fig. 2.1 B and Fig. A1 K). Of these, seven were upregulated and 19 were downregulated. 
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As expected, ERK1 and ERK2 (MAPK3 and MAPK1) activities were by far the most 
strongly downregulated upon ERKi treatment (Fig. 2.1 B). 
Importantly, many of the same kinases were altered upon pharmacological 
inhibition of ERK and upon genetic suppression of KRAS. Nine of the kinases 
downregulated by siKRAS (Fig. 2.1 A) were also downregulated by ERKi (Fig. 2.1 B), 
including many involved in progression through mitosis. Similarly, DDR1, JAK1 and SRC 
were among kinases upregulated by both siKRAS and ERKi. Spearman’s rank correlation 
analysis of siKRAS- and ERKi-mediated kinome changes revealed significant overlap 
between the 222 kinases detected in both datasets (rho = 0.434, p = 1.77e-11) (Fig. 2.1 
C). The significant overlap in kinase signaling changes following either ERK inhibition or 
KRAS suppression is consistent with the predominant role of ERK MAPK in supporting 
KRAS-dependent PDAC growth (82,86). We conclude that the observed kinome changes 
conferred by genetic suppression of KRAS were mediated in large part through loss of 
ERK1/2 signaling.  
2.2.2. INHIBITION OF DDR1, BUT NOT JAK, IMPAIRS PDAC GROWTH 
 We speculated that upregulated kinases, in particular those with known driver roles 
in cancer, may represent compensatory activities in response to loss of KRAS. Among 
the kinases upregulated following KRAS knockdown, JAK1 was notable because the 
JAK1-STAT3 signaling axis has been shown to be important for PDAC tumorigenesis and 




Fig. 2.1. KRAS knockdown induces kinome-wide alterations primarily through ERK. 
(A) Heatmap summarizing kinases that were significantly altered (p adjusted < 0.05) after 
72 hours of non-specific control siRNA (siNS) or siKRAS treatment, followed by MIB/MS 
enrichment. Lysates were collected from six KRAS-mutant PDAC cell lines [SW 1990, 
MIA PaCa-2, PANC-1, HPAC, AsPC-1 and Panc 10.05]. Unsupervised clustering was 
used to visualize distance metrics of log-transformed fold change values for significant 
kinases following ANOVA analysis. Kinase class annotations were added from UniProt 
classification and index of kinases. (B) Volcano plot showing results of significance testing 
after ANOVA [y-axis] with the log-transformed mean fold change in ERKi (SCH772984) 
over DMSO control (24 hours). Significant kinases are colored red [increased] or blue 
[decreased] if p-value is significant (p.adj < 0.05) following Benjamini-Hochberg correction 
(n = 3). (C) Spearman’s rank correlation analysis of siKRAS/siNS samples versus 
ERKi/DMSO samples, 222 kinases were shared among dataset. 
 
showed that four of five cell lines displayed significant (p-adjusted < 0.05) activation of 
STAT3 following KRAS knockdown (Fig. 2.2 A), as indicated by phosphorylation at the 
JAK family site Tyr705 (147). Phosphorylation of STAT3 at Ser727, which is not a JAK site 
but a possible ERK or JNK target (148), also increased in a cell line dependent manner 
(148), as did phosphorylation of STAT1 and STAT5. STAT6 phosphorylation at Tyr641 
was the most consistent of all, in agreement with our previous finding of significant 
upregulation of JAK signaling through this site upon blockade of the MAPK cascade (80). 
To determine whether JAK1-STAT3 was similarly affected, we directly inhibited signaling 
through ERK MAPK. In the presence of the ERK1/2 inhibitor SCH772984, STAT3 
phosphorylation (Tyr705) was increased in Pa02C and Pa16C and unchanged in MIA 
PaCa-2 and PANC-1 cells (Fig. 2.2 B). We conclude that upregulation of JAK1-STAT 
signaling induced by KRAS suppression was mediated through loss of ERK effector 
signaling. 
 We next determined if upregulation of JAK signaling is a compensatory response 
that can offset the growth suppression induced by loss of KRAS or ERK. We utilized three 
different JAK inhibitors, targeting JAK1 (filgotinib), JAK1/2 (ruxolitinib), and JAK1/3 
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(tofacitinib) (149). All three JAK inhibitors reduced STAT3 phosphorylation in a dose-
dependent manner, though PANC-1 cells were resistant to filgotinib (Fig. A2 A). JAK 
inhibitors alone had no effect on anchorage-dependent proliferation of four PDAC cell 
lines (Fig. 2.2 C), indicating the lack of dependence on JAK when KRAS is present. 
Further, co-treatment of four PDAC cell lines with each JAK inhibitor in combination with 
ERKi revealed that concurrent JAK inhibition did not further enhance ERKi-mediated 
growth suppression (Fig. 2.2 D and Fig. A2 B). Thus, while JAK activity was increased 
upon loss of KRAS, subsequent inhibition of JAK family kinases did not potentiate the 
antiproliferative effect of direct ERK inhibition in PDAC. 
 To further investigate whether upregulated kinases could compensate for the loss 
of KRAS, we next evaluated the discoidin domain receptor 1 (DDR1). DDR1 is a receptor 
tyrosine kinase that transduces collagen-mediated proliferative signaling from stroma-
associated extracellular matrix (150), and pharmacologic inhibition of DDR1 function 
impaired PDAC growth in vivo in a mouse model (151,152). Given our identification of 
DDR1 as a kinase that was upregulated upon KRAS suppression in PDAC cell lines in 
vitro (Fig. 2.1 A), we sought to determine whether upregulated DDR1 could also serve as 
an increased pro-proliferative signal in a KRAS-dependent, tumor cell-intrinsic manner. 
We first determined that both KRAS knockdown and ERK inhibition increased DDR1 
protein levels (Figs. 2.2, E and F, respectively). Additionally, ERK inhibition increased 
phosphorylation of the DDR1 effector PYK2 (pPYK2, Fig. 2.2 F) at the DDR1 
phosphorylation site, Tyr402 (152), in three of four cell lines. Thus, we confirmed that DDR1 
signaling is responsive to KRAS-ERK signaling. 
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To evaluate the possibility that DDR1 upregulation is a compensatory response to 
the growth suppression mediated by loss of KRAS-ERK, we first determined if inhibition 
of DDR1 alone is deleterious to growth. We treated PDAC cells with 7rh, a potent and 
selective ATP-competitive DDR1 inhibitor (153) and observed comparable IC50 
(suppression of PYK2 Tyr402) and GI50 values, supporting on-target growth inhibition (Fig. 
2.2 G and Fig. A2, C and D) (153). We found that concurrent inhibition of DDR1 and ERK 
caused dose-dependent loss of cell viability (Fig. 2.2 H and Fig. A2 E), ranging between 
additivity and synergy, according to BLISS analysis (Fig. A2 F). Overall, our evaluation of 
kinases upregulated by siKRAS or ERKi has revealed a novel compensatory mechanism 
in DDR1 and a surprising dispensability of JAK signaling for PDAC anchorage-dependent 
cell growth and viability. 
 
2.2.3. LOSS OF KRAS OR MAPK SIGNALING CAUSES LOSS OF G2/M AND DNA-
DAMAGE RESPONSE KINASES 
In order to better understand the relationships among downregulated kinases 
following KRAS genetic suppression, we performed STRING analysis on significantly 
altered kinases (Fig. 2.3 A). Eleven of the 13 downregulated kinases formed a tight 
interaction node, with only EPHA2 and TNIK involved in distinctly separate signaling 
networks. Next, we utilized Panther Gene Ontology to determine the relevant biological 
processes (Fig. 2.3 B). Given that our queried genes exclusively encode protein kinases, 
it was expected that “protein phosphorylation” was the top gene set identified. 
Additionally, a main function of KRAS signaling through the ERK cascade is to promote 
cell cycle progression through G1 by transcriptional stimulation of CCND1 (encoding 
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Figure 2.2. DDR1, but not JAK, is a therapeutic vulnerability in PDAC. (A) Reverse 
phase protein array (RPPA) of five PDAC cell lines following 72 hour siRNA knockdown 
of KRAS. Values are log2-transformed fold change with respect to median siNS value (n 
= 4). (B) Immunoblot of PDAC cell lines following treatment with vehicle or ERKi 
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(SCH772984) for 24 hours (n = 4). Ratios of pSTAT3/STAT3 are reported below the blot. 
(C) Proliferation of PDAC cells (5 days) following treatment with JAK1i (filgotinib), JAK1/2i 
(ruxolitinib), or JAK1/3i (tofacitinib) at various concentrations. Cell numbers at endpoint 
were normalized to vehicle-treated control (100% growth) for each cell line. Curves were 
fit using a 4-parameter log-logistic function and the drm package in R (n = 3). (D) 
Proliferation of Pa02C cells (5 days) following combination treatment with JAK1i, JAK1/2i, 
or JAK1/3i and ERKi (SCH772984) at various concentrations. Cell numbers were 
normalized and curves were fit as in panel (C) (n = 3). (E) Immunoblot of PDAC cell lines 
following treatment with non-specific (NS) or KRAS-targeting (K1, K2) siRNA constructs 
for 72 hours. Relative DDR1 levels are indicated below the blot (total DDR1 normalized 
for loading differences as determined by β-actin). “Short” and “long” indicate shorter and 
longer exposures of the same membrane, respectively (n = 3). (F) Immunoblot of PDAC 
cell lines following treatment with vehicle or ERKi (SCH772984) for 24 hours (n = 4). 
Relative pPYK2 levels (vs. DMSO) in each cell line are indicated below the blot. (G) 
Proliferation of PDAC cells (5 days) following treatment with DDR1i (7rh) at various 
concentrations. Cell numbers were normalized and curves were fit as in panel (C) (n = 3). 
(H) Proliferation of Pa02C cells (5 days) following combination treatment with DDR1i (7rh) 
and ERKi (SCH772984) at various concentrations. Cell numbers were normalized and 
curves were fit as in panel (C) (n = 3). 
 
 
cyclin D1), leading to CDK4/6-dependent phosphorylation and inactivation of the RB 
tumor suppressor (154). Thus, it was unexpected that we observed that multiple 
downregulated kinases are involved in G2/M checkpoint and mitotic functions (table A1). 
Consistent with KRAS promotion of G1/S cell cycle progression, flow cytometry analyses 
in four PDAC cell lines showed that KRAS knockdown caused an increase (14-24%) in 
cells in G1 and a corresponding decrease (15-22%) in cells in S, albeit no significant 
change in the G2/M cell population (Fig. A3, A and B). 
Interestingly, the 13 downregulated kinases identified in the chemical proteomics 
screen were also enriched for roles in DNA damage checkpoints and maintaining DNA 
integrity (Fig. 2.3 B). We therefore queried our RPPA data for genes related to both DNA-
damage repair and cell cycle, which revealed a mixed response to KRAS knockdown (Fig. 
A3 C). Cyclin D1 levels were reduced whereas cyclin A levels either increased or 
remained unchanged. Additionally, phosphorylation of ATM at Ser1981 increased whereas 
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phosphorylation of ATR at Ser428 was diminished in all cell lines. Taken together, these 
changes suggest that loss of KRAS causes a loss of specific cell cycle promoting factors. 
Additionally, the changes in ATM and ATR phosphorylation, though divergent, suggest 
that KRAS knockdown may induce genomic stress that could also contribute to cell cycle 
factor changes.  
While significant literature points to the importance of KRAS and ERK in promoting 
G1 progression, fewer studies outline the role of mutant KRAS in maintaining DNA 
damage checkpoint kinases such as WEE1, PKMYT1, and CHEK1 (Fig. 2.3 A) (155-157). 
We confirmed that KRAS knockdown caused loss of WEE1, CHEK1, and PLK1 proteins 
(Fig. 2.3 C). A recent transcriptome analysis of PDAC identified WEE1 as a potential 
therapeutic target (158). Therefore, we focused our further investigations on this DNA-
damage checkpoint kinase. 
To address a basis for the loss of WEE1 protein caused by KRAS suppression, we 
first examined WEE1 protein stability. Treatment with the proteasome inhibitor MG132 
prevented WEE1 degradation more robustly in KRAS-suppressed samples as compared 
to control samples. This suggests that the absence of KRAS signaling destabilizes WEE1 
protein (Fig. 2.3, D and E, and Fig. A3, D and E). We hypothesized that KRAS, through 
its extensive transcriptional network, may also regulate WEE1 transcription. Indeed, RT-
PCR analyses demonstrated that loss of KRAS decreased WEE1 transcripts in all five 
cell lines tested (Fig. 2.3 F). We conclude that WEE1 protein stability and transcription 
are both reduced upon KRAS suppression. 
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2.2.4.  INHIBITION OF WEE1 KINASE INDUCES GROWTH ARREST AND 
APOPTOSIS IN PDAC CELLS 
The loss of WEE1 observed upon KRAS knockdown-induced growth suppression 
suggests that WEE1 activity may contribute to KRAS-mutant PDAC proliferation and 
therefore that direct inhibition of WEE1 may suppress KRAS-mediated cell proliferation. 
To address this possibility, we first treated cells with siRNA targeting WEE1 and verified 
that loss of phosphorylation of the WEE1 substrate, CDK1 (Tyr15; pCDK1) was a reliable 
biomarker for loss of WEE1 function in PDAC (Fig. 2.4 A). Similarly, treatment with the 
WEE1-selective clinical candidate inhibitor adavosertib/AZD1775 (WEE1i) dose-
dependently reduced CDK1, with >80% reduction at 100 nM (Fig. 2.4 B and Fig. A4 A). 
Additionally, WEE1i treatment inhibited the proliferation of all six PDAC cell lines 
evaluated, with GI50 values (38 to 168 nM) comparable to the IC50 values (< 100 nM), 
supporting on-target growth suppression (Fig. 2.4 C and Fig. A4, A to C). Similar growth 
inhibitory activities of WEE1i were also seen in clonogenic colony formation assays (Fig. 
2.4 D). Consistent with previous studies (159), we found that pharmacological inhibition 
of WEE1 led to accumulation in S- and G2/M-phases of the cell cycle (Fig. 2.4 E, and Fig. 
A4, D and E). Additionally, WEE1i caused an approximately fivefold increase in apoptotic 
cells (Fig. 2.4 F). Taken together, these results support our conclusion that 
downregulation of WEE1 contributes to the growth suppression induced by loss of KRAS. 
2.2.5. COMBINED INHIBITION OF WEE1 AND ERK CAUSES SYNERGISTIC 
GROWTH ARREST AND APOPTOSIS 
Paradoxical activation of ERK has been reported previously in response to 
pharmacological inhibition of CHK1 (160,161), another protein kinase involved in 
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Figure 2.3. Loss of KRAS/MAPK signaling contributes to loss of G2/M and DNA-
damage response kinases. (A) Downregulated kinase identifiers from the MIB-MS 
screen (Fig. 1A) were used as input into the STRING database, and the resulting bitmap 
was downloaded. Edges (lines between nodes) represent known or predicted protein-
protein associations. (B) Downregulated kinase identifiers were used as input for Gene 
Ontology enrichment analysis of biological processes (162,163). Selected enriched gene 
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sets (p-adjusted < 0.05) are displayed along the y-axis, with the –log10-transformed p-
values displayed along the x-axis. (C) Immunoblot analysis of PDAC cell lines following 
treatment with non-specific (NS) or KRAS-targeting (K1, K2) siRNA constructs for 72 
hours (n = 4). (D) Protein stability of WEE1 as determined by 4-hour MG132 proteasomal 
inhibitor treatment following 26-hour treatment with non-specific (NS) or KRAS-targeted 
(K1, K2) siRNA constructs (n = 3). (E) Quantification of blot in panel (D). Densitometry 
estimates were first normalized for loading efficiency using β-actin. Next, each sample 
value was calculated as a ratio of MG132+/MG132- and paired by siRNA construct. (F) 
qRT-PCR was performed on five PDAC cell lines following 72-hour treatment with non-
specific (NS) or KRAS-targeted (K1, K2) siRNA. Relative expression [y-axis] of WEE1 
transcripts was measured (n = 3). 
 
 
checkpoint inhibition in response to DNA damage. To determine if there is a similar 
response to WEE1 inhibition, we examined pERK in PDAC cell lines treated with 
adavosertib for 48 hours. We observed a dose-dependent increase in pERK in all treated 
lines (Fig. 2.4 B and Fig. A4, A and F). Evaluation at shorter time-points showed that 
WEE1 activity (pCDK1) was rapidly suppressed after 6 to 24 hours, whereas increased 
pERK was seen only after 48 hours (Fig. A4 C). This delayed onset is consistent with 
compensatory reactivation of ERK to offset WEE1 inhibition-induced growth suppression. 
To address this possibility, we determined whether concurrent ERK inhibition enhances 
WEE1i growth inhibitory activity. We treated a panel of cell lines with both WEE1i and the 
ERK1/2-selective inhibitor SCH772984 (ERKi), which resulted in fewer colonies than 
treatment with either inhibitor alone (Fig. 2.5 A). BLISS synergy analysis revealed that the 
combination exhibited synergistic activity in three cell lines (MIA PaCa-2, Pa16C and 
Pa02C), and additive activity in three cell lines (Fig. 2.5, B and C). Combining low-dose 
ERK inhibition (IC25-IC50) with WEE1 inhibition also synergistically induced apoptosis in 
four of four cell lines (Fig. 2.5, D and E). We conclude that concurrent inhibition of WEE1 
and ERK synergistically induces both growth arrest and apoptosis in PDAC cell lines. 
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Figure 2.4. Inhibition of WEE1 kinase induces growth arrest and apoptosis in PDAC 
cells. (A) Immunoblot analysis of PDAC cell lines following treatment with non-specific 
(NS) or WEE1-targeting (W1-1, W1-2) siRNA for 24 or 48 hours (n = 3). (B) Immunoblot 
analysis of Pa02C cells following treatment with WEE1i for 48 hours (n = 4). (C) 
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Proliferation of PDAC cells following treatment for 5 days with WEE1i (adavosertib) at 
various concentrations. Cell numbers at endpoint were normalized to vehicle-treated 
control (100% growth) for each cell line. Curves were fit using a 4-parameter log-logistic 
function and the drm package in R (n = 3). (D) PDAC cells were plated at low density to 
allow for clonogenic growth and various concentrations of WEE1i were added. After 10 
days, plates were stained with crystal violet and colonies were imaged (n = 4). (E) Cells 
were treated with vehicle or adavosertib (100 nM for Pa02C, 200 nM for Pa16C) for 24 
hours, then fixed and stained with propidium iodide. Flow cytometry quantification of cell 
cycle populations is shown for two representative cell lines (n = 3). (F) Annexin V-FITC 
staining followed by flow cytometry in PDAC cell lines after 72-hour treatment with 500 
nM WEE1i (n = 4). 
 
2.2.6.  INHIBITION OF WEE1+ERK1/2 ARRESTS GROWTH OF PDAC ORGANOIDS 
Three-dimensional (3D) patient-derived PDAC organoids maintained in Matrigel 
are believed to better model the therapeutic response of PDAC patients than cells grown 
in two-dimensional (2D) culture (17,164). Therefore, we next evaluated the impact of 
concurrent WEE1 and ERK inhibition on proliferation of KRAS-mutant PDAC organoid 
cultures. The combination of inhibitors caused organoids to collapse and shrink more than 
either inhibitor alone (Fig. 2.6 A, and Fig. A5, A and B). Concurrent WEE1 and ERK 
inhibition caused additive or synergistic effects on viability, depending on doses (Fig. 2.6, 
B and C). Taken together with anchorage-dependent growth assays, we conclude that 
concurrent ERKi treatment to block compensatory ERK activation can enhance WEE1 
inhibition-mediated growth suppression.  
 
2.3.  DISCUSSION  
It is now well-appreciated that the effectiveness of pharmacologic inhibition of key 
cancer drivers is offset by the induction of compensatory activities (129,130). Therefore, 
identification of treatment-induced compensatory mechanisms can guide the 
development of combination approaches to better achieve long-term and durable clinical 
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Figure 2.5. Combined inhibition of WEE1 and ERK induces growth arrest and 
apoptosis. (A) PDAC cells were plated at low density and various concentrations of 
WEE1i (adavosertib) and/or ERKi (SCH772984) were added to the media. Cells were 
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permitted to grow for 10 days to allow for clonogenic growth. Plates were then stained 
with crystal violet and imaged (n = 3). (B) Proliferation of PDAC cells following treatment 
for 5 days with WEE1i (adavosertib) and ERKi (SCH772984) at various concentrations in 
combination. Cell numbers at endpoint were normalized to vehicle-treated control (100% 
growth) for each cell line. Curves were fit using a 4-parameter log-logistic function and 
the drm package in R (n = 4). (C) BLISS Synergy scores were calculated using the 
proliferation effect sizes from panel (B). Scores < 1 indicate synergy (red), scores = 1 
indicate additivity (white), and scores > 1 indicate antagonism (blue) (n = 4). (D) Annexin 
V-FITC staining followed by flow cytometry in PDAC cell lines after 72-hour treatment with 
WEE1i. Quantification of apoptosis at each dose combination is displayed for the 
indicated cell lines (n = 4). (E) BLISS Synergy scores were calculated using the 
proliferation effect sizes from panel (D). Scores as for panel (C), representative heatmaps 
are shown (n = 4). 
 
responses. The recent development of direct inhibitors of KRAS (124,125) has made it 
even more critical to understand the compensatory activities that can drive resistance to 
KRAS suppression. In the present study, we applied an activity-dependent chemical 
proteomics strategy, MIB/MS, to profile the KRAS-dependent kinome in KRAS-mutant 
PDAC. We identified a diverse spectrum of kinases that were downregulated or 
upregulated in response to KRAS depletion; many of these had not previously been 
associated with KRAS effector signaling. We speculated that both groups of kinases may 
be effective therapeutic targets, with upregulated kinases representing compensatory 
mechanisms that drive resistance to KRAS suppression. We identified upregulation of 
DDR1 as one such mechanism and showed that DDR1 inhibition suppressed the growth 
of KRAS mutant PDAC lines. Conversely, our characterization of one downregulated 
kinase, WEE1, showed that this DNA damage checkpoint inhibitor can also serve as a 
therapeutic target. Our study demonstrates the utility of kinome-wide profiling to identify 
novel strategies for targeting KRAS-mutant PDAC. 
Our application of the MIB/MS proteomics screen identified a spectrum of kinases 
that were down- or upregulated upon acute KRAS suppression. We detected a total of 
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Figure 2.6. Inhibition of WEE1+ERK1/2 arrests growth of PDAC organoids. (A) hM1A 
PDAC organoids were seeded for three days in Matrigel and organoid maintenance 
factors, followed by treatment for 10 days with ERKi or WEE1i or the combination. 
Representative images are shown; scale bar is equivalent to 200 µm (n = 4). (B) 
Quantification of CellTiter-Glo 3D cell viability assay in organoids at single dose 
combination from (A). (C) Organoids from (A) were quantified using CellTiter-Glo 3D cell 
viability assay across a range of WEE1i (adavosertib) and ERKi (SCH772984) doses. 




227 kinases in one or more of the six KRAS-mutant PDAC cell lines analyzed. Of these, 
125 (55%) were altered in activation and/or expression in one or more lines upon KRAS 
suppression, underscoring the diverse consequences that aberrant KRAS function 
confers upon the human kinome. It is likely that even this is a substantial underestimate: 
the human kinome encodes over 500 protein kinases. Some kinases were not detected 
here because they are not recognized by any one of the six broad-spectrum kinase 
inhibitors used in the affinity purification step; others were not detected due to low or lack 
of expression in pancreatic cancer (165).  
Further, although the genetic landscape of PDAC is dominated by the frequent 
occurrence of alterations in only four genes (KRAS, TP53, CDKN2A and SMAD4), the 
majority of genetic alterations are found at frequencies of less than 5% (166). Of the 125 
KRAS-deregulated kinases, only 28 (22%) were altered across all six KRAS-mutant 
PDAC lines. This observed heterogeneity is thus consistent with the genetic 
heterogeneity of PDAC, and highlights the distinct and significant impact that co-occurring 
mutations may have on KRAS function, and, consequently, on response to specific 
therapies.  
We observed significant overlap of the kinase activity/expression changes caused 
by acute genetic suppression of KRAS compared with those caused by pharmacologic 
inhibition of ERK. Nine of 13 KRAS-downregulated kinases and four of 15 KRAS-
upregulated kinases were also altered upon ERK inhibition. That we observed a dominant 
role of the ERK MAPK cascade in regulating the KRAS-dependent kinome is consistent 
with the critical role of this protein kinase cascade in driving KRAS-dependent PDAC 
growth. Nevertheless, many of the 28 KRAS-regulated kinases are not known to be 
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directly associated with ERK signaling. Only eight (CKIIε, CDK1, CHK1, ERK1, EPHA2, 
SRPK2, TNIK and TTK) are listed in a recent compilation of direct or indirect ERK 
substrates from 14 different phosphoproteomic studies (46). However, it is still possible 
that some of the other 20 KRAS-regulated kinases are ERK substrates. The compilation 
includes no studies performed in PDAC. In our ongoing phosphoproteomic analyses of 
ERK-dependent phosphorylation in PDAC, we have identified numerous potential direct 
or indirect ERK substrates that have not been identified previously. Finally, none of the 
28 kinases identified in the present study are listed in the GSEA KRAS gene signature, 
indicating that many of the kinases we detected are altered in activity rather than by gene 
expression. 
Finally, some observed alterations may be indirect rather than associated 
specifically with KRAS signaling. For example, reduced kinase expression may be a 
consequence of the incomplete G1 arrest caused by KRAS suppression. NEK2 is 
undetectable during G1, but accumulates progressively throughout S phase, reaching 
maximal levels in late G2 (167). 
Our working hypothesis for this study was that the kinases that are upregulated 
upon KRAS suppression would be distinct from those typically utilized by KRAS for its 
transforming activities. Instead, it is now well-established that compensatory kinome 
reprogramming occurs upon pharmacologic inhibition of RAF and PI3K signaling 
(133,134). We hypothesized that loss of KRAS signaling would similarly induce 
compensatory kinome reprogramming, such that the upregulated kinases would enable 
maintenance of the transformed phenotype. Consistent with this possibility was the 
significant enrichment of upregulated tyrosine kinases, a class that includes many 
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oncogenic kinases (e.g., EGFR, HER2, etc.). To evaluate this possibility, we selected two 
kinases, JAK1 and DDR1, for validation analyses. Since there is evidence that JAK1 can 
act as a cancer driver in multiple cancer types (168), we were surprised that 
pharmacologic inhibition of JAK1, either alone or together with ERK inhibition, did not 
negatively impact PDAC growth. This finding emphasizes that the potential therapeutic 
value of an upregulated or hyperactivated kinase requires functional validation, not simply 
evidence of increased expression or activity. 
In contrast to JAK1, we verified that pharmacological inhibition of DDR1 alone or 
in combination with an ERK inhibitor caused additive or synergistic growth suppression 
of PDAC cell lines. To date, there has been limited effort in the pursuit of DDR1 as a 
therapeutic target in PDAC and there are no clinically tractable DDR1-specific inhibitors. 
However, the DDR1-selective pharmacological inhibitor 7rh, together with chemotherapy, 
impaired tumorigenic growth of PDAC cell lines (152). In a complementary study, genetic 
ablation of Ddr1 in the KPC (KrasG12D/+; Tp53R172/+) mouse model of PDAC impaired 
metastatic tumor growth (151). Finally, a recent kinome profiling screen using a different 
experimental method than MIB/MS demonstrated upregulation of DDR1 expression in 
patient-derived PDAC cell lines (169). In agreement, we observed that direct 
pharmacologic inhibition of DDR1 with the small molecule inhibitor 7rh suppressed PDAC 
cell proliferation in vitro. Additionally, we observed synergistic reduction in proliferation 
when we combined the DDR1 inhibitor with the ERK1/2-selective inhibitor SCH772984, 
supporting further evaluation of this combinatorial therapeutic strategy. 
The downregulated kinases were enriched (11 of 13) in kinases that modulate cell 
cycle progression, particularly processes involved in mitosis. Inhibition of some of these 
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individual kinases are sufficient to impair cancer growth, indicating that KRAS regulates 
growth through a multitude of mechanisms. For example, polo-like kinase (PLK1) has 
been identified as a synthetic lethal interactor with mutant RAS (170). We showed 
previously that pharmacologic inhibition of TTK impaired PDAC growth (171). In 
agreement with previous studies (166,172), we showed here that inhibition of WEE1 
suppresses PDAC growth. Additionally, we found that concurrent ERK inhibition, to 
counter the compensatory ERK activation associated with WEE1 inhibition, further 
enhanced WEE1i growth-inhibitory activity. The WEE1i adavosertib is currently being 
evaluated alone or in combination with other anti-cancer therapies in 20 active or 
recruiting clinical trials, including one in pancreatic cancer (NCT02194829, accessed Feb. 
22, 2021). 
In summary, the MIB/MS chemical proteomics strategy provides a powerful 
experimental approach to delineate a more complete understanding of the KRAS-
dependent kinome, implicating kinases not identified by other methods. We additionally 
showed that both downregulated and upregulated kinases upon loss of KRAS represent 
potential therapeutic targets for PDAC treatment. Our findings also further establish 
mechanisms by which the ERK MAPK effector pathway drives KRAS-dependent PDAC 
growth, through regulation of multiple distinct regulators of cell cycle progression, 
particularly mitosis. Finally, that KRAS suppression caused upregulation of a diverse 
spectrum of functionally distinct kinases underscores the need to develop combination 
inhibitor therapies to thwart treatment-induced kinome reprogramming, that will result in 
acquired resistance and limit the long-term efficacy of mutant-specific KRAS inhibitors. 
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2.4.  MATERIALS AND METHODS 
2.4.1. CELL CULTURE 
Cell lines were obtained from the American Type Culture Collection (AsPC-1, 
Panc10.05, SW-1990, MIA PaCa-2, PANC-1, HPAC and HPAF-II) or were a gift from J. 
Fleming at MD Anderson Cancer Center (Pa01C, Pa02C, Pa14C and Pa16C). Cells were 
maintained in either Dulbecco’s minimum essential medium (DMEM) (Gibco, 11995-065; 
MIA PaCa-2, PANC-1, HPAC, HPAF-II, Pa01C, Pa02C, Pa14C and Pa16C) or RPMI-
1640 (Gibco; AsPC-1, Panc 10.05 and SW-1990) supplemented with 10% fetal bovine 
serum (Sigma-Aldrich), penicillin and streptomycin (Sigma-Aldrich). All cell lines were 
short-tandem repeat (STR)-profiled to confirm their identity. All cell lines tested negative 
for mycoplasma contamination. 
2.4.2.  ANTIBODIES AND REAGENTS 
SCH772984 was provided by Merck. The following compounds were purchased 
from Selleckchem: adavosertib (S1525), filgotinib (S7605), ruxolitinib (S5243), and 
tofacitinib (S2789); or from Sigma-Aldrich: 7rh (SML1832), MG-132 (M7449). The 
following antibodies were obtained from Cell Signaling Technology: anti-DDR1 (5583S), 
anti-PYK2 (3090S), anti-STAT3 (9139S), anti-phosphorylated STAT3 Tyr705 (9145S), 
anti-WEE1 (13084S), anti-CHK1 (2360S), anti-PLK1 (4513T), anti-ERK (4696S), anti-
phosphorylated ERK Thr202/Tyr204 (4370S), anti-phosphorylated CDC2 Tyr15 (4539S), 
anti-phosphorylated HistoneH3 Ser10 (53348S); from Sigma-Aldrich: anti-vinculin 
(V9131), anti-β-actin (A5441) and anti-KRAS (WH0003845M1); from Invitrogen: anti-
phosphorylated PYK2 Tyr402 (44-618G); or from Santa Cruz Biotechnology: anti-CDC2 
(sc-54).  
52 
2.4.3. RNAI KNOCKDOWN STUDIES 
Short-interfering RNA (siRNA) experiments were performed with 10 nM siRNA and 
RNAiMAX Lipofectamine (Invitrogen, 13778150) according to the manufacturer’s 
protocol. siRNAs were obtained from Thermo Fisher: Non-specific siRNA (4390844), 
siKRAS-1 (4390825-s7939), siKRAS-2 (4390825-s7940), siWEE1-1 (4390824-s21), 
siWEE1-2 (AM51331-404), siDDR1-1 (4390824-s2298), and siDDR1-2 (4390824-
s2230). On day 1, cells were plated at 2 x 105 cells per well of a 6-well plate. On day 0, 
Lipofectamine was warmed to room temperature and added to Opti-MEM (Gibco, 31985-
070) to a final concentration of 20x before low-speed vortex. siRNAs were added to 
individual tubes of Opti-MEM at 20x concentration. Both Lipofectamine and siRNA tubes 
were incubated at RT separately for 5 min. After incubation, Lipofectamine in Opti-MEM 
was combined at a 1:1 ratio with individual siRNAs in Opti-MEM. Tubes were carefully 
inverted five to seven times to mix Lipofectamine and siRNA in Opti-MEM and were 
subsequently incubated at RT for 30 min. Two hundred µl of the Lipofectamine with siRNA 
were added to 1.8 ml of fresh cell culture media per well. Cells were incubated for 
specified times before collection for immunoblotting, proliferation, clonogenic, cell cycle 
or apoptosis assays. 
 For qRT-PCR experiments, the above transfection protocol was modified to 
combine the day 1 and day 0 steps. Cells (2 x 105) were plated in 1.8 ml cell culture 
medium with the addition of 200 µl of Lipofectamine with respective siRNA on day 0. 
2.4.4. MIB/MS 
Samples were prepared according to the RNAi knockdown protocol outlined in 
Materials and Methods. Following 72 hours of RNAi knockdown with either non-specific 
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siRNA or siKRAS 1, the cell plates were placed on ice and the cells were washed 5x with 
large-volume, ice cold phosphate-buffered saline (PBS). The final PBS wash was 
thoroughly aspirated and MIB/MS lysis buffer (50 mM HEPES (pH 7.5), 0.5% Triton X-
100, 150 mM NaCl, 1 mM EDTA, 1 mM EGTA, 10 mM sodium fluoride, 2.5 mM sodium 
orthovanadate, protease inhibitor cocktail (Roche), 1% phosphatase inhibitor cocktail 2 
(Sigma-Aldrich), and 1% of phosphatase inhibitor cocktail 3 (Sigma-Aldrich) was added 
to the adherent cells and permitted to incubate on ice for 5 min. Using a rubber cell 
scraper, cell lysates were transferred from the plates to 1.7 ml microcentrifuge tubes and 
placed on ice for 10 min. Cell lysates were subsequently sonicated four times for 15 sec 
at 50% power, alternating between samples to allow cooling on ice between pulses. Cell 
lysates were then centrifuged at top speed (13,200 rpm) for 10 min at 4°C. Supernatants 
were clarified using a 0.2 µm filter, transferred into labeled tubes and stored at -80°C (~5 
mg protein per experiment). A small portion of lysate was removed for Bradford assay 
estimation of protein concentration. The lysates were thawed and gravity-flowed over 
multiplexed kinase inhibitor beads (MIBs; Sepharose conjugated to VI-16832, CTx-
0294885, PP58, Purvalanol B, UNC8088A, and UNC21474). MIBs were then washed 
with high salt (1 M NaCl) and low salt (150 mM NaCl + 0.1% SDS) lysis buffers without 
the inhibitors. The samples were boiled with the elution buffer (100 mM tris-HCl, 0.5% 
SDS, and 1% β-mercaptoethanol, pH 6.8) at 100°C for 5 min to elute the bound kinases 
from MIBs. The eluted kinases (proteins) were concentrated with Amicon Ultra-4 (10K 
cutoff) spin columns (Millipore), purified by removing the detergent using 
methanol/chloroform extraction, and digested by sequencing grade trypsin (Promega) 
overnight at 37°C. Hydrated ethyl acetate extraction was used to remove Triton, and 
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PepClean C18 spin columns (Thermo Scientific) were used to de-salt the digested 
peptides. 
Biological triplicates of the MIB samples were analyzed by LC-MS/MS as we 
described previously (81). Briefly, each sample was injected onto an EASY-Spray 
PepMap C18 column (75 mm id 3 25 cm, 2 mm particle size) (Thermo Scientific) and 
separated over a 2-hour method. The gradient for separation consisted of 5%–32% 
mobile phase B at a 250 nl/min flow rate, where mobile phase A was 0.1% formic acid in 
water and mobile phase B consisted of 0.1% formic acid in ACN. The Thermo QExactive 
HF was operated in data-dependent mode where the 15 most intense precursors were 
selected for subsequent HCD fragmentation (set to 27%). 
Following MaxQuant processing of data and generation of Label-free quantification 
(LFQ) intensity values, data files were analyzed using R (version 3.5.2). Kinases were 
excluded if they were not present in >50% of samples or if they contained two or more 
peptides. For imputation of missing values, a normal distribution was modeled on the non-
missing LFQ intensity values of the kinases containing missing intensity values. Imputed 
values were drawn randomly from this distribution. Following filtering and imputation, LFQ 
intensity values were log2 transformed and the fold change over the median vehicle value 
was calculated for each kinase. Kinases significantly different between treatments with 
siNS and siKRAS, or with DMSO and ERKi, were determined using one-way ANOVA 
(Benjamini-Hochberg adjusted p value < 0.05). Euclidean distance and average linkage 





Plates containing the PDAC cell lines were washed with PBS and lysed with Triton 
X-100 lysis buffer (25 mM tris buffer, 100 mM NaCl, 1 mM EDTA and 1% Triton X-100), 
supplemented with cOmplete protease inhibitor (Roche) and Phosphatase Inhibitor 
Cocktail (Sigma-Aldrich). Cells were incubated on ice for 10 min before scraping into a 
microcentrifuge tube and placed back on ice. Sample tubes were centrifuged for 10 min 
at 13,200 rpm at 4°C. The supernatant was collected and used to determine protein 
concentration using a Bradford Assay (Bio-Rad), and samples were prepared with 4x 
Laemmli Sample Buffer (Bio-Rad). Samples were then boiled and stored at -20°C. Ten 
percent polyacrylamide gels were used to clarify lysates before transferring onto PVDF 
membranes (Millipore, IPVH00010) at 90 V for 90 min. Membranes were blocked for 1 
hour in 5% BSA solution diluted in TBST (TBS with 0.05% Tween-20) and washed with 
TBST. Membranes incubated overnight in primary antibodies diluted in 5% BSA solution 
supplemented with sodium azide. Secondary antibodies used were goat anti-mouse 
(Invitrogen, 31432) and goat anti-rabbit (Invitrogen, 31462). Membranes were washed 
with TBST before imaging using the ChemiDoc MP Imaging System (Bio-Rad) and ECL 
reagent.  
2.4.6. QUANTITATIVE REAL-TIME PCR 
Cells were grown in 6-well plates, transfected with siRNA as indicated, and 
harvested. RNA was extracted using the RNeasy Isolation Kit (Qiagen) and converted to 
cDNA using the High-Capacity cDNA Reverse Transcription Kit (Applied Biosystems). 
RT-PCR was performed using the TaqMan system (Applied Biosystems) in a 384-well 
format. FAM-labeled target primer and endogenous human ACTB control (beta actin) 
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(Thermo Fisher Scientific) were mixed with master mix and template, and after 40 cycles 
were analyzed on an QuantStudio 6 Flex Real-Time PCR System (Applied Biosystems). 
2.4.7. FLOW CYTOMETRY 
For apoptosis assays, TACS Annexin V-FITC Kits (BD Biosciences) were utilized 
to measure apoptosis. The following protocol is closely adapted from the manufacturer’s 
specifications. Prior to trysonization, floating cells in the spent culture medium were 
collected. Cells were then trypsinized cells and collected, mixed, and centrifuged at 300g 
for 5 min at room temperature. The cells were washed with phosphate buffered saline 
(PBS) and centrifuged at 300g for 5 min before incubating the cell pellet in annexin V 
staining solution (1% Annexin V-FITC, 1x propidium iodide solution, in 1x calcium-
containing binding buffer) in the dark for 15 min at room temperature. Cell mixture was 
subsequently diluted 1:5 in binding buffer. For cell cycle analysis, adherent cells were 
washed with PBS prior to being trypsinized. After trysponization, cells were centrifuged 
at 300g for 5 min before washing once in PBS. Cells were pelleted and resuspended in 1 
ml PBS before adding 9 ml of 70% ethanol drop-wise to each tube with gentle agitation. 
Cells were permitted to fix for a minimum of 18 hours at 4°C. Fixed cells were then 
pelleted, washed once in PBS, resuspended in 40 μg/ml propidium iodide (PI), 100 μg/ml 
RNase A in PBS, and incubated at 37°C for 3 hours. 
Apoptosis assays were analyzed using FCS Express. A FSC-A vs. SSC-A dot plot 
was used to exclude debris and generate a “cells” gate. “Cells” were plotted in a FITC-A 
(x) vs. PI-A (y) dot plot and apoptotic cells (FITC+) were analyzed. Cell cycle analyses 
were performed with FCS Express. After first establishing a "cells" gate, a “singlets” gate 
was determined using a FSC-A (x) vs. FSC-H (y) dot plot. Singlets were then analyzed in 
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a histogram for PI-A content before employing the Multicycle algorithm to analyze cell 
cycle. 
2.4.8. RPPA 
Samples were prepared according to the RNAi knockdown protocol outlined in 
Materials and Methods. Following 72 hours of RNAi-mediated knockdown with non-
specific siRNA, siKRAS-1, or siKRAS-2, plates were washed three times with PBS. Cell 
lysates were prepared as previously described (80). Coomassie Protein Assay Reagent 
kit (Thermo Fisher Scientific) was used to measure protein concentration, following the 
manufacturer’s instructions. Tris-glycine SDS 2x sample buffer (Life Technologies) with 
5% β-mercaptoethanol was used to dilute cell lysates to 0.5 mg/ml. Samples were boiled 
for 8 min and stored at -20°C until arrayed. An Aushon 2470 automated system (Aushon 
BioSystems) (173) was used to immobilize cell lysates and the internal controls and print 
in technical replicates (n = 3) onto nitrocellulose-coated glass slides (Grace Bio-Labs). 
Sypro Ruby Protein Blot Stain (Molecular Probes) was used to quantify protein 
concentration in each sample, following the manufacturer’s instructions. Reblot Antibody 
Stripping solution (Chemicon) was used to pretreat the remaining arrays (15 min at room 
temperature). The arrays were washed with PBS and incubated in Iblock (Tropix) for 5 
hours before antibody staining (142). Arrays were incubated with 3% H2O2, avidin, biotin 
(DakoCytomation), and an additional serum-free protein block (DakoCytomation) to 
reduce nonspecific binding of endogenous proteins. Staining was performed using an 
automated system (DakoCytomation) was used. Each slide was probed for 30 min with 
one antibody targeting the protein of interest, with 149 antibodies that target proteins 
involved in signaling networks that regulate cell growth, survival and metabolism were 
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used to probe arrays (table S3). All antibodies used were validated as described 
previously (174). Signal amplification was determined by using biotinylated anti-rabbit 
(Vector Laboratories) or anti-mouse secondary antibody (DakoCytomation) and a 
commercially available tyramide-based avidin-biotin amplification system (Catalyzed 
Signal Amplification System, DakoCytomation). IRDye 680RD streptavidin (LI-COR 
Biosciences) fluorescent detection system was used. TECAN laser scanner was used to 
scan Sypro Ruby and antibody-stained slides, and the images were analyzed using 
commercially available software (MicroVigene Version 5.1.0.0, Vigenetech) as previously 
described (175). 
2.4.9. PROLIFERATION ASSAYS 
For 96-well-format growth assays, 103 cells per well were plated on Day 1 in 200 
µl cell culture media. Following overnight incubation, one plate per cell line was isolated 
on Day 0 and quantified by counting calcein AM positive (500 nM, 20 min) labeled live 
cells using the SpectraMax i3x multimode detection platform (Molecular Devices) for the 
assessment of plating efficiency. Next, we utilized the TECAN 300D dispenser to add 
inhibitor titrations to the plates. Dose ranges used are indicated in figures and/or figure 
panels. DMSO was kept at or below 0.01% final concentration. Cells were incubated at 
37°C and 5% CO2 for 5 days. Plates were quantified using calcein AM staining (500 nM, 
20 min) followed by counting of positively stained cells using the SpectraMax i3x 
multimode detection platform. Raw cell numbers were minimally adjusted by cell line 
depending on the plating efficiency determined on Day 0. Next, raw cell counts (positively 
labeled with calcein AM) were normalized to the untreated wells. One hundred % growth 
was assigned to an average of the untreated well cell counts, all treated wells were 
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calculated relative to this number and technical replicates were averaged together. 
Growth curves were constructed by first modeling the raw data with the drc R package 
(version 3.0-1) and the four-parameter log-logistic function LL.4 (4PL). Next, we isolated 
the GI50 values from the models and drew the growth curves using the ggplot2 package 
in R (version 3.3.2).  
2.4.10. BLISS SYNERGY ANALYSIS 
First, quantifications of proliferation assays (2D or 3D cultures) were normalized to 
untreated controls (100% growth). Next, treatment effect sizes were calculated by 
subtracting the growth percentage (as a decimal) from 1. Values above 1 were removed 
from BLISS analysis (corresponding to treatments that stimulated cell growth above 
untreated control). Expected effect sizes for each treatment combination were calculated 
according to the BLISS algorithm (176). Expected effect size was then divided by 
observed effect size and the results were mapped to a color scale (0-1 are shades of red, 
indicative of “synergy”; 1 is white, indicative of additivity; greater than 1 are shades of 
blue, indicative of “antagonism”) and plotted as a heatmap using the ComplexHeatmap 
package in R (version 2.4.3). 
2.4.11. PROTEASOME INHIBITOR STUDIES 
Knockdown was performed in the manner described in Materials and Methods 
using either non-specific siRNA, siKRAS 1, or siKRAS 2. Following incubation with 
respective siRNA for 68 hours, the cell culture medium was replaced with standard cell 
culture medium supplemented with vehicle or 10 µM MG132. The cells were then 
incubated at 37°C for 4 hours before using the standard immunoblotting protocol as 
described in Materials and Methods. 
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CHAPTER 3 – LOW-DOSE VERTICAL INHIBITION OF THE RAF-MEK-ERK 
CASCADE CAUSES APOPTOTIC DEATH OF KRAS-MUTANT CANCERS123 
3.1. SIGNIFICANCE 
The key role of the RAF-MEK-ERK kinase cascade in driving KRAS-dependent 
pancreatic cancer growth is well-established. However, the most effective pharmacologic 
approach for inhibition of this three-tier kinase network remains to be determined. 
Although our chemical library screens identified diverse functional classes of inhibitors 
that caused apoptotic anti-tumor activity upon combination with RAF, MEK or ERK 
inhibitors, concurrent inhibition of RAF and ERK was the most effective combination, 
synergizing to cause apoptotic death at far lower doses compared with single inhibitor 
treatment. This combination caused insensitivity to feedback mechanisms of ERK 
reactivation and induced system-wide disruption of gene transcription to drive cell cycle 
arrest, apoptosis, and mesenchymal-to-epithelial transition. Concurrent RAF and ERK 
inhibition can provide a therapeutic approach that enhances tumor cell cytotoxicity and 
decreases normal cell toxicity. 
 
 
1 This chapter previously appeared as an article in the journal Cell Reports. The original citation is as 
follows: I. Ozkan-Dagliyan et al., Low-Dose Vertical Inhibition of the RAF-MEK-ERK Cascade Causes 
Apoptotic Death of KRAS Mutant Cancers. Cell Rep. 31, 107764 (2020) 
2 I contributed the following figure panels to this publication: Fig. 3.1 D, Fig. 3.2 A, Fig. 3.3 A and B, Fig. 3.4 
A, Fig. 3.5 D. Additionally, I contributed the following panels to the associated Appendix B: Fig. B1 I, Fig. 
B2 A to C, Fig. B3 F and G, Fig. B5 A and B, Fig. B6, Fig. B7 A and B, Fig. B7 F, Fig. B8 A, Fig. B10 H and 
J.  
3 Tables S1, S2, and S3 referenced here are available online with the original publication. 
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3.2. INTRODUCTION 
The genetic basis of pancreatic ductal adenocarcinoma (PDAC) is well-established 
(177), yet current standards of care are comprised of conventional cytotoxic drugs rather 
than targeted therapies. Among the four major genetic alterations in PDAC, only KRAS 
functions as an oncogene. Given the >95% KRAS mutation frequency in PDAC, and 
substantial experimental evidence that KRAS is essential for PDAC maintenance 
(50,178), KRAS is the most attractive target for therapeutic intervention in this disease 
(45). 
 Despite significant recent progress in developing direct inhibitors of mutant KRAS 
(179,180), with two now under clinical evaluation, these are selective for KRASG12C, a 
mutant that is found infrequently (only ~2%) of PDAC (42). Inhibitors of KRAS effector 
signaling remain promising KRAS-targeted therapies (126,181). Of the multitude of 
effectors, substantial experimental studies and PDAC patient data support the key role of 
the RAF-MEK-ERK mitogen-activated protein kinase (MAPK) cascade in driving KRAS-
dependent PDAC growth. Mutationally activated BRAFV600E can phenocopy mutant KRAS 
and drive development of invasive and metastatic PDAC (86), and BRAF mutations are 
found in ~50% of the rare PDAC that are KRAS wild-type (WT) (14). Further, an effector 
siRNA screen demonstrated that KRAS-dependent cancers are driven largely by RAF 
(182). These observations support the RAF-MEK-ERK cascade as the key effector 
pathway driving KRAS-dependent PDAC. However, to date, therapeutic targeting of MEK 
in KRAS-mutant lung cancer demonstrated limited to no efficacy in patients (183,184). 
Challenges to effective use of inhibitors of ERK MAPK signaling include toxicity in normal 
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cells (185) and adaptive responses to inhibitor treatment, resulting in ERK reactivation 
and bypass of inhibitor action (139).  
Another challenge in targeting the ERK MAPK cascade is determining which level 
of the three-tiered kinase cascade will provide the most effective and long-term 
therapeutic response. At the top of the pathway are the three highly related RAF isoforms, 
ARAF, BRAF and CRAF/RAF1, that exhibit distinct roles in RAS-driven cancers (186). 
BRAF-selective inhibitors caused paradoxical activation of ERK signaling in RAS-mutant 
cancers (100,102). Pan-RAF inhibitors overcome paradoxical activation and showed 
greater activity in KRAS-mutant cancers (187,188). However, genetic deletion studies in 
Kras-driven mouse models argue that pan-RAF inhibition may be limited by normal cell 
toxicity and that a CRAF-selective strategy may provide a tumor-selective therapy 
(185,189). In contrast, Craf deficiency in a KrasG12D-driven PDAC model had no inhibitory 
effect on tumor development or progression (190). Thus, the role of specific RAF isoforms 
in KRAS-driven oncogenesis may be highly tissue-selective. 
Recently, we addressed the limitations of RAF and MEK inhibitors by using 
ERK1/2-selective inhibitors in KRAS-mutant PDAC (82). We found that ERK1/2 inhibition 
suppressed PDAC growth, and that sensitivity correlated with ERK inhibition-mediated 
loss of MYC protein. In search of combinations to enhance the anti-tumor efficacy of 
inhibitors of the RAF-MEK-ERK cascade, we identified inhibitors that target a spectrum 
of functionally diverse proteins that synergized with a pan-RAFi to cause apoptotic death. 
Surprisingly, the strongest synergistic and apoptotic activity resulted from concurrent 
inhibition of RAF and ERK, which was more effective than concurrent inhibition of either 
RAF and MEK, or MEK and ERK, and was particularly striking at low doses. We have 
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delineated a multi-faceted mechanistic basis for the anti-tumor potency of this vertical 
inhibition of the ERK MAPK cascade. 
 
3.3. RESULTS 
3.3.1. ARAF, BRAF AND CRAF CONTRIBUTE TO GROWTH OF KRAS-MUTANT 
PANCREATIC CANCER 
Previous studies evaluating the three RAF serine/threonine kinase isoforms 
suggested distinct tissue-specific dependencies in the development of KRAS-driven 
cancers, with Craf critical for Kras-driven lung cancer (185,189) but not pancreatic cancer 
(190). We previously determined that a panel of nine conventional KRAS-mutant PDAC 
lines exhibited KRAS-dependent growth (82). To further address the role of RAF isoforms 
in the growth of KRAS-mutant PDAC, we additionally verified the KRAS-dependent 
growth of four KRAS-mutant cell lines established from patient-derived xenograft (PDX) 
PDAC tumors (Fig. 3.1 A, and Fig. B1, A and B). Applying previously characterized 
shRNA vectors for selective suppression of ARAF, BRAF or CRAF (191), we found that 
suppression of any RAF isoform alone was sufficient to partially impair growth of all six 
KRAS-mutant PDX PDAC cell lines (Fig. 3.1 A and Fig. B1, C and D), demonstrating that 
each RAF gene contributes to KRAS-dependent PDAC growth, with the general hierarchy 
of significance CRAF>BRAF>ARAF. This finding is similar to that made by McCormick 
and colleagues, where concurrent siRNA suppression of all three RAF genes were 
required to cause an equivalent suppression of growth of KRAS-mutant cell lines as seen 
with KRAS suppression (182). 





Figure 3.1. Concurrent Inhibition of All RAF Isoforms Diminishes PDAC Growth (A) 
PDAC cell lines were infected by lentivirus vectors encoding nonspecific (NS) control or 
distinct shRNAs targeting ARAF, BRAF, CRAF or KRAS sequences. Colonies were 
stained by crystal violet ~10 days after plating. Data are presented as median. All p values 
shown are in comparison to the vehicle control for individual graph. Adjusted p values are 
from Dunnett’s multiple comparison test. Adjusted p values = Pa01C (ARAF-sh1 = 
0.6792, ARAF-sh2 = 0.6726, BRAF-sh1 = 0.8883, BRAF-sh2 = 0.0592, CRAF-sh1 = *, 
0.0024, CRAF-sh2 = 0.6350), (KRAS-sh = ***, 0.0010). Pa02C (ARAF-sh1 = 0.7153, 
ARAF-sh2 = 0.0692, BRAF-sh1 = 0.8788, BRAF-sh2 = 0.1990, CRAF-sh1 = 0.0539, 
CRAF-sh2 = 0.2738), (KRAS-sh = **, 0.0068). Pa14C (ARAF-sh1 = ****, <0.0001, ARAF-
sh2 = ****, <0.0001, BRAF-sh1 = *, 0.0103, BRAF-sh2 = ****, <0.0001, CRAF-sh1 = ****, 
<0.0001, CRAF-sh2 = ****, <0.0001,  KRAS-sh = ****, <0.0001). Pa16C (ARAF-sh1 = 
0.9995, ARAF-sh2 = 0.7500, BRAF-sh1 = 0.9977, BRAF-sh2 = ****, <0.0001, CRAF-sh1 
= ****, <0.0001, CRAF-sh2 = ****, <0.0001, KRAS-sh = ****, <0.0001). MIA PaCa-2 
(ARAF-sh1 = 0.5520, ARAF-sh2 = **, 0.0051, BRAF-sh1 = 0.2316, BRAF-sh2 = **, 
0.0076, CRAF-sh1 = **, 0.0086, CRAF-sh2= **, 0.0098). PANC-1 (ARAF-sh1= 0.3213, 
ARAF-sh2 = ****, <0.0001, BRAF-sh1 = 0.0586, BRAF-sh2 =**, 0.0025, CRAF-sh1 = ****, 
<0.0001, CRAF-sh2 = ****, <0.0001). (B) PDAC cell lines were treated with RAFi (0.04-
10 M, 72 hr). Cell lysates were immunoblotted to determine levels of the indicated 
proteins. Data are representative of three independent experiments. (C) PDAC cell lines 
were treated with RAFi (0.01-2.5 M, 72 hr). Proliferation was measured by Calcein AM 
cell viability assay. Data are the mean average of three independent experiments. Error 
bars are shown as ± S.E.M. (D) CRISPR screen. PDAC cell lines were infected with the 
CRISPR library and treated with vehicle control or RAFi (w2: 2 weeks, w4: 4 weeks; a 
and b indicate replicate samples). The enrichment score indicates either enrichment (red) 
and or depletion (blue) of the indicated genes in cells treated with RAFi relative to vehicle 
control. (E) Cell lines were infected by lentivirus vectors encoding NS or two distinct ARAF 
shRNAs (72 hr) and treated with RAFi (0.01-2.5 M, 120 hr). Proliferation was measured 
by Calcein AM cell viability assay. Data are the mean average of three technical 
replicates. Error bars are shown as ± S.E.M. Summary of GI50 values. 
 
This finding suggested that optimal inhibition of RAF in KRAS-mutant PDAC will require 
a pan-RAF inhibitor. We utilized the pan-RAF inhibitor LY3009120 (RAFi), which displays 
potent nanomolar inhibition of all three RAF proteins in vitro (187). As observed previously 
(100,102), the mutant BRAF-selective inhibitor vemurafenib caused dose-dependent 
paradoxical activation rather than inactivation of ERK in KRAS-mutant PDAC cells (Fig. 
B1 E). In contrast, treatment with RAFi caused dose-dependent inhibition of ERK, with 
IC50 values ranging from 0.20 to 2.37 M (Fig. 3.1 B and Fig. B1 F, Table S1 A). 
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We next determined the effects of RAFi treatment on the growth of a panel of 
KRAS-mutant PDAC cell lines (Fig. 3.1 C; Tables S1, A, C and D). Defining sensitivity as 
a GI50 of <2.5 M, a concentration where pERK is suppressed, we observed that four cell 
lines were sensitive (GI50 0.20-2.41 μM), and five lines were resistant (GI50 > 2.5 μM) after 
three days of treatment. However, after a 5-day treatment, only two lines remained 
resistant. Interestingly, sensitivity to RAFi did not correspond to sensitivity to either the 
MEK1/2-selective inhibitor selumetinib or the ERK1/2-selective inhibitor SCH772984 (82) 
(Table S1 A). These distinct sensitivities indicate that inhibition of the ERK MAPK cascade 
at different levels may not have equivalent consequences, although off-target activities of 
each inhibitor and other factors (e.g., mode of action, binding affinity) may contribute to 
these differences. 
To identify a genetic basis for sensitivity and resistance to RAFi, we performed a 
CRISPR screen targeting the druggable genome in the presence of a sublethal (GI30) 
concentration of RAFi in a sensitive (Pa02C) and a resistant (Pa01C) PDAC line. We 
identified genes whose loss increased or decreased sensitivity to RAFi (Fig. B1, G to I).  
Shown in the heatmap are 45 genes where three or more sgRNAs scored in the top 25% 
of ranked hits on average for each condition; for the majority of these, their loss increased 
RAFi sensitivity (Fig. B1 I). Among the 37 genes in that category are some identified 
previously to regulate sensitivity to MEK/ERK inhibitors (e.g., HDAC7, PIK3CB, PDGFRB) 
(192,193). Surprisingly, ARAF was among the top 10% of hits (Fig. 3.1 D), with stable 
suppression of ARAF causing up to a 4-fold shift in GI50 in both RAFi-sensitive and -
resistant PDAC cell lines (Fig. 3.1 E and Fig. B1 J). Suppression of BRAF or CRAF also 
67 
increased sensitivity to RAFi (Fig. B1 K). These results may reflect non-kinase functions 
are not blocked by an ATP-competitive inhibitor of kinase activity.  
3.3.2. CHEMICAL LIBRARY SCREEN IDENTIFIES SYNERGISTIC ERK MAPK 
VERTICAL INHIBITION COMBINATIONS 
To determine if co-treatment with other signaling inhibitors could overcome RAFi 
de novo resistance, we utilized a 525-compound chemical library comprised of approved 
or clinical candidate oncology inhibitors (194) (Table S1 E) in a panel of 20 KRAS-mutant 
human or mouse PDAC cell lines (Fig. B2 D). We applied both viability (CellTiter-Glo) and 
cytotoxicity (CellTox Green) assays to identify drug combinations that enhanced RAFi 
growth inhibitory or cytotoxic activity, respectively. Combinations were identified as 
synergistic when the deltaDSS score [DSS (drug+RAFi)-DSS (drug alone)] was >5 or 
antagonistic when deltaDSS was <-5 (194). Synergy or antagonism identified in two or 
more cell lines are shown for cytotoxicity and viability assays (Fig. 3.2 A and Fig. B2 A). 
Reflecting the genetic heterogeneity of PDAC (45), we observed significant cell line 
variability in drug sensitivity. The screens identified multiple chemically distinct inhibitors 
of the same functional class of proteins.  
 We focused on the RAFi combinations identified in the cytotoxic assay (Fig. 3.2 
A). As expected, we identified multiple inhibitors of PI3K-AKT-mTOR signaling in the 
viability screen, and to a significantly lesser degree in the cytotoxicity screen (Fig. 3.2 A 
and Fig. B2 A). Multiple inhibitors of EGFR/HER2 receptor tyrosine kinases, HSP90, 
histone deacetylases, and microtubule organization were also able to cause cell death 
when combined with RAFi.  
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Unexpectedly, we found that cytotoxic RAFi combinations included MEK or ERK, 
but not RAF inhibitors. Similarly, combinations with the MEK inhibitor trametinib (MEKi) 
or the ERK inhibitor SCH772984 (ERKi) were with EGFR/HER2, pan-RAF and ERK, but 
not other MEK inhibitors (Fig. B2 B), or with EGFR/HER2, pan-RAF and MEK inhibitors, 
but not other ERKi (Fig. B2 C), respectively. These findings suggest that, for a vertical 
combination to be synthetic lethal, each inhibitor must target a distinct node of the RAF-
MEK-ERK pathway (Fig. B2 E).  
We performed Bliss analyses to determine whether the inhibitory activities of each 
combination were additive or synergistic; Bliss scores greater than 1.0 indicate synergy. 
Concurrent inhibition of RAF and ERK (designated RAFi/ERKi hereafter) not only caused 
cytotoxicity in RAFi-sensitive KRAS-mutant PDAC lines in a dose-dependent manner but 
was also able to sensitize RAFi-resistant cells (Fig. 3.2 B and Fig. B3 A). This combination 
was highly synergistic, with average synergy scores of 12.5 and 15.5 for Pa02C and 
Pa16C cell lines, respectively (Table S1 F), particularly at lower concentrations of each 
inhibitor. In ERKi-resistant Pa16C cells, the GI50 for RAFi alone was 839 nM, whereas it 
was only 5 nM when combined with a low dose of ERKi (80 nM) (Table S1 D). Thus, 168-
fold less RAFi was able to produce similar efficacy when used as a component of vertical 
pathway inhibition. 
Interestingly, the ERKi screen did not identify BRAF-selective inhibitors (Fig. B2 C) 
and BRAFi in combination with ERKi resulted in no significant enhancement in activity 
(Fig. B3 B and Table S1 I). This result supports the requirement to inhibit all RAF isoforms 
to disrupt KRAS signaling to ERK (Fig. 3.1 A and Fig. B1, C and D). 
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Figure 3.2. Identification of Synergistic Drug Combinations that Enhance ERK 
MAPK Inhibitor Cytotoxicity (A) Cell lines were treated with a 525-inhibitor library with 
or without RAFi (2 M, 72 hr). Cell death was measured by CellTox Green. Drug sensitivity 
score (ΔDSS) was used to quantify inhibitor responses and plotted as red (> additive), 
blue (< additive) or white (no effect). (B) Pa02C and Pa16C were treated with RAFi (0.01-
2.5 M) alone or in combination with ERKi (0.08-1.25 M), (C) MEKi (0.25-4 nM), or (D) 
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EGFRi (0.08-1.25 M) for 120 hr. Proliferation was measured by Calcein AM cell viability 
assay. Representative bliss synergy score heatmap for 3 independent experiments is 
shown (left). Red (synergy), green (antagonism), white (no effect). Averaged dose 
response curves of three independent experiments (with 3 technical replicates) are shown 
(right). Error bars are ± S.E.M. Synergyavg = average bliss synergy score. 
 
Consistent with the requirement to target distinct nodes, ERKi did not synergize 
with the mechanistically distinct ERK inhibitor ulixertinib/BVD-523 (Fig. B3 C and Table 
S1 J). On the other hand, a second pan-RAF inhibitor, lifirafenib/BGB-283, also 
synergized with ERKi (Fig. B3 D and Table S1, K and L). Similarly, RAFi also synergized 
with another ERK inhibitor, LY3214996 (Fig. B3 E and Table S1, M and N). Finally, 
leveraging additional combinations with RAFi targeting different nodes of the MAPK 
pathway, we found that RAFi, in combination with either erlotinib (EGFRi) or trametinib 
(MEKi), also synergistically suppressed growth (Fig. 3.2, C and D; Table S1, G and H). 
In summary, synergistic cytotoxic growth suppression was seen only when the 
combinations involve inhibitors of distinct nodes of the pathway. 
Since a common mechanism for resistance to MEK inhibitors involves reactivation 
of ERK (133,195,196), we speculated that the RAFi/ERKi combination is more effective 
than the RAFi/MEKi combination, in part, due to resistance to ERK reactivation. To 
address this possibility, we applied MIB/MS kinome profiling, a kinome-wide unbiased 
method that has been used to monitor drug-induced compensatory signaling activities 
(139). The kinase activity/expression changes caused by 72 hr RAFi/MEKi or RAFi/MEKi 
showed near-identical profiles (Fig. B3, F and G). However, RAFi/ERKi but not 
RAFi/MEKi showed strong suppression of ERK1/2 activities. Immunoblot analyses also 
showed that the RAFi/ERKi combination caused greater suppression of ERK signaling 
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and phosphorylation of the ERK substrate RSK (Fig. B3 H). Thus, the RAFi/MEKi 
combination showed greater resistance to ERK reactivation. 
3.3.3. RAFI/ERKI TREATMENT SUPPRESSES ERK SIGNALING DESPITE LOSS OF 
NEGATIVE FEEDBACK INHIBITION 
Immunoblot analyses of six PDAC cell lines verified that RAFi/ERKi synergistically 
reduced pERK levels (Fig. 3.3C and Fig. B5, C and D), and that RAFi similarly synergized 
with the chemically distinct ERK1/2-selective inhibitor, LY3214996 (Fig. B5 E). To identify 
changes in signaling pathways and the resulting alterations in gene transcription that were 
quantitatively or qualitatively different upon combination treatment versus each inhibitor 
alone, we performed reverse phase protein array (RPPA) (142) pathway activation 
mapping (Fig. 3.3 A) and RNA-Seq analyses (Fig. 3.3 B). Together, these datasets show 
how RAFi/ERKi disrupted multiple signaling networks that in turn disrupted multiple 
transcription factor-driven transcriptomes (Fig. B4).  
RPPA-based pathway mapping revealed dynamic changes in protein 
phosphorylation and total protein components of signaling networks (Fig. 3.3 A and Table 
S2, A and B). These changes were much more robust upon concurrent treatment with 
RAFi/ERKi compared to the limited time-dependent alterations caused by either inhibitor 
alone. The combination suppressed ERK signaling (pRSK, pMYC) more strongly than did 
single agents (Fig. 3.3 A). Additionally, RAFi/ERKi treatment strongly reduced SRC family 
kinase (SFK) phosphorylation and activation. SFK phosphorylation of ARAF and CRAF 
is a critical RAS-mediated step in activation of RAF kinase activity (195). Decision tree 
analysis confirmed the significant alterations of these proteins (Table S2 C). Finally, 
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consistent with the growth inhibitory consequences, the RAFi/ERKi combination also 
reduced phosphorylation and activation of mitotic kinases, Aurora and PLK1 (Fig. 3.3 A). 
We applied MIB/MS and confirmed that 3-day treatment with RAFi/ERKi caused 
additive or synergistic alterations in kinase activity and/or expression compared to RAFi 
or ERKi alone (Fig. B6 A). While RAFi alone reduced activity/expression of BRAF but not 
ERK1 or ERK2, and ERKi alone reduced ERK1 and ERK2, but not BRAF, the combination 
reduced both BRAF and ERK. Consistent with our previous observation that loss of MYC 
protein correlated with ERK inhibitor sensitivity, RPPA and MIB/MS revealed that the 
combination much more effectively reduced MYC protein levels (Fig. 3.3 A and Fig. B5, 
C to E). Finally, MIB/MS also indicated that the combination reduced the 
activity/expression of Aurora and PLK1 (Fig. B6 A). 
To compare the resulting gene transcription changes induced by RAFi/ERKi or 
each agent alone, we performed RNA-Seq analyses after 4 or 24 h of treatment (Figure 
3B). The strongest induction of gene transcription was of the interferon (IFN)-α/γ-related 
gene sets (Fig. 3.3 B and Table S2, D to I). This is consistent with a study of Kras-driven 
colon cancer, where Kras strongly downregulated IFN-α/γ gene sets, suppressing a T-
cell immune response (197). Consistent with the major role of the ERK MAPK effector 
pathway in driving KRAS-regulated gene expression, Gene Set Enrichment Analysis 
(GSEA) revealed that RAFi/ERKi suppressed genes upregulated by KRAS and increased 
expression of genes downregulated by KRAS (Fig. 3.3 B and Fig. B5, A and B). In 
particular, RAFi/ERKi strongly suppressed MYC transcription (Fig. B6 B) as well as 
potently silenced the expression of MYC-regulated genes (Fig. 3.3 B and Fig. B6 C). 




Figure 3.3. Concurrent RAF and ERKi Inhibition Disrupts ERK-dependent Signaling 
and Cellular Processes (A) RPPA analyses of PDAC cell lines treated with vehicle 
control, RAFi (0.3 M), ERKi (0.04 M) or the combination for multiple time points (0.25, 
1, 8, 24 and 72 hr). RAFi/ERKi treated PDAC cells were normalized to their respective 
vehicle control. Proteins with significant phosphorylation or expression changes at 72 hr 
time point are plotted as fold changes. Red (increased fold change), blue (decreased fold 
change), white (no change). (B) GSEA of the cell lines shown in Fig. 3.3 A. Enriched or 
depleted gene sets treated with RAFi/ERKi compared to RAFi (upper graph) or ERKi 
(below graph) are shown (24 hr). (C) Pa16C cells were treated with vehicle control, RAFi 
(0.3 M) and ERKi (0.04 M) alone or the combination (120 hr). Cell lysates were 
immunoblotted to determine levels of pERK, total ERK, total MYC and vinculin. Data are 
representative of three independent experiments. 
 
factor, FOSL1. Both MYC and FOSL1 are well-validated drivers of KRAS-dependent 
PDAC growth (81,198). 
Previous studies showed that single agent inhibition of any node of the RAF-MEK-
ERK cascade is limited by loss of negative feedback on the pathway, causing ERK 
reactivation (133,195,196). Given its potent suppression of ERK signaling, RAFi/ERKi 
also robustly decreased inhibitory feedback on ERK. RPPA pathway mapping 
demonstrated that RAFi/ERKi increased phosphorylation at PAK phosphorylation sites 
on ARAF and CRAF that enhance RAF kinase activity (199) (Fig. 3.3 A). PAK signaling 
drives resistance to combined BRAF and MEK inhibition in BRAF-mutant melanoma by 
causing ERK reactivation (200). Similarly, there was strong suppression of genes 
encoding diverse negative regulators of ERK signaling. These include proteins (e.g., 
DUSP4-7) that directly dephosphorylate ERK as well as proteins (e.g., SPRY2/4, 
SPRED1/2) that inhibit RTK activation of RAS via its exchange factor SOS1 or that 
inactivate RAS via its negative regulator NF1, respectively (Fig. B6 B). To determine how 
RAFi/ERKi treatment was able to retain strong suppression of ERK signaling despite the 
extensive loss of negative feedback on ERK, we examined SHP2, essential for RTK 
activation of RAS and ERK (201). RAFi/ERKi treatment reduced SHP2 phosphorylation 
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(Fig. 3.3 A) and also suppressed transcription of the gene (PTPN11) encoding SHP2 (Fig. 
B6 D). RAFi/ERKi  treatment also reduced phosphorylation of the SHP2 docking site on 
FRSα (Y436), an adaptor protein that links the FGFR RTK to SOS1 and RAS activation. 
FRSα is phosphorylated and inactivated by ERK feedback inhibition (202). Thus, 
downregulation of SHP2 contributes to the effectiveness of the RAFi/ERKi combination, 
by creating insensitivity to the loss of ERK negative feedback. 
3.3.4. RAFI/ERKI TREATMENT DECREASES CELL CYCLE PROGRESSION, 
SUPPRESSES PROTEIN TRANSLATION SIGNALING AND INCREASES 
APOPTOSIS 
Pathway mapping at the levels of transcriptional control (RNA-seq), protein 
abundance (WB, RPPA, MIB/MS) and protein activity (RPPA, MIB/MS), all showed that 
the biological consequences of RAFi/ERKi treatment are due to multiple distinct 
mechanisms (Fig. B4). RAFi/ERKi resulted in numerous changes that decreased the 
ERK-dependent events that facilitate G1 progression, including increased 
phosphorylation of p27KIP1, decreased expression of CCND1 (encoding cyclin D1) (Fig. 
B6 B), decreased phosphorylation of the RB tumor suppressor (Fig. 3.3 A), loss of E2F1 
gene transcription (Fig. B6 D), and decreased transcription of E2F target genes (Fig. B6 
E). RAFi/ERKi suppressed genes normally upregulated during G2/M checkpoint 
progression more strongly than did either RAFi or ERKi alone (Fig. B6 E), and suppressed 
the activities/expression of mitotic kinases that are critical regulators of the G2 to M 
transition (Fig. 3.3 A and Fig. B6 E). Reflecting these activities was a time-dependent 
decrease in the proliferation marker Ki67 (Fig. 3.3 A). 




Figure 3.4. Concurrent RAF and ERK Inhibition Causes Apoptosis (A) Fold changes 
(log2) of RNA expression of pro-apoptosis and pro-survival genes as the averaged values 
of MIA PaCa-2, Pa02C, Pa14C and Pa16C cell lines treated with RAFi/ERKi (0.3 M and 
0.04 M, respectively) and compared to RAFi (0.3 M) (24 hr) (left). Error bars are shown 
as standard error. All p values shown are in comparison to the vehicle control for individual 
graph. p values are from Wald test. Adjusted p values = BAX (0.2971), BAK1 (0.7226), 
BAD (*, 0.0332), BID (0.3363), BIK (0.2635), HRK (**, 0.003), BCL2L11 (****, 1.49E-05), 
PUMA/BBC3 (*, 0.0221), CASP1 (0.3642), CASP2 (**, 0.0034), CASP3 (0.6314), CASP4 
(0.1526), CASP6 (0.5876), CASP7 (0.5114), CASP8 (0.9215), CASP9 (0.2887), BCL2 
(***, 0.0014), BCL2L1 (0.1569), MCL1 (0.9338), BCL2L2 (0.9080). Fold changes (log2) 
of the transcripts of the cells treated with RAFi/ERKi (0.3 M and 0.04 M, respectively) 
and compared to ERKi (0.04 M) (24 hr) (right). Error bars are shown as standard error. 
All p values shown are in comparison to the vehicle control for individual graph. p values 
are determined from the Wald test. Adjusted p values = BAX (***, 0.0003), BAK1 (0.4834), 
BAD (0.6736), BID (0.1958), BIK (0.2171), HRK (***, 0.0011), BCL2L11 (****, 7.12E-06), 
PUMA/BBC3 (*, 0.0148), CASP1 (0.3406), CASP2 (*, 0.0250), CASP3 (0.7561), CASP4 
(*, 0.0229), CASP6 (*, 0.0615), CASP7 (0.1599), CASP8 (0.4119), CASP9 (0.2582), 
BCL2 (****, 0.0001), BCL2L1 (**, 0.0032), MCL1 (0.7493), BCL2L2 (0.9250). (B) Pa01C, 
Pa02C or Pa14C cells were treated with vehicle, RAFi (0.3 M), ERKi (0.04 M) or the 
combination (72 hr). Cell lysates were immunoblotted to determine levels of the indicated 
proteins. (C) Percent apoptosis of Pa02C and Pa16C cells treated with the vehicle control, 
RAFi (0.3 or 0.6 M), ERKi (0.04 or 0.08 M) or the combinations (120 hr). Error bars are 
shown as ± S.E.M. (D) Representative images of % apoptosis of the cell lines in Fig. 3.4 
C. FACS analysis was used to measure apoptosis. 
 
Pathway activation mapping also indicated that RAFi/ERKi synergistically suppressed 
mTORC1 signaling, that promotes protein translation, as indicated by reduced 
phosphorylation of mTORC1 substrates 4EBP1 and S6K, and of the S6K substrate 
ribosomal protein S6 (Fig. 3.3 A). Strong suppression of mTORC1-stimulated gene 
expression was also seen with RAFi/ERKi (Fig. 3.3 B and Fig. B7 F). 
 Further, RAFi/ERKi suppressed essentially all genes in the glycolytic pathway (Fig. 
B6 E), consistent with studies demonstrating that mutant KRAS drives increased  
transcription of glycolytic genes through ERK and MYC (50,79). RAFi/ERKi also strongly 
suppressed genes involved in mitochondrial biogenesis, mitophagy and impaired 
mitochondrial function (Fig. B6 E). Thus, RAFi/ERKi-mediated growth suppression 
involves suppression of key metabolic processes. 
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Finally, pathway activation mapping also identified increases in markers of 
apoptosis caused by RAFi/ERKi, increased cleaved caspases 3, 6 and 7 and PARP, and 
increased expression of the pro-apoptotic proteins BIM and BAD (Fig. 3.3 A). RAFi/ERKi 
also strongly increased transcription of genes encoding pro-apoptotic proteins (e.g., HRK, 
BCL2L11 [encoding BIM], PUMA, CASP1), and reduced transcription of genes encoding 
pro-survival proteins (BCL2L1 [encoding BCLXL], MCL1) than either single agent (Fig. 
3.4 A and Fig. B7, A and B). RAFi/ERKi treatment-mediated increases in BIM and BAD 
were further verified by immunoblotting (Fig. 3.4 B). Induction of apoptosis was verified 
by flow cytometry analysis. Whereas RAFi or ERKi treatment alone did not significantly 
increase apoptosis over vehicle control (<10%), the percentage of apoptotic cells was 
more than tripled with RAFi/ERKi (Fig. 3.4, C and D; Fig. B7, C to E). Thus, RAFi/ERKi 
treatment impairs processes that promote cell proliferation and enhances processes that 
lead to cell death. 
3.3.5. COMBINATION RAFI/ERKI TREATMENT STIMULATES MESENCHYMAL-TO-
EPITHELIAL TRANSITION 
We noted from the RPPA analyses that combined RAFi/ERKi treatment increased 
E-cadherin protein levels (Fig. 3.3 A and Fig. B8 A), suggesting induction of the 
mesenchymal-to-epithelial transition (MET) program. RAFi/ERKi treatment substantially 
increased E-cadherin expression (2.4- to 7.3-fold) in four of six cell lines evaluated (Fig. 
3.5, A and B; Fig. B8, A and B; Table S3, A and B), whereas RAFi or ERKi treatment alone 
did so to a lesser degree (Fig. 3.5 B). RAFi/MEKi or MEKi/ERKi treatment also increased 
E-cadherin expression. In contrast, BRAFi in combination with either ERKi or MEKi did 
not significantly increase E-cadherin expression. The limited change in vimentin  
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Figure 3.5. Concurrent RAF and ERK Inhibition Induces Mesenchymal-to-Epithelial 
Transition (A) Pa02C and Pa16C cells were treated with RAFi (0.3 M), BRAFi (1 M), 
MEKi (0.5 nM) or ERKi (0.04 M) alone or in combination as indicated (120 hr). Cell 
lysates were immunoblotted to determine the levels of the indicated proteins. (B) 
Expression levels of the proteins in Fig. 3.5 A are plotted as fold changes. All the proteins 
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are normalized to loading control and their respective vehicle control. Error bars are 
shown as ± S.E.M. (C) Representative immunofluorescence images of Pa02C cells 
treated with vehicle, RAFi (0.3 M), ERKi (0.04 M) or the combination to visualize E-
cadherin expression and distribution (72 hr). Scale bar, 20 m. (D) Fold changes in RNA 
expression of epithelial and mesenchymal markers are plotted for the mean average of 
MIA PaCa-2, Pa02C, Pa14C and Pa16C cell lines. Error bars are shown as standard 
error. p values shown are from Wald test and are in comparison to the vehicle control. 
Adjusted p values = CDH1 (*, 0.0252), CLDN1 (0.8818), TJP1 (0.7301), VIM (0.8465), 
CDH2 (0.3881), CTNNB1 (0.2445), SNAI1 (0.2542), SNAI2 (0.5672), ZEB1 (*, 0.0262). 
 
transcription and protein levels upon RAFi/ERKi treatment (Fig. 3.3 B; Fig. 3.5, A and B; 
Fig. B8 B) is consistent with a partial MET program. The degree of E-cadherin increase 
correlated with the degree of pERK reduction, which was caused most effectively by 
combination RAFi/ERKi compared to treatment with any single inhibitor or other 
combinations. Increases in E-cadherin also correlated with induction of apoptosis (Fig. 
3.4, B to D; Fig. B7, C to E). In the lines in which E-cadherin was upregulated, RAFi/ERKi 
also synergistically induced apoptosis. In contrast, in Pa01C cells, RAFi/ERKi did not alter 
E-cadherin levels (Fig. B8 B) and caused only weak induction of apoptosis (Fig. 3.4 B 
and Fig. B7, C to E). Finally, immunofluorescence analyses determined that RAFi but not 
ERKi treatment alone enhanced E-cadherin staining at cell peripheries and at cell-cell 
junctions, and combined RAFi/ERKi treatment caused the strongest upregulation of E-
cadherin (Fig. 3.5 C and Fig. B8 C).  
We used RNA-Seq and GSEA to identify the mechanistic underpinnings of MET 
induced by RAFi/ERKi. Expression of CDH1, which encodes E-cadherin, was increased 
by the combination (Fig. 3.5 D), consistent with reduced levels of several transcription 
factors that suppress CDH1 transcription (SNAI1, SNAI2 and ZEB1) (203) (Fig. 3.5 D). 
Conversely, RPPA analyses showed that TGFβ/SMAD2, a well-established signaling 
pathway that drives EMT, was also reduced by RAFi/ERKi (Fig. 3.3 A). RAFi/ERKi caused 
81 
significant reduction in PLK1 activity (Fig. 3.3 A and Fig. B6 A), a driver of EMT through 
ERK and FRA1 (204), with FRA1 also significantly reduced transcriptionally (FOSL1) by 
this combination (Fig. B6 B). Thus induction of MET-like reprogramming, synergistically 
induced by RAFi/ERKi treatment, correlated with induction of apoptosis. 
3.3.6. CONCURRENT INHIBITION OF COMPENSATORY SIGNALING ENHANCES 
RAFI/ERKI CYTOTOXICITY 
We next addressed two additional potential improvements in response to the 
combination. First, we determined if sequential treatment could be more effective than 
concurrent treatment. We compared low-dose sequential inhibitor treatment to low-dose 
concurrent treatment. For sequential treatment, cells were treated with the initial RAFi or 
ERKi for 3 days and then the other inhibitor [(RAFi + ERKi) or (ERKi + RAFi)] was added. 
In Pa02C cells, RAFi/ERKi resulted in 70% fewer cells than vehicle or either inhibitor 
alone (Fig. 3.6 A). In contrast, sequential treatment in either order caused much more 
limited decrease (~20-25%). In Pa14C cells, whereas treatment with either RAFi or ERKi 
alone caused ~25% decrease, concurrent RAFi/ERKi treatment caused near-complete 
suppression of proliferation (~95%). By comparison, RAFi followed by ERKi, or ERKi 
followed by RAFi, caused ~75% or ~50% reduction, respectively. Thus concurrent 
treatment was more effective than sequential inhibitor treatment. 
Second, we determined if further concurrent inhibition of additional feedback 
mechanisms can further enhance RAFi/ERKi treatment in Pa02C cells, where there was 
room for improvement over the RAFi/ERKi combination (Fig. 3.6 A). We observed that 
RAFi/ERKi was associated with increased PAK activity. For example, RPPA 
demonstrated increased phosphorylation at the PAK phosphorylation site in CRAF (S338)  
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Figure 3.6. Concurrent Inhibition of Compensatory Signaling Enhances RAFi/ERKi 
Growth Inhibition (A) Pa02C and Pa14C cells were treated with RAFi (0.3 M), ERKi 
(0.04 M), FRAX597 (PAKi, 1 M) or MK2206 (AKTi, 0.6 M) alone or in combination (‘’/‘‘ 
concurrent inhibition; ‘‘+‘‘ sequential inhibition, inhibitor addition after 72 hr). Remaining 
cells were stained with crystal violet after a total of 5 days. Data are the mean average of 
two independent experiments. Error bars are shown as ± S.E.M. (B) Pa02C and Pa14C 
cells were treated as in (A) for a total of 5 days. Cell lysates were immunoblotted to 




(199) (Fig. 3.3 A and Fig. B4), and this was verified by immunoblotting (Fig. 3.6 B). 
Increased LIMK phosphorylation and activation, supported by increased phosphorylation 
at S3 of the actin-severing LIMK substrate Cofilin (Fig. 3.3 A and 3.6 B), was also 
consistent with upregulation of PAK activity. S3 phosphorylation inactivates Cofilin, 
stimulating actin polymerization (205), which is also consistent with the MET-associated 
changes (203) that we observed. Immunofluorescence images revealed F-actin 
rearrangement upon RAFi and/or ERKi treatment (Fig. B8 C). Thus, RAFi/ERKi was 
associated with increased PAK activation, likely through upregulation of RTK signaling 
(206). Therefore, we determined if adding the PAK inhibitor FRAX597 (PAKi) would 
further enhance RAFi/ERKi growth inhibition. PAKi treatment alone reduced pCRAF 
without affecting proliferation. However, the triple combination of RAFi/ERKi/PAKi was 
able to nearly ablate proliferation (Fig. 3.6 A and Fig. B9, A to C). 
Another potential compensatory activity is PI3K-AKT activation, which has been 
described in response to MEK inhibitor treatment. This also explains how concurrent 
PI3Ki can enhance ERK MAPK inhibitory activity (Fig. 3.2 A). Accordingly, RAFi/ERKi 
treatment of Pa02C cells increased AKT pS473, which was blocked by the AKT inhibitor 
MK2206 (AKTi) (Fig. 3.6 B). Like PAKi, AKTi alone did not affect proliferation, but 
concurrent or sequential AKTi treatment caused more growth suppression than 
RAFi/ERKi treatment alone (Fig. 3.6 A and Fig. B9, A to C). Thus, as with PAKi, concurrent 
AKTi treatment blocked a compensatory activation mechanism and further enhanced 




3.3.7. LOW-DOSE RAFI/ERKI VERTICAL INHIBITION IS EFFECTIVE IN KRAS-
MUTANT ORGANOIDS AND TUMOR-BEARING RATS 
We next evaluated the activity of the RAFi/ERKi combination in other KRAS-
mutant cancer cell lines, and in PDAC organoids and tumor-bearing animals. RAFi/ERKi 
also caused synergistic growth suppression in KRAS-mutant colon and lung cancer cell 
lines (Fig. 3.7 A and Fig. B10 A). Extending these analyses to models that may better 
reflect patient tumor response, we observed strong synergistic growth inhibition due to 
the RAFi/ERKi combination in patient-derived KRAS-mutant PDAC and CRC organoid 
models (Fig. 3.7, B and C; Fig. B10, B and C). 
Finally, we extended the analyses of the RAFi/ERKi combination to evaluate anti-
tumor activity. Since RAFi has poor pharmacokinetics in mice, our analyses were limited 
to analyses of PDAC cell line-induced tumors in immune-compromised rats. For these 
analyses, we utilized three PDAC lines that showed different degrees of response to 
vertical inhibition combinations. HPAF-II cells exhibit strong synergistic growth 
suppression with RAFi in combination with ERKi, MEKi and EGFRi (Fig. B10, E to G; 
Table S1 D; Table S1, F to H). CFPAC1 cells were also responsive to vertical inhibition 
combinations, but to a lesser degree, and SW1990 cells showed very limited increased 
growth suppression with the combinations. Whereas ERKi and RAFi alone simply 
reduced the rate of tumor growth in HPAF-II PDAC xenografts, the RAFi/ERKi vertical 
inhibition combination was able to induce tumor regression even at low doses, and did so 
without statistically significant toxicity (Fig. 3.7 D). The target-based mechanism of tumor 
regression is supported by immunoblot analyses of remaining tumor tissue isolated 4 hr 
after the last treatment (day 21), where the combination reduced ERK signaling more 
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potently than either inhibitor alone (Fig. 3.7 E and Fig. B10 D). Analyses of CFPAC-1 also 
determined that RAFi/ERKi showed greater activity than each inhibitor alone (Fig. B10, H 
and I). In contrast, RAFi alone did not significantly reduce SW1990 tumor growth, 
whereas ERKi alone or in combination with RAFi show comparable limited tumor 
reduction (Fig. B10 J). No significant toxicity was observed for both models, as indicated 
by maintained body weight (Fig. B10, H and J). Thus, the in vivo responses closely 
mirrored the different sensitivities of each cell line when evaluated in cell culture. 
 
3.4. DISCUSSION 
Despite the essential role of the RAF-MEK-ERK cascade in KRAS-dependent 
PDAC growth, single agent pharmacologic inhibition of this cascade has been ineffective, 
due to loss of ERK-dependent negative feedback inhibitory mechanisms that then cause 
ERK reactivation and drug resistance in cancer cells. Normal tissue toxicity has also been 
a limitation. To address these limitations, we applied a chemical screen to identify 
combinations that enhance the apoptotic activity of RAF-MEK-ERK inhibitors. While we 
identified multiple mechanistically distinct apoptotic combinations, surprisingly, the most 
potent combination was concurrent inhibition of two distinct nodes of the three-tiered ERK 
MAPK cascade, where treatment with a pan-RAF inhibitor together with an ERK-selective 
inhibitor (RAFi/ERKi) exhibited the strongest synergistic activity. Despite strong induction 
of compensatory signaling activities that can drive ERK reactivation, the RAFi/ERKi 
combination was able to cause synergistic suppression of ERK activation and system- 




Figure 3.7. Vertical ERK MAPK Inhibition is Effective in Organoid and Rat Models 
of KRAS-mutant Cancers (A) KRAS mutant cancer cell lines were treated with RAFi 
(0.01-2.5 M) and ERKi (0.08-1.25 M) alone or in combination for 120 hr. Proliferation 
was measured by Calcein AM cell viability assay. Representative bliss synergy score 
heatmaps for 3 independent experiments is shown (left). Red (synergy), green 
(antagonism), white (no effect). The averaged dose response curves of 3 independent 
experiments are shown (right). Error bars are ± S.E.M. Synergyavg = average bliss synergy 
score. (B) KRAS mutant PDAC (10 days) and CRC organoids (5 days) were treated with 
RAFi (0.01-2.5 M) and ERKi (0.04-0.63 M) alone or in combination. Proliferation was 
measured by CellTiter-Glo 3D cell viability assay. Dose response curves and bliss 
synergy scores were calculated and represented as in Fig. 3.7 A. (C) Representative 
images of PDAC organoid hM1A treated with the vehicle control DMSO, RAFi (0.16 M), 
ERKi (0.04 M) alone or in combination (left). Scale bar, 200 m. Representative images 
of CRC organoid OT238 treated with DMSO, RAFi (0.31 M), ERKi (0.04 M) alone or in 
combination (right). Scale bar, 100 m. (D) Relative tumor volume of the NIH nude rats 
with implanted HPAF-II cells were treated with RAFi (20 mpk, BID) alone or in combination 
with the ERK inhibitor LY3214996 (LY ERKi, 10 mpk, QD) for 36 days (left). Body weight 
changes are shown (right). Error bars are shown as ± S.E.M. (E) Quantitation of blot 
analysis to determine levels of pRSK of tumor lysates (n = 5 animals per group). Error 
bars are shown as ± S.E.M. 
 
apoptosis, loss of MYC-, E2F- and FRA1-dependent transcriptomes, impaired 
metabolism and induction of MET. That the synergistic apoptotic growth suppression was 
strongest at lower inhibitor concentrations suggests that combined vertical inhibition of 
the ERK MAPK signaling circuitry can overcome the limitations seen with single agent 
inhibition and lead to tumor regression rather than stasis at doses that can reduce normal 
tissue toxicity. 
The concept of vertical inhibition of ERK MAPK was first demonstrated in BRAF-
mutant melanoma, where BRAFi/MEKi combinations are now approved. This 
combination strategy delays onset of resistance and reduces toxicity compared with 
BRAF inhibitor treatment alone, albeit without any reduction in the dosing compared with 
BRAFi treatment alone (207-209). Extending this concept further, it was shown that a 
triple RAFi/MEKi/ERKi combination, with each used in the combination at the maximum 
tolerated dose, further delayed onset of resistance and exhibited stronger suppression of 
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BRAF-mutant tumors, and further reduced toxicity compared with the double combination 
MEKi/ERKi (210).  
Similar to our RAFi/ERKi vertical inhibition strategy, two recent studies showed 
that concurrent RAFi/MEKi treatment blocked ERK reactivation caused by MEKi 
treatment alone in KRAS-mutant or wild-type cancer cell lines (188,211). A third study 
showed that concurrent MEKi/ERKi treatment exhibited stronger inhibition of ERK and 
increased anti-tumor activity compared with either inhibitor alone (212). While our study 
found that combined inhibition of any two distinct nodes of the EGFR-RAF-MEK-ERK 
cascade is superior to any single node treatment, our analyses support the RAFi/ERKi 
combination as the optimal combination. MEK and ERK inhibitors are limited by CRAF 
reactivation, whereas RAF and MEK inhibitors are limited by ERK reactivation – therefore, 
the RAFi/ERKi combination targets the two key reactivation nodes. We also determined 
that concurrent rather than sequential inhibitor treatment allowed more effective ERK 
inhibition and growth suppression. Finally, we demonstrated that triple combinations with 
a third inhibitor that targets additional compensatory mechanisms (PAK or AKT activation) 
further enhance RAFi/ERKi activity.  
 To address a mechanistic basis for the synergistic and apoptotic growth 
suppression of the RAFi/ERKi combination, we applied RPPA and RNA-Seq analyses to 
identify activities seen with RAFi/ERKi but not with each inhibitor alone. Together, these 
analyses identified a spectrum of ERK-dependent signaling activities and cellular 
processes driven more potently by RAFi/ERKi than RAFi or ERKi alone, where any one 
perturbation alone would be expected to significantly impair cancer cell proliferation. 
Perhaps most significant is the synergistic loss of a key ERK substrate, MYC, and 
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suppression of MYC-regulated gene transcription. We showed recently that loss of MYC 
is a key basis for ERK inhibitor sensitivity in PDAC and that MYC suppression alone 
impairs PDAC tumorigenic growth (81,82).  
 RAFi/ERKi induced more robust suppression of ERK signaling than was 
achievable even by high dose treatment with each inhibitor alone. Along with this, it also 
more robustly induced changes associated with loss of ERK negative feedback 
mechanisms (195,196), such as suppressing transcription of multiple DUSP family genes 
encoding protein phosphatases that dephosphorylate and inactivate ERK, and activating 
RTKs that promote PAK-dependent phosphorylation and activation of CRAF. However, 
although these changes would be expected to reactivate ERK signaling, the combination 
nevertheless retained the ability to strongly suppress ERK signaling. Thus, another basis 
for the synergistic activity of RAFi/ERKi is insensitivity to the compensatory activation 
mechanisms that limit the effectiveness of RAF, MEK or ERK inhibitors when used as 
single agent therapies. An additional unexpected consequence of RAFi/ERKi was 
inhibition of SHP2, a key relay mechanism that connects RTK activation with downstream 
activation of RAS and ERK signaling. Recent studies showed that concurrent treatment 
with a SHP2 inhibitor can negate the RTK-mediated compensatory activities that are 
stimulated by ERK MAPK inhibition and can synergistically enhance MEK inhibitor activity 
(201,213-216). 
 Concurrent RAFi/MEKi treatment also caused apoptotic cell death not seen with 
each inhibitor alone. A mechanistic basis for this was identified, where the combination 
showed stronger promotion of pro-apoptotic and suppression of pro-survival activities. 
Similarly, RAFi/ERKi synergistically caused G1 arrest through RB activation of loss of 
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transcription of E2F-mediated gene expression. Together, these activities provide a basis 
for the ability of RAFi/ERKi to suppress PDAC growth at lower concentrations of each 
inhibitor. Thus, vertical inhibition of the ERK MAPK cascade may reduce the normal tissue 
toxicity seen with single agent therapy and promote cytotoxic rather than cytostatic 
inhibition of cancer cell proliferation. 
 We also observed that RAFi/ERKi induced a partial MET program by 
transcriptional suppression of SNAI1/2 and ZEB1, the latter of which encodes a 
transcription factor suppressor of CDH1 transcription (203). With enhanced CDH1 
expression promoting enhanced E-cadherin expression, a key driver of MET, RAFi/ERKi-
treated PDAC cells exhibit a transition from a mesenchymal to an epithelial state. Further, 
we observed a trend in which MET was the strongest in the PDAC cell lines where 
RAFi/ERKi caused the strongest induction of apoptosis. This relationship mirrors the 
earlier findings, where KRAS-mutant cancer cell lines with a mesenchymal phenotype 
were those that escaped KRAS addiction, whereas KRAS-mutant cell lines with an 
epithelial phenotype were susceptible to KRAS suppression-induced apoptosis (143). 
Similarly, McCormick and colleagues found that KRAS-mutant cancer cells with an 
epithelial but not mesenchymal phenotype exhibited ERK-dependency (182). 
 Our determination that the RAFi/ERKi combination caused both G1 arrest and 
apoptosis in cancer cells shows the ability of this combination to block tumorigenic growth 
and cause tumor regression. Additionally, we found that RAFi/ERKi may enhance an anti-
tumor immune response. Whereas EPHA2 has been shown to suppress anti-tumor T-cell 
immunity (217), kinome profiling upon RAFi/ERKi treatment revealed reduction of EPHA2 
expression/activity. Further, one of the strongest consequences of RAFi/ERKi was 
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stimulation of interferon-α/γ genes, which would also stimulate a T-cell immune response 
(197). Thus, RAFi/ERKi may cause potent anti-tumor activity both by suppressing tumor 
cell growth as well as by stimulating a host immune response. Our analyses showed that 
RAFi/ERKi caused tumor regression in immune-suppressed rats. We speculate that the 
RAFi/ERKi combination will elicit robust tumor regression in syngeneic PDAC mouse 
models where there is an intact immune system. 
 During the course of our studies, a clinical trial evaluating LY3009120 in patients 
with advanced or metastatic cancer was terminated early based on the lack of sufficient 
clinical efficacy observed (NCT02014116), emphasizing the need to consider vertical 
inhibition combination approaches. One ongoing clinical trial is evaluating the pan-RAF 
inhibitor LXH254 in combination with either an ERK or MEK inhibitor in patients with 
advanced or metastatic KRAS-mutant lung cancer or NRAS-mutant melanoma 
(NCT02974725). This study will provide a clinical comparison of a RAFi/ERKi versus 
RAFi/MEKi combination. 
 In summary, while we identified inhibitors of diverse cellular components that 
enhanced the anti-tumor activity of a pan-RAF inhibitor, the most potent combination 
involved vertical inhibition of the RAF-MEK-ERK cascade that was effective at low doses. 
Our evidence shows that RAFi/ERKi, despite stimulating robust compensatory 
mechanisms that can drive ERK reactivation, is refractory to these mechanisms and 
consequently achieves pathway suppression at a level not achievable with each inhibitor 
alone. This concept is further supported by our triple combinations with inhibitors of PAK- 
or AKT-dependent compensatory mechanisms. This causes loss of a spectrum of ERK-
dependent cellular processes driven by aberrant gene transcription (G1 progression, pro-
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survival, EMT) that then promotes cancer cell death and tumor regression. Finally, since 
we found that RAFi/ERKi was effective in KRAS-mutant pancreatic, lung and colorectal 
cancer cell lines, this combination may serve as a pan-KRAS mutant cancer therapy. 
 
3.5. MATERIALS AND METHODS 
3.5.1. DATA AND CODE AVAILABILITY 
Binary sequence alignment/map (BAM) files of RNA-seq data of cell lines MIA 
PaCA-2, Pa02C, Pa14C and Pa16C are available from the EMBL-EBI European 
Nucleotide Archive (ENA) database - http://www.ebi.ac.uk/ena/ with accession number 
PRJEB38063 are accessible via http://www.ebi.ac.uk/ena/data/view/PRJEB38063. The 
file names containing "R" indicate RAF inhibitor treated samples, "E" indicate ERK 
inhibitor treated samples, "C" indicate combination treated samples and "V" indicate 
vehicle control. The file names containing "4" and "24" indicate treatment time of 4 hours 
and 24 hours respectively." 
3.5.2. CELL CULTURE 
The patient-derived xenograft (PDX) human pancreatic cancer cell lines Pa01C, 
Pa02C, Pa03C, Pa04C, Pa14C and Pa16C were gifted by Dr. Anirban Maitra (MD 
Anderson Cancer Center). Conventional human pancreatic cancer cell lines (MIA PaCa-
2, PANC-1, HPAF-II, CFPAC-1 and SW 1990), lung cancer cell lines (A549, NCI-H358 
and SW900) and colorectal cancer cell line (SW620) were obtained from American Type 
Culture Collection (ATCC). PDX pancreatic and colorectal cancer cell lines were 
maintained in Dulbecco’s Modified Eagle medium (DMEM) supplemented with 10% fetal 
bovine serum (FBS). HPAF-II, CFPAC-1 and SW 1990 pancreatic cancer cell lines were 
maintained in RPMI 1640 medium supplemented with 10% fetal bovine serum (FBS), 
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respectively. Lung cancer cell lines were maintained in RPMI medium supplemented with 
10% FBS. Cell lines were tested for mycoplasma. Pancreatic cancer cell line identities 
were verified by Short Tandem Repeat (STR) analysis. 
3.5.3. PATIENT-DERIVED ORGANOIDS 
The human pancreatic cancer organoids were provided by Dr. David Tuveson 
(Cold Spring Harbor Laboratory). The patient-derived PDAC organoids hM1A KRASG12D 
and hT2 KRASG12R were cultured at 37°C in 5% CO2. Cells were seeded in growth factor 
reduced Matrigel (Corning) domes and fed with complete human feeding medium: 
advanced DMEM/F12 based WRN condition media (L-WRN (ATCC CRL-3276)), 1x B27 
supplement, 10 mM HEPES, 0.01 µM GlutaMAX, 10 mM nicotinamide, 1.25 mM N-
acetylcysteine, 50 ng/mL hEGF, 100 ng/mL hFGF10, 0.01 µM hGastrin I, 500 nM A83-
01, 1 µM PGE2 and additionally 10.5 µM Y27632 (17). Organoids were tested for 
mycoplasma. The patient-derived colorectal organoids OT227 KRASG13D, OT238 
KRASG12D and OT302 KRASG12D were previously fully characterized in terms of genomic 
alterations by (218). CRC organoids were cultured in crypt culture medium (CCM) 
containing advanced DMEM/F12 (Gibco) supplemented with 1x GlutaMAX™ (Gibco), 10 
mM HEPES buffer (Gibco), Penicillin/Streptomycin (100 U/ml/100 μg/ml), 1 mM N-
acetylcysteine (Sigma), 1x N2 Supplement (Gibco), 1x B27 Supplement (Gibco) and 
prepared with freshly added hFGF basic/FGF2 (20 ng/ml) (Sigma) and hEGF (50 ng/ml) 
(Sigma).  
3.5.4. RATS 
All in vivo studies were performed in accordance with the American Association 
for Laboratory Animal Care institutional guidelines and approved by The Eli Lilly and 
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Company Animal Care and Use Committee. HPAF-II, CFPAC-1 and SW1990 pancreatic 
cancer cells (ATCC cat#CRL-1997)) were cultured in MEM supplemented with 10% heat 
inactivated fetal bovine serum, sodium pyruvate, and nonessential amino acids. Cell lines 
were tested for mycoplasma and identity was confirmed by STR-based DNA finger 
printing and multiplex PCR (IDEXX-Radil). Logarithmically growing cells with < 7 passage 
from the thaw were used for implantation.  
In all three studies (HPAF II, CFPAC1 and SW1990), 7-8 weeks old (120-145 
grams) female NIH Nude (NIHRNU-IVI) rats from Taconic Farms Inc were used. Animal 
maintenance and care:12 hr light/dark cycle, Temp: 68-75oC, Humidity: 30-70% relative, 
3-5 animals /cage, Bedding: Bed o cob, Filtered water, Feeding: Ad libitum, Feed: 
Standard chow 
3.5.5. SHRNA AND PLASMID TRANSFECTIONS 
The shRNAs targeting ARAF (TRCN0000000567, TRCN0000000568), BRAF 
(TRCN0000006290, TRCN0000006291), and CRAF (TRCN0000001065, 
TRCN0000001066) were provided Deborah K. Morrison (NCI), and shRNA targeting 
KRAS (TRCN0000010369) was provided by J. Settleman (Genentech). 0.9 x 106 
HEK293T cells were seeded on T25 flasks and incubated overnight. To generate lentiviral 
particles, HEK293T cells were transfected with plasmids by using FuGENE6 (Roche) 
protocol. Vector (4 g), pSPAX2 (3 g) and pMD2.G (1 g) plasmids were diluted in 400 
l Opti-MEM medium. 24 Transfection reagent FuGENE6 (24 l) was added into the 
diluted plasmid mixture and incubated for 15 min at room temperature. Transfection 
mixture was added onto HEK293T cells dropwise and incubated overnight. Transfection 
medium was replaced with DMEM with 20% FBS and incubated for 48 hr. Virus particles 
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were collected. 106 cells were infected by 0.5 l virus combined with polybrene (final 
concentration of 8 g/l) in 2 ml medium. The medium was replaced with complete 
medium (DMEM with 10% FBS) after 8 hr. Antibiotic selection was started after 12-16 hr 
of incubation in complete medium. Upon 72 or 120 hr of antibiotic selection, cells were 
collected for immunoblotting, anchorage-independent colony formation, or proliferation 
assays. 
To quantify anchorage-independent colony formation, 400-100 cells per well 
(depending on the cell line) were seeded on 6-well plates and incubated for ≥ 10 days at 
37°C until colonies were formed. Colonies were stained by crystal violet and quantified 
by ImageJ (version 2.0.0). Briefly, the 6-well plate images were converted to 8-bit images. 
The same thresholding was applied to all the wells to subtract background. The mean 
intensities were normalized by dividing each value to the average intensity of its 
respective control well. 
To quantify proliferation, 2x105 cells per well were seeded and incubated overnight 
at 37°C. The next day cells were treated with LY3009120 (0.3 M), SCH772984 (0.04 
M), the PAK1 inhibitor FRAX-597 (0.5 M), or the pan-AKT1/2/3 inhibitor MK-2206 (0.6 
M) alone or in various combinations as indicated in the figures for a total of 10 days. 
Cells were stained by crystal violet and quantified by ImageJ as described above. 
3.5.6. IMMUNOBLOTTING 
The human pancreatic cancer cells were washed with ice-cold PBS, lysed with ice-
cold 1% RIPA buffer (50 mM Tris-HCl, pH 8.0, 150 mM NaCl, 0.01% SDS, 0.5% sodium 
deoxycholate, 1% NP-40) supplemented with protease (Roche) and phosphatase 
(Sigma) inhibitors, scraped and incubated in cold tubes for 10 min on ice. Cell lysates 
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were centrifuged at 18,213 x g (12,700 rpm) at 4°C for 10 min, and the supernatant was 
used for determining protein concentration by Bradford assay (Bio-Rad). Standard 
immunoblotting procedures were followed. Membranes were blocked in 5% BSA diluted 
in TBST (TBS with 0.05% Tween 20) for 1 hr.  
3.5.7. PROLIFERATION ASSAYS 
The cancer cells (103 per well) were seeded in 96-well plates, incubated overnight, 
and treated with small molecule inhibitors. Cells were treated with a pan-RAF inhibitor 
LY3009120 (0.01-2.5 M) alone or in combination with ERK1/2 inhibitor SCH772984 
(0.04-1.25 M, 72 or 120 hr), ERK1/2 inhibitor LY3214996 (0.04-1.25 M, 120 hr), 
MEK1/2 inhibitor trametinib (Mekinist) (0.125-4.0 nM, 120 hr), or EGFR inhibitor erlotinib 
(Tarceva) (0.01-2.5 M, 120 hr). Cells were treated with ERK1/2 inhibitor SCH772984 
(0.04-0.16 M) alone or in combination with mutant BRAF-selective inhibitor vemurafenib 
(Zelboraf) (0.01-2.5 M), ERK1/2 inhibitor ulixertinib (BVD-523) (0.01-2.5 M), or RAF 
family kinases and EGFR inhibitor BGB-283 (lifirafenib) (0.01-2.5 M) for 120 hr. Vehicle 
control DMSO was kept ≤ 0.01%. Cells were incubated at 37°C 72 or 120 hr. Proliferation 
was measured by counting calcein AM (500 nM, 20 min) (Invitrogen) labeled live cells by 
using a SpectraMax i3x multimode detection platform (Molecular Devices). Bliss synergy 
scores were calculated using SynergyFinder (version 1.6.1) package of R (version 3.5.1) 
environment. An R script was used to convert the 96-well plate format data into 
SynergyFinder data table format. SynergyFinder data table includes the identifiers for 
inhbitiors, row and column numbers, the name of the inhibitors in a dose-response matrix, 
the concentration and its unit for each well, and the response, which is % inhibition in cell 
growth. SynergyFinder calculates a synergy score based on Bliss model (219). 
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3.5.8. DESIGN AND CLONING OF THE CRISPR LIBRARY 
In order to assemble a library of druggable, cancer-relevant genes, we manually 
curated 2,240 genes from six broad domains of interest: chromatin modifiers (including 
epigenetic readers, writers, erasers), the full kinome, pathways responsible for mediating 
and repairing DNA damage, genes/proteins that represent the target of FDA-approved 
drugs for any indication, genes that are frequently mutated in cancer, and genes that 
comprise the pathways most frequently dysregulated in tumorigenesis, tumor 
maintenance, and drug resistance.  Beyond these genes of interest, we also selected 150 
genes, chosen for their demonstrated dispensability or non-dispensability across a series 
of essentiality studies (220), to be used as control genes. We selected five constructs to 
represent each of these 2,390 genes, producing a subtotal of 11,950 short guide RNA 
(sgRNA) constructs.  Finally, we included 50 non-targeting control constructs for a total 
of 12,000 sgRNAs.  All of the CRISPR constructs used in this library were selected from 
a previously characterized and published library (221). sgRNA inserts corresponding to 
the entire 12,000 sgRNA library were synthesized by CustomArray, Inc in the form: 
GGAAAGGACGAAACACCGXXXXXXXXXXXXXXXXXXXXGTTTTAGAGCTAGAAATA
GCAAGTTAAAATAAGGC. Where "X" denotes variable 20mer sgRNA sequence unique 
to each construct. The resulting library was cloned using previously published methods 
(222). In brief, the oligo pool was diluted 1:100 in molecular biology grade water and 








PCR protocol: 98°C/30 s, 18 × [98°C/10 s, 63°C/10 s, 72°C/15 s], 72°C/3 min. Resulting 
inserts were processed with Axygen PCR clean-up beads (ratio of 1.8 x starting volume; 
Fisher Scientific) and reconstituted in half the volume of molecular biology grade water. 
In parallel, the lentiCRISPRv2 vector (Addgene ID 52961) was digested with BsmBI 
(Thermo Fisher) at 37°C for 2 hr. The product was run out for size-selection on a 1% 
agarose gel and the ~13 kB band was gel-extracted. Using 100 ng of BsmBI-cleaved 
lentiCRISPRv2 and 40 ng of sgRNA oligo insert as substrates, a Gibson assembly 
reaction was performed (total volume of 20 μl, for 30 min, at 50°C). Following Gibson 
assembly, 1 μl of the product was electroporated into electrocompetent Lucigen 10G-elite 
cells, spread onto LB-ampicillin plates and incubated at 37°C for 16 hr. The efficiency of 
transformation was estimated by plating limiting dilutions on LB-ampicillin plates.  Multiple 
electroporations were performed, producing an estimated 500,000 total colonies, 
sufficient to cover the entire library of 12,000 constructs more than 40-fold.  The colonies 
were collected in LB and plasmid extra was performed using a plasmid maxiprep kit 
(QIAGEN). DNA was used to make lentivirus. 
3.5.9. CRISPR/CAS9 LIBRARY LENTIVIRUS GENERATION AND INFECTION  
Lentivirus generation was performed as described previously (137). HEK 293T 
cells were seeded in 15 cm dishes and grown up to 50% confluency. Library plasmid 
(6.25 μg), psPAX2 (5.6 μg), pVSVg (0.625 μg) and transfection reagent FuGENE6 
(Roche) was incubated for 30 min. The transfection mixture was added to the cells and 
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incubated overnight. Harvest media (DMEM with 30% FBS) was added the next day and 
incubated for 48 hr. Virus particles were collected and filtered through a 0.45 μm filter. 
Virus tittering was performed as described previously (137). 
 Human pancreatic cancer cell lines (5x105 per well) were seeded in 6-well plates 
and incubated overnight. Next day, virus was added at an MOI of 0.3. Upon puromycin 
selection, a day 2 sample is taken to ensure library representation and the remaining cells 
were seeded in 500 cm dishes. The cells were maintained in puromycin media for 10 
days to achieve 1,000x coverage of the library. The cells were either treated with vehicle 
control DMSO (≤ 0.01%) or LY3009120 RAF inhibitor (GI20-30). The cells were collected 
after 2 and 4 weeks, DNA was extracted with DNeasy Blood & Tissue Kit (QIAGEN) and 
prepared for sequencing. 
3.5.10. DRUG SENSITIVITY RESISTANCE TESTING (DSRT) CHEMICAL LIBRARY 
SCREEN  
The DSRT platform that has been described previously (194,223) was adapted for 
the PDAC cell lines. 525 different oncological compounds were utilized in this study 
(Supplementary Table S2J). The compounds were plated to white clear bottom 384-well 
plates (Corning #3712) in 5 concentrations in 10-fold dilution steps, thus covering an 
individually optimized 10,000-fold concentration range for each compound using an Echo 
550 Liquid Handler (Labcyte). Cell killing 100 μM benzethonium chloride (BzCl2) and 0.1% 
dimethyl sulfoxide (DMSO) vehicle were used as positive and negative controls 
respectively. For the combination screenings, single concentration of RAFi (LY3009120), 
MEKi (trametinib), ERKi (SCH772984) in final concentrations of 2 M, 25 nM, or 100 nM 
respectively, were added on top of 525 compound 5-concentrations plates using Echo 
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550. Pa01C, Pa02C, Pa03C, Pa04C, Pa14C, Pa18C and MDA-PATC53 were screened 
in combination with ravoxertinib whereas the remaining cell lines were screened in 
combination with SCH772984. All subsequent liquid handling was performed using a 
MultiDrop dispenser (Thermo Scientific). The pre-dispensed compounds were dissolved 
in 5 l of culture media, containing viability and cytotoxicity measurement reagents, 
RealTime-Glo and CellTox Green (Promega), respectively and left on a plate shaker 
at room temperature for 30 min. Twenty l cell suspension containing optimized number 
of cells per well were seeded in the drugged plates. After 72 hr incubation, the multiplexed 
cell viability (luminescence) and cytotoxicity (fluorescence) was recorded using a 
PheraStar plate reader (BMG Labtech). The raw luminescence and fluorescence data 
were analyzed in Breeze software, an in-house developed data analysis pipeline at 
Institute for molecular Medicine Finland (FIMM), to calculate the drug sensitivity scores 
(DSS) (224). The drug combination selective effect was calculated as combination DSS 
minus single agent DSS, termed as “Delta DSS”.  
3.5.11. REVERSE PHASE PROTEIN ARRAY (RPPA) 
Human pancreatic cancer cell lines MIA PaCA-2, Pa02C, Pa14C and Pa16C were 
seeded (2x105 cells per well) onto 6-well plates. The next day cells were treated with 
vehicle control DMSO (≤ 0.01%), LY3009120 RAFi (0.3 M), SCH772984 ERKi (0.04 
M), or the combination of the two inhibitors for 15 min, and 1, 8, 24 or 72 hr. Cells were 
lysed and processed as previously described (142). Coomassie Protein Assay Reagent 
kit (Thermo Fisher Scientific) was used to measure protein concentration, following the 
manufacturer’s instructions. 2X Tris-glycine SDS sample buffer (Life Technologies) with 
5% β-mercaptoethanol was used to dilute cell lysates to 0.5 mg/ml. Samples were boiled 
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for 8 min and stored at -20°C until arrayed. An Aushon 2470 automated system (Aushon 
BioSystems) (173) was used to immobilize cell lysates and the internal controls and print 
in technical replicates (n = 3) onto nitrocellulose-coated glass slides (Grace Bio-Labs). 
Sypro Ruby Protein Blot Stain (Molecular Probes) was used to quantify protein 
concentration in each sample, following the manufacturer’s instructions. Reblot Antibody 
Stripping solution (Chemicon) was used to pretreat the remaining arrays (15 min at room 
temperature). The arrays were washed with PBS and incubated in I-block (Tropix) for 5 
hr before antibody staining (142). Arrays were incubated with 3% H2O2, Avidin, Biotin 
(DakoCytomation), and an additional serum-free protein block (DakoCytomation) to 
reduce nonspecific binding of endogenous proteins. Staining was performed using an 
automated system (DakoCytomation) was used. Each slide was probed for 30 min with 
one antibody targeting the protein of interest, with 157 antibodies that target proteins 
involved in signaling networks that regulate cell growth, survival and metabolism were 
used to probe arrays (Supplementary Table S2J). All antibodies used were validated as 
described previously (174). Signal amplification was determined by using biotinylated 
anti-rabbit (Vector Laboratories) or anti-mouse secondary antibody (DakoCytomation) 
and a commercially available tyramide-based avidin-biotin amplification system 
(Catalyzed Signal Amplification System, DakoCytomation). IRDye 680RD streptavidin 
(LI-COR Biosciences) fluorescent detection system was used. TECAN laser scanner was 
used to scan Sypro Ruby and antibody stained slides, and the images were analyzed 
using commercially available software (MicroVigene Version 5.1.0.0, Vigenetech) as 
previously described (175). 
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3.5.12. RNA SEQUENCING 
The human pancreatic cancer cell lines MIA PaCA-2, Pa02C, Pa14C and Pa16C 
were seeded at ~50% confluency. The next day the cells were treated with the vehicle 
control DMSO (≤ 0.01%), LY3009120 (RAFi, 0.3 M), SCH772984 (ERKi, 0.04 M) or 
the combination of the two inhibitors for 4 or 24 hr. The cells were washed twice with ice-
cold PBS and before scrape removal in ice-cold PBS. The cells were collected by 
centrifugation at 326 x g (500 rpm) at 4°C for 10 min, and the cell pellets were flash frozen 
by liquid nitrogen. Whole transcriptome libraries were generated from total RNA (50 ng) 
of the human pancreatic cancer cell lines by using Illumina’s Truseq RNA Sample Prep 
to perform RNA sequencing. Oligo(dT) magnetic beads were used to select Poly(A) 
mRNA, and TruSeq PCR Master Mix and primer cocktail were used to enrich the libraries. 
The Agilent Bioanalyzer and Invitrogen Qubit were used to clean and quantify the 
amplified products. The Illumina HiSeq 2500 was used to sequence the clustered flowcell 
for paired 100-bp reads by using Illumina’s TruSeq SBS Kit V3. Lane level fastq files were 
appended together if they were sequenced across multiple lanes. These fastq files were 
then aligned with STAR 2.3.1 to GRCh37.62 using ensembl.74.genes.gtf as GTF files. 
Transcript abundances were quantified by HTSeq in total read counts per transcript.  
3.5.13. MIB/MS 
The human pancreatic cancer cell line MIA PaCA-2 was treated with the vehicle 
control DMSO (≤ 0.01%), LY3009120 (RAFi; 0.3 M), trametinib (MEKi; 0.5 nM), 
SCH772984 ERKi (0.04 M), or the combinations of RAFi/MEKi and RAFi/ERKi for 72 hr. 
The samples were prepared as described previously (139). Briefly, the cells were 
processed on ice by using MIB lysis buffer [50 mM HEPES (pH 7.5), 0.5% Triton X-100, 
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150 mM NaCl, 1 mM EDTA, 1 mM EGTA, 10 mM sodium fluoride, 2.5 mM sodium 
orthovanadate, 1X protease inhibitor cocktail (Roche), 1% phosphatase inhibitor cocktail 
2 (Sigma-Aldrich), and 1% of phosphatase inhibitor cocktail 3 (Sigma-Aldrich)]. The cell 
lysates were sonicated (3 x 10 sec) on ice and were collected by centrifugation (10,000 x 
g) at 4°C for 10 min. The supernatant was filtered through a 0.2 mm SFCA membrane. 
The lysates (~5 mg protein per experiment) were gravity-flowed over multiplexed kinase 
inhibitor beads (MIBs) (Sepharose conjugated to VI-16832, CTx-0294885, PP58, 
Purvalanol B, UNC8088A, UNC21474). MIBs were washed with high (1 M NaCl) and low 
salt (150 mM NaCl + 0.1% SDS) lysis buffers without the inhibitors. The samples were 
boiled with the elution buffer (100 mM Tris-HCl, 0.5% SDS, and 1% -mercaptoethanol, 
pH 6.8) at 100°C for 5 min to elute the bound kinases from MIBs. The eluted kinases 
(proteins) were concentrated with Amicon Ultra-4 (10K cutoff) spin columns (Millipore), 
purified by removing the detergent using methanol/chloroform extraction, and digested by 
sequencing grade Trypsin (Promega) overnight at 37°C. Hydrated ethyl acetate 
extraction was used to remove triton, and PepClean C-18 spin columns (Pierce, Thermo 
Scientific) were used to de-salt the digested peptides. 
Biological triplicates of the MIB samples were analyzed by LC-MS/MS as 
described previously (81). Briefly, each sample was injected onto an Easy Spray PepMap 
C18 column (75 μm id × 25 cm, 2 μm particle size) (Thermo Scientific) and separated 
over a 2 hr method. The gradient for separation consisted of 5–32% mobile phase B at a 
250 nl/min flow rate, where mobile phase A was 0.1% formic acid in water and mobile 
phase B consisted of 0.1% formic acid in ACN. The Thermo QExactive HF was operated 
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in data-dependent mode where the 15 most intense precursors were selected for 
subsequent HCD fragmentation (set to 27%).  
3.5.14. FLOW CYTOMETRY 
TACS® Annexin V-FITC Kit (BD Biosciences) was used to measure apoptosis 
according to the manufacturer’s instructions. Detached cells in the culture medium and 
the trypsinized cells were collected, mixed and centrifuged at 300 x g for 5 min at room 
temperature. The cells were washed with ice-cold PBS and incubated in Annexin V 
Incubation Reagent (1% Annexin V-FITC, 1X propidium iodide solution, in 1X calcium-
containing binding buffer) in the dark for 15 min at room temperature. Cell mixture was 
diluted 1:5 in 1X binding buffer. BD LSRFortessa flow cytometer was used to analyze the 
cells. FACSDiva v8.0.1 was used to collect and export 30,000 cells to be analyzed with 
Cytobank. A “cells“ gate was generated to avoid small and large debris in the bottom right 
corner or off-scale on either axis by using a side scatter area (SSC-A) (y) versus forward 
scatter area (FSC-A) (x) dot plot. Propidium iodide area (PI-A) (y) versus fluorescein 
isothiocyanate area (FITC-A) (x) dot plot was used to measure apoptosis. Vehicle control 
DMSO (≤ 0.01%) treated cells were assigned as the healthy cell population by a quadrant 
gate (PI-A negative, FITC-A negative). 
3.5.15. IMMUNOFLUORESCENCE 
Human pancreatic cancer cells Pa01C and Pa02C were plated on 10 g/ml 
fibronectin-coated glass coverslips and treated with DMSO (≤ 0.01%), LY3009120 RAFi 
(0.3 M), SCH772984 ERKi (0.04 M), or the combination of the two inhibitors for 72 hr. 
The cells were washed twice with PBS, fixed in 3.7% formaldehyde (Fisher Scientific) for 
10 min at room temperature, washed with PBS and permeabilized with 0.1% Triton-X100 
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(Sigma) for 5 min at room temperature. Non-specific signals were blocked using 2% BSA 
(Sigma) in PBS for 30 min at room temperature. Cells were incubated with the primary 
antibody (diluted in 2% BSA-PBS) for 40 min at room temperature, followed by three 
washes with PBS and incubation with the secondary antibody (diluted in 2% BSA-PBS) 
for 45 min at room temperature. After washing three times with PBS, cells were mounted 
with Prolong Diamond antifade mounting media (Invitrogen). E-cadherin was visualized 
by anti-rabbit E-cadherin (clone 24E10; Cell Signaling, 1:100) followed by a goat-anti-
rabbit Alexa-Fluor-568 conjugated secondary antibody (Invitrogen, 1:200). Phalloidin 
conjugated with an Alexa-488 fluorophore (Invitrogen, 1:200) was used to visualize F-
actin and DAPI (Invitrogen, 1:10000) was used to label the nucleus. Images were 
acquired in five random fields on an Olympus FV1000 confocal microscope using a 40x 
objective (1.2 zoom) and a maximally opened pinhole. 
3.5.16. ORGANOID VIABILITY ASSAY 
PDAC organoids were dissociated and 3000 single cells per well were seeded in 
150 µl of 10% growth factor reduced Matrigel (Corning) and 90% human organoid feeding 
media + 10.5 µM Y27632 (Selleckchem) into Poly(2-hydroxyethyl methacrylate) (SIGMA) 
coated 96-well clear flat bottom plates (Corning Ref. 3903). On the second day after 
seeding organoids were drugged with SCH772984 (0.04 μM to 0.63 μM) and LY3009120 
(0.01 μM to 2.5 μM). Ten days after drugging, organoids were imaged with the Molecular 
Devices SpectraMax i3x MiniMax 300 imaging cytometer. After image acquisition 
organoid viability was accessed with CellTiter-Glo 3D Cell Viability Assay (Promega) 
according to manufactures protocol on the SpectraMax i3x plate reader. Colorectal 
organoid cultures were immersed in 90% Matrigel (BD, Cat# 356231), plated onto 24-well 
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plates in 20 µl drops per well and upon solidification overlaid with 500 µl CCM. For 
inhibitor experiments the organoids were harvested and trypsinized until single cell 
suspension was available for plating onto flat bottom 96-well format (Corning, Cat. No. 
3603) (outer wells filled with PBS only). Per well 1000-1500 single cell organoids were 
plated in a 6 µl Matrigel drop and 150 µl CCM was added to culture PD3D’s for two days 
prior inhibitor addition. The inhibitors were added to the CRC PD3D’s as specified using 
the Tecan 300D dispenser and incubated for 5 days prior monitoring of proliferation by 
microscopy (Exp1-3, Tecan Spark, Exp 4 and 5, Keyence BZ-X710) and CellTiter-Glo 
3D measurement. 
Bliss synergy scores were calculated using SynergyFinder as described in “Proliferation 
assays”. 
3.5.17. PDAC XENOGRAFT STUDY 
Five x 106 HPAF II (ATCC# CRL-1997), CFPAC-1 (ATCC# CRL-1918) or SW1990 
(ATCC# CRL-2172) pancreatic cancer cells in a 1:1 Matrigel mix (HPAF-II and SW1990; 
0.2 ml total volume) were injected subcutaneously into the right hind flank of 7- to 8-week 
old (125-150 gm) female athymic NIH (NIHRNU-IVI) nude rats (Taconic Farms). After 
tumors reached 200-300 mm3, animals were randomized into groups of six. Both 
LY3214996/ERKi and LY3009120/RAFi were administered orally (gavage) in 0.2 ml 
volume of vehicle (1%HEC/0.25% Tween 80/0.05% Antifoam) for 21 days. Tumor volume 
and body weight are measured twice weekly.  Tumor volume is estimated by using the 
formula:  v = l x w2 x 0.536 where l = larger of measured diameter and w = smaller of 
perpendicular diameter.   
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3.5.18. PRISM SOFTWARE 
GraphPad Prism (versions 7.0.4 and 8.0.2) built-in tests were used to analyze the 
data provided. For the box plots and growth inhibition curves, data are the mean average 
of 3 independent experiments and error bars are represented as ±S.E.M. (unless 
otherwise noted). p values are indicated on the graphs and the absolute values are 
denoted in the figure legends. All data presented are normalized to their respective 
vehicle control. Technical and biological replicates are as indicated in the figure legends. 
3.5.19. IMAGEJ SOFTWARE 
ImageJ (version 2.0.0) software was used to analyze images (225). 
3.5.20. SYNERGYFINDER 
Bliss synergy scores were calculated using SynergyFinder (version 1.6.1) R 
(version 3.5.1) package (226) as described in “Proliferation assays”.  
3.5.21. DECISION TREE AND FOREST ANALYSES 
Decision tree and forest analyses were performed by using Sci-Kit Learn (version 
0.20.3) in Python (version 3.6.3). RPPA data set was grouped into five categories: vehicle 
control versus RAFi, vehicle control versus ERKi, vehicle control versus RAFi + ERKi, 
RAFi versus RAFi + ERKi, and ERKi versus RAFi + ERKi. RPPA data set was further 
grouped into two categories as training and test data. Training (70% of RPPA data set) 
and test data (remining 30% of RPPA data set) comprise equal distribution of samples 
from the five categories described above. Decision trees were generated by using these 
training and test data. Accuracy for decision trees was above 80%. 
For decision forest analysis, 70% of the data from each of the five categories 
(described above) were fit to a decision forest by a Random Grid Search to optimize for 
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the best fitting forest based on F1 macro score (number of estimators between 300 and 
500 and max features between 30 and 150). Once a model was obtained, accuracy on 
the test set was accessed (greater than 90% for all categories) and feature importance’s 
from the model were used to rank the most critical proteins. 
3.5.22. CRISPR ANALYSIS 
CRISPR sequencing was performed at UNC (High-Throughput Sequencing 
Facility, Chapel Hill, NC) and Hudson Alpha (HudsonAlpha Genomic Services Laboratory, 
Huntsville, AL). Single-end sequencing (75 bp) was performed by using Illumina NextSeq 
500 with ~10% PhiX (varied depending on the run). Read counts for individual samples 
were quantified using the protocol outlined in (222). Briefly, unaligned reads in FASTQ 
format were used to generate a Burrows-Wheeler index using the Bowtie build-index 
function. Reads were then aligned to the index using the Bowtie aligner, followed by the 
quantification of the number of reads per sgRNA. For each pair of samples (vehicle control 
and drug treated), guide constructs were removed if they were not identified in the vehicle 
control. Missing values in the treated samples were imputed with the mean value of all 
guide constructs for that gene in the treated sample. Reads were then normalized 
between samples by converting them to a percentage of total reads per sample. The ratio 
of vehicle/treated for each construct yielded an “enrichment ratio” for the pair of samples 
per guide construct. To summarize results per gene, the average enrichment ratio (AER) 
was calculated for each gene among all constructs. Genes with a standard deviation in 
enrichment ratio greater than three were removed. Genes were rank ordered by their AER 
and assigned to bins according to their position in the ranked list. Genes were then given 
a value according to their bin assignment: top 10% sensitizers (bin value = 2), top 25% 
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sensitizer, excluding top 10% (bin value = 1), top 10% antagonizer (bin value = -2), top 
25% antagonizer, excluding top 10% (bin value = -1), neither sensitizer nor antagonizer 
(bin value = 0). Given the variability of genetic CRISPR-Cas9 screens (between samples 
and replicates), this bin placement method permitted greater comparability between 
sample pairs. 
3.5.23. DSRT CHEMICAL LIBRARY SCREEN ANALYSIS 
Inhibitors included in the screen were categorized by their known primary protein 
target (194,223,224). Cell lines and drugs were hierarchically clustered using average 
linkage and Euclidean distance; DSS values are displayed. 
3.5.24. RPPA ANALYSIS 
Antibody intensity values were imported into R (version 3.5.2) and missing values 
were imputed with the median intensity value for the respective antibody. Data were log2 
transformed and the fold change over the median vehicle value was calculated for each 
antibody, factored by cell line and time point. Euclidean distance and average linkage 
were utilized for semi-supervised hierarchical clustering of log2 fold-change values for 
antibodies. 
3.5.25. RNA SEQUENCING ANALYSIS 
Counts data were imported into R (version 3.5.2) and differential expression 
analysis was performed with the DESeq2 package (version 1.22.2) (227-231). Significant 
hits were defined by an adjusted p-value < 0.05. Gene set enrichment analysis (GSEA) 
was performed using the GSEA Desktop application (version 3.0, available at 
http://software.broadinstitute.org/gsea/index.jsp) and curated gene sets were obtained 
from MSigDB (v6.2, available at 
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http://software.broadinstitute.org/gsea/msigdb/index.jsp). Specific gene sets are 
referenced in figure legends. GSEAPreranked was run using the DESeq2 test statistic as 
the weighted ranking factor for each comparison.  
3.5.26. MIB/MS ANALYSIS 
Following MaxQuant processing of data and generation of Label-free quantification 
(LFQ) intensity values, data files were analyzed using R (version 3.5.2). A total of 207 
kinases were identified with 191 present in >50% of samples and containing two or more 
peptides. 27/191 kinases were missing one or more values after this filtering and these 
values were imputed. A normal distribution was modeled on the non-missing LFQ 
intensity values of the kinases containing missing intensity values. Imputed values were 
drawn randomly from this distribution. Following filtering and imputation, LFQ intensity 
values were log2 transformed and the fold change over the median vehicle value was 
calculated for each kinase. significant kinases between DMSO, ERKi, RAFi, and 
ERKi+RAFi treatments were determined using one-way ANOVA (Benjamini-Hochberg 
adjusted p-value < 0.05). Euclidean distance and average linkage were utilized for 
unsupervised hierarchical clustering of log2 fold-change values for significant kinases. 
3.5.27. TUMOR XENOGRAFT STATISTICAL ANALYSIS 
The statistical analysis of the tumor volume data begins with a data transformation 
to a log scale to equalize variance across time and treatment groups. The log volume 
data are analyzed with a two-way repeated measures analysis of variance by time and 
treatment using the MIXED procedures in SAS software (Version 9.3). The correlation 
model for the repeated measures is Spatial Power. Treated groups are compared to the 
control group at each time point. The MIXED procedure is also used separately for each 
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treatment group to calculate adjusted means and standard errors at each time point.  Both 
analyses account for the autocorrelation within each animal and the loss of data that 
occurs when animals with large tumors are removed from the study early. The adjusted 
means and standard errors (s.e.) are plotted for each treatment group versus time. 
Analysis for tumor volume is based on log10 and spatial power covariance structure. P 
value is based on the comparison between two specific groups.  
3.5.28. TUMOR XENOGRAFT COMBINATION ANALYSIS METHOD (BLISS 
INDEPENDENCE) 
First, the usual repeated measures model is fit to log volume versus group and 
time. Then contrast statements are used to test for an interaction effect at each time point 
using the 2 specific treatments that are combined.  This is equivalent to the Bliss 
Independence method and assumes that tumor volumes can, in theory, reach zero, i.e., 
complete regression. The expected additive response (EAR) for the combination is 
calculated on the tumor volume scale as: response (EAR) EAR volume = V1 * V2/V0, 
where V0, V1, and V2 are the estimated mean tumor volumes for the vehicle control, 
treatment 1 alone, and treatment 2 alone, respectively. If the interaction test is significant, 
the combination effect is declared statistically more than additive or less than additive 
depending on the observed combination mean volume being less than or more than the 
EAR volume, respectively. Otherwise, the statistical conclusion is additive.  In addition, a 
biologically relevant range of additivity can be defined as X% above and below the EAR 
volume. Typically, X would be 25 to 40%. Then a biological conclusion can be made for 
the combination as synergistic (greater than additive), additive, or less than additive if the 
observed combination mean volume is below, in, or above the interval of additivity. 
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There may be situations were stasis is the best expected response. In those 
situations, the Bliss method can be applied directly to the % delta T/C values to obtain an 
EAR percent response:  EAR % delta T/C = Y1 * Y2/100, where Y1 and Y2 are the 
percent delta T/C values for the single-agent treatments. Currently, there is no statistical 
test to compare the observed % delta T/C in the combination group versus the EAR, but 





CHAPTER 4: CONCLUSIONS AND FUTURE DIRECTIONS 
The work presented in this dissertation supplements our understanding of the 
signaling mechanisms that drive PDAC as well as the tumor cell response to targeted 
therapeutics. As the third-leading cause of cancer mortality in the US (1), it is critically 
important to develop new strategies to suppress growth or to kill pancreatic cancer cells 
in patients. Here, we demonstrate the importance of a number of kinase signaling 
pathways, including the MAPK cascade, in the maintenance of tumor cell proliferation. 
Additionally, in an effort to combat tumor resistance to single-agent MAPK cascade 
inhibition, we show that vertical inhibition of the RAF and ERK nodes provides a viable 
strategy to suppress growth and prevent feedback pathway reactivation. 
 In Chapter 2, we took a broad approach to better understand KRAS-regulated 
kinase signaling in pancreatic cancer. We hypothesized that KRAS suppression would 
alter kinase activity to support continued PDAC growth in the absence of the key pro-
proliferative oncogene. Our data support multiple known and previously undescribed 
mechanisms by which PDAC compensates for loss of KRAS, including upregulation of 
SRC and DDR1. Both SRC and DDR1 have previously been shown to play a role in PDAC 
tumor maintenance, but our findings support the additional pro-survival role of DDR1 in 
the absence of mutant KRAS (151,232). The DDR1 kinase is also a therapeutic target, 
though currently available small molecule inhibitors are only in the early stages of 
development (153). In the present study, we also show that WEE1 kinase is a viable 
therapeutic target in PDAC. We provide evidence that WEE1 kinase activity is important 
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for preventing apoptosis and maintaining cell proliferation in PDAC. Loss of WEE1 kinase, 
either by genetic suppression or small molecule inhibition, renders PDAC cells unable to 
survive the stress of cell division and traps cells in S/G2/M-phase of the cell cycle. 
Additionally, we show a synergistic reduction in proliferation and induction of apoptosis 
when cells are co-treated with an ERK inhibitor and a WEE1 inhibitor. 
PDAC is a highly stromal cancer; one known function of DDR1 is to transmit 
contextual clues from the surrounding extracellular matrix to intracellular signaling 
cascades. The tumor stroma in PDAC has also been shown to modulate the response of 
the tumor to chemotherapy, typically by reducing the efficacy of a drug (233). Future work 
on DDR1 might include the evaluation of the tumor and the stroma response to DDR1 
inhibition in organoid or mouse models of pancreatic cancer. If DDR1 is important in 
stromal maintenance in PDAC, DDR1 inhibition or genetic suppression may potentiate or 
synergize with current chemotherapies or other targeted therapies. The next steps in the 
evaluation of DDR1 as a target need to be carried out in in vivo models of PDAC, such 
as the KPC mouse model described in Chapter 1. Looking beyond inhibitors of DDR1, 
characterization of the interaction between tumor and stroma should be an emphasis 
during the preclinical evaluation of novel combination therapies. Small molecule therapies 
administered systemically are likely to have an impact on tumor, stromal cells and the 
immune system alike. We need to improve our understanding of the impact of potential 
treatments on the tumor microenvironment in addition to their growth inhibitory effects on 
2D PDAC cultures. 
Our data also supports inhibition of the DNA-damage response kinase WEE1 as 
a therapeutic option in PDAC. This observation has been made previously and is currently 
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under evaluation in clinical trials; synergistic growth reduction in PDAC cells upon co-
treatment with an ERK inhibitor and WEE1 inhibitor has never been shown (234). 
Additional evaluation of this combination is needed in order to understand the mechanistic 
basis for the success of tumor inhibition. Inhibition of WEE1 or other DNA-damage 
response kinases, such as CHK1, causes an S-phase and G2/M-phase arrest and in 
some cases mitotic catastrophe (235,236). Our data also shows that KRAS knockdown 
or ERK inhibition causes an incomplete G1-phase arrest. It is possible that an in vitro cell 
population harbors sufficient genetic or phenotypic heterogeneity that can be exploited by 
utilizing inhibitors that cause divergent cell cycle responses. Further, to definitively 
evaluate the preclinical efficacy of WEE1 inhibition combined with ERK inhibition, future 
work must be carried out in tumors harbored in mice. In this context, we could better 
measure both the efficacy and the potential toxicity of this combination. 
In Chapter 3 of this work, we set out to address the limitations observed with single 
agent inhibition of the MAPK pathway. We first applied a chemical inhibitor screen to 
identify combinations of inhibitors that enhanced apoptotic activity of MAPK inhibitors. To 
our surprise, the most effective combinations were those that included two inhibitors of 
distinct nodes of the RAF-MEK-ERK cascade. Further evaluation of these combinations 
revealed that vertical inhibition of the MAPK cascade blocked feedback regulatory 
signaling that would normally overcome single-node inhibition. Additionally, we showed 
that combination inhibition of RAF and ERK caused a system-wide collapse in ERK-
dependent signaling, including transcriptional processes regulated by the oncogene 
MYC. We also observed the strongest synergy in induction of apoptosis at the lowest 
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doses of either the RAF or the ERK inhibitor, which could be leveraged to help prevent 
normal tissue toxicity. 
Despite the clear link between KRAS mutation status and successful PDAC growth 
suppression by RAF-MEK-ERK vertical inhibition, heterogeneity in responses between 
PDAC cell lines remains present in vitro and in vivo. This heterogeneity does not appear 
to correlate with the mutational status in driver mutations typically found in PDAC. 
Investigation of the basis of this heterogeneity could help us identify biomarkers that could 
predict success of a vertical RAF-MEK-ERK inhibition strategy in patients. Additionally, 
we describe here a strategy for complete or near-complete suppression of MAPK 
signaling. It is possible that resistance or compensatory signaling mechanisms will arise 
that do not depend on the RAF-MEK-ERK cascade, circumventing the utility of the 
proposed RAFi + ERKi treatment strategy. Expanding the cohort of PDAC cell line and 
organoid models in which we evaluated this combination may help us identify and 
investigate non-responding cell populations before trialing this combination in human 
patients. 
The concept of vertical inhibition of the RAF-MEK-ERK cascade was first shown 
in melanoma using BRAF-mutant selective inhibitors with MEK inhibitors (207,208,210). 
Extensive work has now demonstrated that the vertical inhibition strategy presented in 
this work can be utilized to delay the onset of resistance to MAPK inhibitors. Given the 
potential for success of vertical inhibition of the MAPK pathway in KRAS mutant cancers, 
future work could focus on vertical inhibition of other critical pathways. For example, 
vertical inhibition of the PI3K/AKT pathway is synergistic in breast cancer (237), and dual 
inhibition of DNA-damage response components has also been met with success in 
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neuroblastoma, ovarian cancer, AML, and melanoma (238-241). We also showed that 
the highest synergy scores for growth inhibition and apoptosis induction were observed 
at some of the lowest doses of both ERK inhibitor and RAF inhibitor. This combination of 
inhibitors holds promise for patients with KRAS-mutant cancer, however the “low-dose” 
framework will be difficult to evaluate in a typical clinical trial framework. Generally, drugs 
are dosed to their maximum tolerated dose (MTD) where side-effects are typically present 
but within a tolerable limit. The driving motivation for this strategy is that more target 
inhibition portends a better clinical response. The data presented here may provide a 
rationale for a different dosing strategy in clinical trials, one in which a minimum effective 
dose is prioritized rather versus a MTD. Future work should focus on evaluating the 
efficacy of drug combinations utilized at lower than maximum tolerated doses, particularly 
when normal tissue toxicity is a concern.  
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Figure A1. KRAS-dependent kinome-wide alterations. (A) Immunoblot analysis of 
siNS- and siKRAS-treated samples submitted for MIB/MS analysis. Prior to submitting 
sample lysates to the UNC Proteomics Core, a small portion of the lysate was retained to 
confirm KRAS knockdown. Replicate 2 of PANC-1 was lost during processing. (B) 
Schematic of MIB/MS method performed. Cells were transfected with respective siRNA 
oligonucleotides for 72 hours prior to cell lysis and kinase enrichment. (C) Heatmap 
summarizing all 227 kinases detected among six KRAS mutant, KRAS-dependent PDAC 
cell lines (SW-1990, MIA PaCa-2, PANC-1, HPAC, AsPC-1 and Panc10.05). Log2(fold-
change) values were calculated by comparing siKRAS and siNS for each cell line. (D) 
Kinase activity/expression changes identified from siKRAS MIB/MS (Fig. S1C) in 
individual cell lines were compared. All 125 kinases significantly (p adjusted < 0.05) 
altered in at least one cell line are displayed here. (E) Volcano plot showing results of 
significance testing after ANOVA [y-axis] with the log-transformed mean fold change in 
siKRAS over siNS (72 hours). Significant kinases are colored red (increased) or blue 
(decreased) if p-value was significant following Benjamini-Hochberg correction (n = 3). 
(F) Pie charts indicating the proportion of kinase class representation in all detected 
kinases (227), upregulated kinases (15), and downregulated kinases (13). (G-H) Tree 
diagrams generated with KinMap (242) showing kinase family relationships of 
upregulated (J) or downregulated (K) kinases detected in 72-hour siKRAS samples from 
Fig 1A. (I) Volcano plot highlighting significantly altered proteins/phosphoproteins 
identified by RPPA analysis (p adjusted < 0.05). Five PDAC cell lines (HPAF-II, Pa02C, 
Pa14C, Pa16C and PANC-1) were transfected with siNS or siKRAS for 72 hours prior to 
sample collection. Significant kinases are colored gold [increased] or violet [decreased]. 
Data are representative of five independent biological replicates. (J) Selected results from 
RPPA analysis are shown for samples from (I). ANOVA was used to determine significant 
alterations among all cell lines (n.s. indicates non-significant; * p value < 0.05; ** p value 
< 0.005; *** p value < 0.0005). (K) Heatmap summarizing all kinases detected among six 
PDAC cell lines in response to ERK inhibition or DMSO treatment. Values were calculated 










Figure A2. Upregulation of DDR1, but not JAK, contributes to PDAC survival upon 
KRAS knockdown. (A) Immunoblot analysis of two PDAC cell lines treated for 24 hours 
with JAK1i (filgotinib), JAK1/2i (ruxolitinib), or JAK1/3i (tofacitinib) at increasing 
concentrations. Data are representative of three independent experiments. (B) 
Proliferation of PDAC cells following treatment for 5 days with JAK1i (filgotinib), JAK1/2i 
(ruxolitinib), or JAK1/3i (tofacitinib) at various concentrations. Cell numbers at endpoint 
were normalized to vehicle-treated control (100% growth) for each cell line. Curves were 
fit using a 4-parameter log-logistic function and the drm package in R (n=3). (C) GI50 
values for the DDR1 inhibitor 7rh (5 days of treatment) were calculated in four PDAC cell 
lines (n = 3). (D) Immunoblot analysis of PDAC cell lines treated for 24 hours with 
increasing doses of the DDR1 inhibitor 7rh (n = 3).  (E) Two dimensional growth of PDAC 
cells following treatment for 5 days with DDR1i (7rh) and ERKi at various concentrations 
in combination. Quantification and analysis is the same as in panel (A) (n = 3). (F) BLISS 
Synergy scores were calculated using the proliferation effect sizes from Fig. 2D. Scores 
< 1 indicate synergy (red), scores = 1 are additive (white), and scores > 1 are antagonistic 
















Figure A3. KRAS or ERK suppression causes loss of checkpoint and DNA damage 
response kinases. (A) Flow cytometry cell cycle analysis was performed following 72-
hour siNS, siKRAS 1 and siKRAS 2 treatment of four PDAC cell lines. Quantification was 
performed in FCS Express (n = 3). (B) Tabular summary of results from panel (A). 
Student’s t-test was used to identify significant differences between KRAS knockdown 
and control. (C) Reverse phase protein array (RPPA) analysis of 5 PDAC cell lines 
following 72-hour siRNA knockdown of KRAS. Relative color of heatmap indicates the 
log2-transformed fold change of siKRAS over siNS, with red indicating a greater value in 
siKRAS compared to siNS and blue indicating a lesser value in siKRAS compared to 
siNS. All 4 replicates for both siKRAS constructs (K1, K2) are shown as individual 
columns (n = 4). (D) Protein stability of WEE1 as determined by 4-hour MG132 
proteasomal inhibitor treatment following 26-hour treatment with non-specific (NS) or 
KRAS-targeted (K1, K2) siRNA (n = 3). (E) Quantification of blot analysis from panel (D). 
Densitometry estimates were first normalized for loading efficiency using β-actin. Next, 







Figure A4. Adavosertib treatment of PDAC induces growth arrest and apoptosis. 
(A) Immunoblot analysis of PDAC cells following treatment with WEE1i (adavosertib) for 
48 hours (n = 4). (B) GI50 values were calculated in six PDAC cell lines for the WEE1 
inhibitor adavosertib after five days of treatment. Data are representative of three 
independent experiments. (C) Immunoblot analysis of Pa16C cells following treatment 
with WEE1i (adavosertib) at various time points (n = 4). (D) Flow cytometry cell cycle 
analysis was performed following 48 hour DMSO or WEE1i (Pa02C 100 nM adavosertib; 
Pa16C, PANC-1, MIA PaCa-2 200 nM adavosertib) treatment of four PDAC cell lines. 
Quantification was performed in FCS Express (n = 4). (E) Tabular summary of results 
from panel (A). Student’s t-test was used to identify significant differences between 
adavosertib treatment and DMSO treated samples.  (F) Quantification of relative pERK 
over ERK ratios using densitometry with 100 nM (Pa02C) or 200 nM WEE1i (Pa16C, MIA 




Figure A5. Combined inhibition of WEE1 and ERK inhibits PDAC organoid growth. 
(A) hM1A PDAC organoids were seeded for three days in Matrigel and organoid 
maintenance factors, followed by treatment for 10 days with ERKi or WEE1i alone or in 
combination across a range of doses. Representative images are shown; scale bar is 
equivalent to 100 µm (n = 4). (B) hT2 PDAC organoids were seeded and treated 




Table A1. KRAS suppression-induced downregulated kinases and their functions. Kinase 
functions are adapted from UniProtKB (https://www.uniprot.org/help/uniprotkb) and GeneCards 
(https://www.genecards.org/) 
Gene Protein Function 
NEK2 
NEK2 NIMA related kinase 2 Ser/Thr protein kinase involved in mitotic regulation by 
controlling centrosome separation and bipolar spindle formation, and 
chromatin condensation in meiotic cells 
WEE1 WEE1 Ser/Thr protein kinase acts as a negative regulator of entry into mitosis (G2 to 
M transition) by protecting the nucleus from cytoplasmically activated cyclin 
B1-complexed CDK1 before the onset of mitosis by mediating phosphorylation 
of CDK1  
TTK TTK Tyr/Ser/Thr protein kinase essential for chromosome alignment at the 
centromere during mitosis and is required for centrosome duplication 
PLK1 PLK1 Polo-like kinase 1 Ser/Thr protein kinase performs several important functions 
throughout M phase of the cell cycle, including the regulation of centrosome 
maturation and spindle assembly, the removal of cohesins from chromosome 
arms, the inactivation of anaphase-promoting complex/cyclosome (APC/C) 
inhibitors, and the regulation of mitotic exit and cytokinesis 
MELK MELK Maternal embryonic leucine zipper Ser/Thr protein kinase involved in cell cycle 
regulation, mitotic spindle pole assembly, apoptosis and splicing regulation 
AURKA Aurora A Ser/Thr protein kinase plays a critical role in microtubule formation and 
stabilization during chromosome segregation in mitosis 
CHEK1 CHK1 Ser/Thr protein kinase is required for checkpoint-mediated cell cycle arrest in 
response to DNA damage. Integrates signals from ATM/ATR protein kinases 
to facilitate cell cycle inhibition 
PKMYT1 PKMYT1 Protein kinase, membrane-associated tyrosine/threonine 1 Ser/Thr protein 
kinase is membrane-associated and negatively regulates the G2/M transition 
of the cell cycle by phosphorylating CDK1 
EPHA2 EPHA2 Ephrin type-A receptor 2 Tyr kinase binds membrane-bound Ephrin-A family 
ligands, regulating cell adhesion and differentiation; overexpressed in cancer, 
with tumor promoting role 
TNIK TNIK TRAF2 and NKC interacting Ser/Thr protein kinase activates the Wnt- -
catenin signaling pathway, with roles in gene transcription, cytoskeletal 
rearrangements and cell spreading 
CDK1 CDK1 Cyclin dependent kinase 1 Ser/Thr protein kinase plays a key role in the 
control of the eukaryotic cell cycle by modulating the centrosome cycle as well 
as mitotic onset; promotes G2/M transition and regulates G1 progress and 
G1/S transition via association with multiple interphase cyclins; required in 
higher cells for entry into S-phase and mitosis 
CDK7 CDK7 Cyclin dependent kinase 7 Ser/Thr protein kinase involved in cell cycle control 
and in RNA polymerase II-mediated RNA transcription; required for activation 
and complex formation of CDK1/cyclin-B during G2/M transition 
CSNK2A1 CKIIε  Casein kinase 2 alpha 1 Ser/Thr protein kinase involved in various cell cycle 
control and apoptosis. During mitosis, functions as a component of the p53-
dependent spindle assembly checkpoint (SAC) that maintains cyclin-B-CDK1 





Table A2. KRAS suppression-induced upregulated kinases and their functions. Kinase 
functions are adapted from UniProtKB (https://www.uniprot.org/help/uniprotkb) and GeneCards 
(https://www.genecards.org/) 
Gene Protein Function 
TGFBR1 
TGFβR1 
Transforming growth factor beta receptor 1 Ser/Thr protein kinase is a 
transmembrane protein that integrates extracellular TGFβ ligand to regulate a 
diverse array of processes including mesenchymal cell proliferation, 
extracellular matrix production, and carcinogenesis; mediates its effects 
through SMAD-family transcription factors 
MAPK3 ERK1 Extracellular signal-regulated kinase 1 Ser/Thr protein kinase is an essential 
component of the RAS-RAF-MEK-ERK MAPK signal transduction cascade; 
mediates diverse biological functions such as cell growth, adhesion, survival 
and differentiation through the regulation of transcription, translation, and 
cytoskeletal rearrangements 
SRPK2 SRSF2 SRSF protein kinase 2 Ser protein kinase regulates mRNA splicing; promotes 
neuronal apoptosis by upregulating cyclin D1 expression 
TK2 TK2 Thymidine kinase 2 deoxyribonucleoside kinase phosphorylates thymidine, 
deoxycytidine, and deoxyuridine in the mitochondrial matrix. mtDNA synthesis 
in non-cycling cells depends solely on TK2 and DGUOK 
CAMKK2 CAMKK2 Calcium/calmodulin-dependent protein kinase kinase 2 Ser/Thr protein kinase 
plays a role in Ca2+/calmodulin-dependent signaling cascade and participates 
in the phosphorylation of AMPK; regulates cell proliferation and migration, 
overexpressed in cancer 
BMPR2 BMPR2  Bone morphogenic protein receptor type 2 Ser/Thr protein kinase is activated 
by ligands from the TGFβ superfamily; involved in bone growth and 
embryogenesis 
ILK ILK Integin-linked Ser/Thr receptor-proximal protein kinase regulates integrin-
mediated signal transduction; important in the epithelial to mesenchymal 
transition, and overexpression implicated in tumor growth and metastasis 
INSR INSR Insulin receptor Tyr protein kinase, regulates glucose uptake and release; 
mediates many of its effects through PI3K-AKT signaling cascade; paralog of 
IGF1R 
YES1 YES1 YES proto-oncogene 1, SRC family Tyr protein kinase is involved in the 
regulation of cell growth and survival, cell-cell adhesion, cytoskeleton 
remodeling. YES1 is recruited to activated receptor tyrosine kinases including 
EGFR, PDGFR,  and FGFR 
SRC SRC SRC proto-oncogene non-receptor Tyr protein kinase participates in signaling 
pathways that control gene transcription, cell adhesion, cell cycle progression, 
migration, and transformation. There is significant redundancy among SRC-
family kinases 
JAK1 JAK1 Janus kinase 1 Tyr protein kinase plays a role in interferon and interleukin 
signaling through STAT family transcription factors 
DDR1 DDR1  Receptor Tyr protein kinase integrates signals from the extracellular matrix to 
facilitate cell attachment, extracellular matrix remodeling, cell migration, 
survival and cell proliferation; can facilitate signaling through SRC and MAP 
kinases 
PI4KA PI4Kα Phosphatidylinositol 4-kinase lipid kinase catalyzes the biosynthesis of 
phosphatidylinositol 4,5-bisphosphate, a lipid component of the plasma 
membrane and the substrate of many important signaling proteins, including as 
an intermediate in the inositol triphosphate/diacylglcerol second messenger 
signaling pathway 
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STK38 STK38 Ser/Thr kinase 38 protein kinase functions in the cell cycle and during 
apoptosis; regulates MYC protein stability 
CAMK2G CAMK2G Calcium/calmodulin-dependent protein kinase type II gamma Ser/Thr protein 
kinase that is regulated by the presence of calcium and calmodulin to regulate 
sarcosplasmic reticulum calcium transport as well as dendritic spine and 
synapse formation in neurons 
 
 
Table A3. RPPA Antibodies.  
Catalog # Antibody  Company 
3661 Acetyl-CoA Carboxylase (S79) CellSig 
05-736 Akt1/PKB alpha (S473) (SK703) Upstate 
9271 Akt (S473) CellSig 
9275 Akt (T308)  CellSig 
4184 AMPKalpha1 (S485)   CellSig 
4181 AMPKBeta1 (S108)  CellSig 
ab47563 Androgen Receptor (S650) Abcam 
07-1375 Androgen Receptor (S81) Millipore 
2416 Arrestin1 (Beta) (S412) (6-24) CellSig 
3761 ASK1 (S83)  CellSig 
2630 Atg5 (part of Autophagy Ab Sampler 
#4445) 
CellSig 
5883 ATM (S1981) (D6H9) CellSig 
2853 ATR (S428) CellSig 
2914 Aurora A (T288)/B (T232)/C (T198) 
(D13A11) 
CellSig 
2696 B-Raf (S445)  CellSig 
9291 Bad (S112)  CellSig 
9295 Bad (S136)  CellSig 
9297 Bad (S155) CellSig 
9292 Bad CellSig 
3814 Bak CellSig 
2772 Bax CellSig 
2872 Bcl-2 CellSig 
2762 Bcl-xL CellSig 
3901 Bcr (Y177)  CellSig 
PRS3613 Beclin-1 Sigma 
2933 BIM CellSig 
H00000645-
M09 
BLVRB (biliverdin reductase B) (2F4) Abnova 
2864 c-Abl (T735) CellSig 
3391 c-Kit (Y719)  CellSig 
9402 c-Myc CellSig 
9427 c-Raf (S338) (56A6) CellSig 
2861 c-Abl (Y245) CellSig 
9662 Caspase-3 CellSig 
9661 Caspase-3, cleaved (D175)  CellSig 
9761 Caspase-6, cleaved (D162) CellSig 
9491 Caspase-7, cleaved (D198)  CellSig 
9505 Caspase-9, cleaved (D315) CellSig 
9501 Caspase-9, cleaved (D330) CellSig 
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9561 Catenin (beta) (S33/37/T41) CellSig 
9565 Catenin (beta) (T41/S45) CellSig 
2267-1 Caveolin-1 (Y14) (EPR2288Y) Epitomics 
2341 Chk1 (S345) CellSig 
2665 Chk2 (S33/35) CellSig 
3313 Cofilin (S3) (77G2) CellSig 
9191 CREB (S133) CellSig 
3491 CrkII (Y221)  CellSig 
3181 CrkL (Y207) CellSig 
2926 Cyclin D1 (DCS6) CellSig 
4656 Cyclin A2 (BF683) CellSig 
4065 E-Cadherin CellSig 
44-794 EGFR (Y1173) BioSource 
3597 eIF2alpha (S51) (119A11) CellSig 
9741 eIF4E (S209) CellSig 
9181 Elk-1 (S383)  CellSig 
9571 eNOS (S1177)  CellSig 
07-357 eNOS/NOS III (S116) Upstate 
IMG-90189 ErbB2/HER2 (Y1248)  Imgenex 
4791 ErbB3/HER3 (Y1289) (21D3) CellSig 
9101 ERK 1/2 (T202/Y204)  CellSig 
9102 ERK 1/2 CellSig 
2515 Estrogen Receptor alpha (S118) CellSig 
3144 Ezrin (Y353)  CellSig 
2781 FADD (S194) CellSig 
3281 FAK (Y576/577)  CellSig 
ab12327 FHL2 Abcam 
9461 FKHR/FOX01 (S256) CellSig 
06-953 FKHRL1/FOX03 (S253) Upstate 
9464 FKHR-FOX01 (T24)/FKHRL1-FOX03a 
(T32)  
CellSig 
14655 FOXM1 (T600) CellSig 
3861 FRS2-alpha (Y436)  CellSig 
D16H11 GAPDH (D16H1) CellSig 
9331 GSK-3alpha/beta (S21/9)  CellSig 
9336 GSK-3beta (S9) CellSig 
sc-11420 Histone Deacetylase 6 (HDAC6) SantaCruz 
06-570 Histone H3 (S10) Mitosis Marker Upstate 
07-145 Histone H3 (S28) Upstate 
3488 HSP90a (T5/7) CellSig 
3021 IGF-1 Rec (Y1131)/Insulin Rec (Y1146)  CellSig 
9246 IkappaB-alpha (S32/36) (5A5) CellSig 
4406 Jak2 (Y1007) (D15E2) CellSig 
M7240 Ki67 (MIB-1) DAKO 
3868 LC3B (D11) CellSig 
2752 Lck CellSig 
3055 LKB1 (S334)  CellSig 
3051 LKB1 (S428)  CellSig 
sc-819 Mcl-1 (S-19) SantaCruz 
3521 MDM2 (S166)  CellSig 
9121 MEK1/2 (S217/221) CellSig 
9128 MEK1 (S298)  CellSig 
3126 Met (Y1234/1235)  CellSig 
3852 MMP-9 CellSig 
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2971 mTOR (S2448)  CellSig 
3033 NF-kappaB p65 (S536) (93H1) CellSig 
MABE1328 p16 INK4a (13H4.1) Millipore 
71-7700 p27 (T187) Zymed 
610241 Kip1/p27 (57) BD 
9211 p38 MAP Kinase (T180/Y182)  CellSig 
9284 p53 (S15) CellSig 
8025 p62/SQSTM1 (D5E2) CellSig 
9202 p70 S6 Kinase CellSig 
9208 p70 S6 Kinase (S371)  CellSig 
9205 p70 S6 Kinase (T389)  CellSig 
9341 p90RSK (S380)  CellSig 
9541 PARP, cleaved (D214) CellSig 
07-021 PDGF Receptor beta (Y716) Upstate 
3061 PDK1 (S241)  CellSig 
9375 PKC alpha/beta II (T638/641)  CellSig 
9374 PKC delta (T505)  CellSig 
9377 PKC theta (T538)  CellSig 
9378 PKC zeta/lambda (T410/403)  CellSig 
44-1100 PRAS40 (T246) BioSource 
9551 PTEN (S380) CellSig 
9421 Raf (S259)  CellSig 
3321 Ras-GRF1 (S916) CellSig 
3322 Ras-GRF1 CellSig 
9309 Rb (4H1) CellSig 
3590 Rb (S780) CellSig 
5176-1 Ron (Y1353) Epitomics 
9348 RSK3 (T356/S360)   CellSig 
4856 S6 Ribosomal Protein (S235/236) (2F9) CellSig 
2215 S6 Ribosomal Protein (S240/244) CellSig 
9251 SAPK/JNK (T183/Y185)  CellSig 
9155 SEK1/MKK4 (S80)  CellSig 
07-206 Shc (Y317)  Upstate 
44-558 SHP2 (Y580) Biosource 
3101 Smad2 (S465/467) CellSig 
3104 Smad2 (S245/250/255)  CellSig 
2101 Src Family (Y416) CellSig 
2105 Src (Y527)  CellSig 
9171 Stat1 (Y701)  CellSig 
9134 Stat3 (S727)  CellSig 
9145 Stat3 (Y705) (D3A7) CellSig 
9351 Stat5 (Y694)  CellSig 
9361 Stat6 (Y641)  CellSig 
2711 Syk (Y525/526)  CellSig 
8155 TAB2 (S372) (D5A4) CellSig 
3614 Tuberin/TSC2 (Y1571)  CellSig 
3111 VASP (S157)  CellSig 
44-488 Vav3 (Y173) Biosource 
2478 VEGFR 2 (Y1175) (19A10) CellSig 
3295 Vimentin CellSig 
9451 4E-BP1 (S65) CellSig 
13008 YAP (S127) (D9W2I) CellSig 
2701 Zap-70 (Y319)/Syk (Y352)  CellSig 
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2546 CDK2 (78B2) CellSig 
13748 c-MYC (S62) CellSig 
2406 HSP27 (S82) CellSig 
06-822 PKC alpha (S657) Upstate 
3221 Ret (Y905)  CellSig 
  
137 




Figure B1. All RAF isoforms are necessary for PDAC growth (A) KRAS mutant PDAC 
cell lines were infected by lentivirus vectors encoding nonspecific (NS) control or KRAS 
shRNA (72 hr). Cell lysates were immunoblotted to determine levels of KRAS and vinculin 
(control for total protein). (B) PDAC cell lines were infected by lentivirus vectors encoding 
NS control or KRAS shRNAs (72 hr) and colonies were stained with crystal violet ~10 
days after plating. Representative images are shown. (C) PDAC cell lines were infected 
by lentivirus vectors encoding NS control or two shRNAs targeting ARAF, BRAF or CRAF 
(72 hr). Cell lysates were immunoblotted to determine levels of ARAF, BRAF, CRAF and 
vinculin. (D) PDAC cell lines were infected by lentivirus vectors encoding NS control, 
ARAF, BRAF or CRAF shRNAs (72 hr). Colonies were stained by crystal violet ~10 days 
after plating. Representative images are shown. (E) PDAC cell lines were treated with 
mutant BRAF-specific inhibitor vemurafenib (BRAFi, 0.04-10 M, 72 hr). Cell lysates were 
immunoblotted to determine levels of phosphorylated ERK, total ERK and vinculin. (F) 
PDAC cell lines were treated with the pan-RAF inhibitor LY3009120 (RAFi, 0.04-10 M, 
72 hr). Cell lysates were immunoblotted to determine levels of phosphorylated ERK, total 
ERK, phosphorylated AKT, total AKT and vinculin.  (G) The composition of the loss-of-
function CRISPR/Cas9 druggable genome (2,500 genes) library screen. (H) 
CRISPR/Cas9 druggable genome library screen schematic. (I) CRISPR screen. PDAC 
cell lines were infected with a pooled CRISPR library and treated with vehicle control or 
RAFi (w2: 2 weeks, w4: 4 weeks; a and b indicate replicate samples). The enrichment 
score indicates either enrichment (red) or depletion (blue) of barcoded sequences 
corresponding to the indicated genes in cells treated with RAFi relative to vehicle control. 
(J) Pa16C cells were infected by lentivirus vectors encoding NS control or two distinct 
shRNAs for ARAF, BRAF or CRAF for 72 hr, and treated with LY3009120 (RAFi, 0.3 M) 
for additional 72 or 120 hr (related to Figure 1E). Cell lysates were immunoblotted to 
determine levels of ARAF, BRAF, CRAF, phosphorylated ERK, total ERK, 
phosphorylated MEK (Ser 298), total MEK and vinculin. 
(K) Related to Figure 1E. Pa02C and Pa16C cell lines were infected by lentivirus vectors 
encoding NS or two distinct BRAF or CRAF shRNAs (72 hr) and treated with LY3009120 
(RAFi, 0.01-2.5 M) for additional 120 hr. Proliferation was measured by Calcein AM cell 
viability assay. Data are the mean average of three technical replicates. Error bars are 






Figure B2. Drug sensitivity resistance testing screen (DSRT) (A) Human or mouse 
KRAS mutant PDAC cell lines were treated with a 525-inhibitor library with or without 
LY3009120 (RAFi, 2 M, 72 hr). Proliferation was measured by Calcein AM viability 
assay. Drug sensitivity score (δDSS) was used to quantify inhibitor responses. Red (> 
additive), blue (< additive) or white (no effect). (B) Human or mouse KRAS mutant PDAC 
cell lines were treated with a 525-inhibitor library with or without trametinib (MEKi, 0.025 
M, 72 hr). Proliferation was measured by Calcein AM viability assay (left), and cell death 
was measured by CellTox Green cytotoxicity assay (right). Inhibitor responses were 
plotted as δDSS. Red (> additive), blue (< additive) or white (no effect). (C) Human or 
mouse KRAS mutant PDAC cell lines were treated as described in Figure S2B with 
SCH772984 (ERKi, 0.1 M, 72 hr). Proliferation and cell death measured as described in 
Figure S2B. (D) The composition of the DSRT screen. (E) Top hits summarized for the 






Figure B3. Concurrent RAF and ERK inhibition causes synergistic growth 
suppression (A) Indicated KRAS mutant PDAC cell lines were treated with the vehicle 
control (lower left of each graph), LY3009120 (RAFi, 0.01-2.5 M, 1:2 dilution) and 
SCH772984 (ERKi, 0.08-1.25 M, 1:2 dilution) alone or in combination for 120 hr. 
Proliferation was measured by Calcein AM cell viability assay. Representative bliss 
synergy score heatmaps of three biological replicates (up). Red (synergy), green 
(antagonism), white (no effect). Averaged synergy scores presented on the synergy 
heatmaps. Averaged dose response curves of three biological replicates (down). Error 
bars are shown as ±S.E.M. (B) PDAC cell lines Pa02C and Pa16C were treated with the 
vehicle control (lower left of each graph), vemurafenib (BRAFi, 0.01-2.5 M, 1:2 dilution) 
and SCH772984 (ERKi, 0.08-1.25 M, 1:2 dilution) alone or in combination for 120 hr. 
Bliss synergy scores and dose response curves are calculated as in Figure S2F. (C) 
Pa02C and Pa16C were treated with the vehicle control (lower left of each graph), the 
ERK1/2 inhibitor ulixertinib (BVD-523, 0.01-2.5 M, 1:2 dilution) and SCH772984 (ERKi, 
0.08-1.25 M, 1:2 dilution) alone or in combination for 120 hr. Bliss synergy scores and 
dose response curves are calculated as in Figure S2F. (D) Pa02C, Pa16C and MIA PaCa-
2 cell lines were treated with the vehicle control (lower left of each graph), the pan-RAF 
inhibitor lifirafenib/BGB-283 (0.01-2.5 M, 1:2 dilution) and SCH772984 (ERKi, 0.08-1.25 
M,1:2 dilution) alone or in combination for 120 hr. Bliss synergy scores and dose 
response curves are calculated as in Figure S2F. (E) KRAS mutant PDAC cell lines 
Pa02C and Pa16C were treated with the vehicle control (lower left of each graph), 
LY3009120 (RAFi, 0.01-2.5 M, 1:2 dilution) and the ERK1/2 inhibitor LY3214996 (0.08-
1.25 M, 1:2 dilution) for 120 hr. Bliss synergy scores and dose response curves are 
shown as in Figure S2F. (F) Kinome-wide chemical proteomics screen by multiplexed 
kinase inhibitor beads and mass spectrometry (MIB/MS). MIA PaCa-2 cells were treated 
with the vehicle control DMSO, LY3009120 (RAFi, 0.3 M), trametinib (MEKi, 0.5 nM), 
SCH772984 (ERKi, 0.04 M) alone or in combination for 72 hr. Fold changes of 
significantly altered kinases (p value ≤ 0.05) are plotted. Each treatment is normalized to 
its respective vehicle control. (G) Average log2 fold-change values (over vehicle control) 
for each kinase identified in MIB/MS were plotted along the x-axis (RAFi+ERKi) or y-axis 
(RAFi+MEKi). The dashed lines indicate differences in log2 fold-change values of 1 or -1. 
(H) Pa16C and PANC-1 cells were treated with LY3009120 (RAFi, 0.3 M, trametinib 
(MEKi, 0.5 nM) or SCH772984 (ERKi, 0.04 M) alone or in combination as indicated (120 
hr). Cell lysates were immunoblotted to determine the levels of phosphorylated and total 




Figure B4. The pathways altered by the concurrent RAF and ERK inhibition. The 
processes altered by LY3009120 (RAFi, 0.3 M) and SCH772984 (ERKi, 0.04 M) 






Figure B5. Concurrent RAF and ERK inhibition blocks ERK reactivation (A) Gene 
set enrichment analysis (GSEA) of RNA transcripts of MIA PaCa-2, Pa02C, Pa14C and 
Pa16C cell lines. Enriched or depleted gene sets treated with RAFi + ERKi combination 
compared to the vehicle control DMSO are shown (24 hr). (B) Gene set enrichment 
analysis (GSEA) of hallmark KRAS signaling. Altered gene expressions are plotted as 
enrichment scores (E.S.). PDAC cells were treated with LY3009120 (RAFi, 0.3 M) and 
SCH772984 (ERKi, 0.04 M) for 24 hr and normalized to the vehicle control DMSO (left), 
RAFi (middle), or ERKi (right). Data shown are the average of four PDAC cell lines MIA 
PaCa-2, Pa02C, Pa14C and Pa16C.  (C) Indicated KRAS mutant PDAC cell lines were 
treated with the vehicle control DMSO, LY3009120 (RAFi, 0.3 or 0.6 M), SCH772984 
(ERKi, 0.04 or 0.08 μM) alone or in combination for 72 hr or (D) 120 hr. Cell lysates were 
immunoblotted to determine levels of phosphorylated ERK, total ERK, MYC and vinculin. 
(E) Pa02C and Pa16C cells were treated with the vehicle control DMSO, LY3009120 
(RAFi, 0.3 or 0.6 μM), the ERK1/2 inhibitor LY3214996 (0.04, 0.08 or 0.16 μM) alone or 
in combination for 72 or 120 hr. Cell lysates were immunoblotted to determine levels of 








Figure B6. The alterations of various signaling pathways upon RAF and ERK 
inhibition (A) Kinome-wide chemical proteomics screen by multiplexed kinase inhibitor 
beads and mass spectrometry (MIB/MS). MIA PaCa-2 cells were treated with the vehicle 
control DMSO, LY3009120 (RAFi, 0.3 μM), SCH772984 (ERKi, 0.04 μM) alone or in 
combination for 72 hr. Fold changes of significantly altered kinases (p value ≤ 0.05) are 
plotted. Each treatment is normalized to its respective vehicle control. (B) Fold changes 
(log2) of RNA expression of ERK gene targets that drive cancer and ERK feedback 
mechanism regulators. MIA PaCa-2, Pa02C, Pa14C and Pa16C cell lines treated with 
RAFi + ERKi (0.3 μM and 0.04 μM, respectively) and compared to RAFi (0.3 μM), ERKi 
(0.04 μM) or the vehicle control (24 hr). Error bars are shown as standard error. p values 
are from Wald test. Adjusted p values for RAFi + ERKi compared to RAFi = MYC (*, 
0.0161), FOSL1 (**, 0.0018), DUSP4 (****, 1.51E-13), DUSP5 (*, 0.0547), DUSP6 (****, 
8.79E-17), DUSP7 (****, 8.90E-07), SPRY2 (***, 0.0002), SPRY4 (****, 5.81E-20), 
SPRED1 (****, 2.17E-29), SPRED2 (****, 3.05E-06), CCND1 (***, 0.0013), LIF (***, 
0.0003). Adjusted p values for RAFi + ERKi compared to ERKi = MYC (**, 0.0112), FOSL1 
(****, 2.74E-11), DUSP4 (****, 6.39E-19), DUSP5 (**, 0.0019), DUSP6 (****, 3.09E-17), 
DUSP7 (****, 5.35E-07), SPRY2 (****, 1.80E-12), SPRY4 (****, 1.40E-22), SPRED1 (****, 
1.12E-29), SPRED2 (****, 2.67E-07), CCND1 (***, 0.002), LIF (****, 1.96E-05). Adjusted 
p values for RAFi + ERKi compared to the vehicle = MYC (****, 1.13E-05), FOSL1 (****, 
5.46E-09), DUSP4 (****, 2.91E-36), DUSP5 (****, 6.44E-19), DUSP6 (****, 1.93E-41), 
DUSP7 (****, 9.59E-20), SPRY2 (***, 0.0001), SPRY4 (****, 4.05E-52), SPRED1 (****, 
2.57E-15), SPRED2 (****, 5.69E-05), CCND1 (**, 0.0039), LIF (****, 6.08E-07). (C) Gene 
set enrichment analysis (GSEA) of hallmark MYC targets. Altered gene expressions are 
plotted as enrichment scores (E.S.). PDAC cells were treated with LY3009120 (RAFi, 0.3 
μM) and SCH772984 (ERKi, 0.04 μM) for 24 hr and normalized to the vehicle control 
DMSO (left), RAFi (middle), or ERKi (right). Data shown are the average of four PDAC 
cell lines MIA PaCa-2, Pa02C, Pa14C and Pa16C. (D) Fold changes (log2) of RNA 
expression of IGF1R, PTPN11 (SHP2) and E2F1. MIA PaCa-2, Pa02C, Pa14C and 
Pa16C cell lines treated with RAFi + ERKi (0.3 μM and 0.04 μM, respectively) and 
compared to RAFi (0.3 μM), ERKi (0.04 μM) or the vehicle control (24 hr). Error bars are 
shown as standard error. p values are from Wald test. Adjusted p values for RAFi + ERKi 
compared to RAFi = IGF1R (n.s., 0.9064), PTPN11 (*, 0.0491), E2F1 (***, 0.0005). 
Adjusted p values for RAFi + ERKi compared to ERKi = IGF1R (n.s., 0.8150), PTPN11 
(n.s., 0.3391), E2F1 (****, 2.49E-08). Adjusted p values for RAFi + ERKi compared to the 
vehicle = IGF1R (n.s., 0.9106), PTPN11 (*, 0.0538), E2F1 (***, 0.0001). Adjusted p values 
for RAFi = IGF1R (n.s., 0.9828), PTPN11 (n.s., 0.2844), E2F1 (n.s., 0.0713). Adjusted p 
values for ERKi = IGF1R (n.s., 0.9916), PTPN11 (n.s., 0.0608), E2F1 (n.s., 0.1325). (E) 
Gene set enrichment analysis (GSEA) of hallmark E2F targets, G2M checkpoint, 
glycolysis, autophagy, mitochondrial biogenesis, and lysosome. Altered gene 
expressions are plotted as enrichment scores (E.S.). PDAC cells were treated with 
LY3009120 (RAFi, 0.3 μM) and SCH772984 (ERKi, 0.04 μM) for 24 hr and normalized to 
the vehicle control DMSO (left), RAFi (middle), or ERKi (right). Data shown are the 






Figure B7. Concurrent RAF and ERK inhibition induces apoptosis (A) Fold changes 
(log2) of RNA expression of pro-apoptosis and pro-survival genes as the averaged values 
of MIA PaCa-2, Pa02C, Pa14C and Pa16C cell lines treated with RAFi + ERKi (0.3 μM 
and 0.04 μM, respectively) and compared to the vehicle control DMSO (24 hr). Error bars 
are shown as standard error. All p values shown are in comparison to the vehicle control. 
p values are from Wald test. Adjusted p values = BAX (0.1030), BAK1 (0.6372), BAD (*, 
0.0195), BID (0.4139), BIK (0.0835), HRK (**, 0.0016), BCL2L11 (0.1258), PUMA/BBC3 
(****, 5.78E-05), CASP1 (0.4693), CASP2 (*, 0.0170), CASP3 (***, 0.0008), CASP4 
(0.9750), CASP6 (**, 0.0050), CASP7 (0.2896), CASP8 (0.8912), CASP9 (*, 0.0158), 
BCL2 (****, 2.83E-07), BCL2L1 (*, 0.0171), MCL1 (****, 1.13E-05), BCL2L2 (0.8906). (B) 
GSEA of hallmark apoptosis signaling. Altered gene expressions are plotted as E.S. 
(enrichment score) PDAC cells were treated with LY3009120 (RAFi, 0.3 μM) and 
SCH772984 (ERKi, 0.04 μM) for 24 hr and normalized to the vehicle control (left), RAFi 
(middle), or ERKi (right). Data are the average of four PDAC cell lines MIA PaCa-2, 
Pa02C, Pa14C and Pa16C. (C) Related to Figure 4D. Representative images of percent 
apoptosis induced by the vehicle control, LY3009120 (RAFi, 0.3 or 0.6 μM), SCH772984 
(ERKi, 0.04 or 0.08 μM) or the combinations (120 hr). FACS analysis of Annexin-
V/propidium iodide labeled cells was used to measure apoptosis. (D) Quantitation of 
percent apoptosis of the indicated KRAS mutant PDAC cells treated with the vehicle 
control, LY3009120 (RAFi, 0.3 or 0.6 μM), SCH772984 (ERKi, 0.04 or 0.08 μM) or the 
combinations for 72 hr or (E) 120 hr. FACS analysis of Annexin V-FITC/propidium iodide-
labeled cells was used to measure apoptosis. (F) Gene set enrichment analysis (GSEA) 
of hallmark mTORC1 signaling. Altered gene expressions are plotted as enrichment 
scores (E.S.). PDAC cells were treated with LY3009120 (RAFi, 0.3 μM) and SCH772984 
(ERKi, 0.04 μM) for 24 hr and normalized to the vehicle control DMSO (upper graph), 
RAFi (middle graph), or ERKi (lower graph). Data are the average of four PDAC cell lines 
MIA PaCa-2, Pa02C, Pa14C and Pa16C. 
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Figure B8. Combined RAF and ERK inhibition causes mesenchymal to epithelial 
transition (A) RPPA. PDAC cells were treated with the vehicle control, LY3009120 (RAFi, 
0.3 μM), SCH772984 (ERKi, 0.04 μM) or the combination for 15 min, 1, 8, 24 and 72 hr. 
The alterations of protein expression of E-cadherin (epithelial marker), vimentin 
(mesenchymal marker) and phosphorylated cofilin (actin polymerization) were plotted 
over time. Data are the mean average of five independent experiments. Error bars are 
shown as ±S.E.M. FC: fold change. (B) Pa01C, Pa14C, MIA PaCa-2 and PANC-1 cells 
were treated with LY3009120 (RAFi, 0.3 μM), vemurafenib (BRAFi, 1 μM), trametinib 
(MEKi, 0.5 nM) or SCH772984 (ERKi, 0.04 μM) alone or in combination as indicated (120 
hr). Cell lysates were immunoblotted to determine the levels of E-cadherin, vimentin, 
phosphorylated ERK and vinculin. (C) Related to Figure 5C. Representative images (the 
same representative image shown in Figure 5C as E-cadherin and nucleus merge) of 
Pa02C cells treated with vehicle control, LY3009120 (RAFi, 0.3 μM), SCH772984 (ERKi, 
0.04 μM) or the combination to visualize F-actin (shown alone or merged with E-cadherin 
and DAPI) expression and distribution (72 hr). Scale bar, 20 μm. 
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Figure B9. Concurrent PAK or AKT inhibition enhances RAFi/ERKi activity (A) 
Pa02C and Pa14C cell lines were treated with LY3009120 (RAFi, 0.01-2.5 μM), 
SCH772984 (ERKi, 0.08-1.25 μM), FRAX597 (PAKi, 0.01-2.5 μM) alone or the 
combination with a constant concentration of a second or third inhibitor as indicated. 
Proliferation was measured after 120 hr by Calcein AM cell viability assay. Data are the 
mean average of two independent experiments. Error bars are shown as ±S.E.M. (B) 
Pa02C and Pa14C cell lines were treated with LY3009120 (RAFi, 0.01-2.5 μM), 
SCH772984 (ERKi, 0.08-1.25 μM), MK2206 (AKTi, 0.01-2.5 μM) alone or the combination 
with a constant concentration of a second or third inhibitor as indicated. Proliferation was 
measured after 120 hr by Calcein AM cell viability assay. Data are the mean average of 
two independent experiments. Error bars are shown as ±S.E.M. (C) Average GI50 values 




Figure B10. Concurrent RAF and ERK inhibition synergistically impairs KRAS 
mutant cancer growth in vitro and in vivo (A) KRAS mutant lung cancer cell lines NCI-
H358 and SW 900 were treated with the vehicle control (lower left of each graph), 
LY3009120 (RAFi, 0.01-2.5 μM) and SCH772984 (ERKi, 0.08-1.25 μM) alone or in 
combination for 120 hr. Proliferation was measured by Calcein AM cell viability assay. 
Representative bliss synergy score heatmaps for three independent experiments is 
shown (left). Red (synergy), green (antagonism), white (no effect). Averaged synergy 
scores presented on the synergy heatmaps. Averaged dose response curves of three 
independent experiments are shown (right). Error bars are ±S.E.M. (B) KRAS mutant 
CRC organoids OT227 were treated with the vehicle control (lower left of each graph), 
LY3009120 (RAFi, 0.01-2.5 μM) and SCH772984 (ERKi, 0.04-0.63 μM) alone or in 
combination for 5 days. Proliferation was measured by CellTiter-Glo 3D cell viability 
assay. Dose response curves and bliss synergy scores were calculated and represented 
as in Figure S10A. (C) Representative images of PDAC organoid hT2 treated with the 
vehicle control DMSO, LY3009120 (RAFi, 0.16 μM), SCH772984 (ERKi, 0.04 μM) alone 
or in combination. Scale bar = 200 μm. (D) Tumors from HPAF-II PDAC rat (n = 5 for 
each condition) were harvested at day 21. Tumor lysates were immunoblotted to 
determine levels of phosphorylated and total RSK, phosphorylated and total ERK, 
phosphorylated ribosomal protein S6 (S240/244), total ribosomal protein S6, MYC and B-
actin (control for total protein). (E) The indicated PDAC cell lines were treated with 
LY3009120 (RAFi, 0.01-2.5 μM) and SCH772984 (ERKi, 0.08-1.25 μM) alone or in 
combination for 120 hr. Proliferation was measured by Calcein AM cell viability assay. 
Averaged dose response curves of three independent experiments are shown. Error bars 
are ±S.E.M. (F) The indicated PDAC cell lines were treated with LY3009120 (RAFi, 0.01-
2.5 μM) and trametinib (MEKi, 0.25 - 4.00 μM) alone or in combination for 120 hr. 
Proliferation was measured by Calcein AM cell viability assay. Averaged dose response 
curves of three independent experiments are shown. Error bars are ±S.E.M.  (G) The 
indicated PDAC cell lines were treated with LY3009120 (RAFi, 0.01-2.5 μM) and erlotinib 
(EGFRi, 0.08-1.25 μM) alone or in combination for 120 hr. Proliferation was measured by 
Calcein AM cell viability assay. Averaged dose response curves of three independent 
experiments are shown. Error bars are ±S.E.M. (H) Relative tumor volume of the NIH 
nude rats with implanted CFPAC-1 cells were treated with LY3009120 (RAFi, 20 mpk, 
BID) alone or in combination with ERK1/2 inhibitor LY3214996 (LY ERKi, 10 mpk, QD) 
for 36 days (left). Body weight changes are shown (right). (I) Quantitation of the western 
blot analysis to determine the levels of phosphorylated RSK of tumor lysates (n = 5 
animals per group). (J) Relative tumor volume of the NIH nude rats with implanted SW 
1990 cells were treated with LY3009120 (RAFi, 20 mpk, BID) alone or in combination with 
ERK1/2 inhibitor LY3214996 (LY ERKi, 10 mpk, QD) for 36 days (left). Body weight 
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